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ABSTRACT
Analysis of the Mechanisms Mediating the Regulation of Acetyl-CoA
Carboxylase Transcription by the Liver X Receptor and
Chenodeoxycholic Acid
Saswata Talukdar
Agonists of the liver X receptor (LXR) prevent and decrease arterial plaque formation in
experimental models of atherosclerosis. The anti-atherosclerotic effects of LXR agonists
are mediated by an increase in expression of genes involved in cholesterol export.
Currently, the therapeutic utility of LXR agonists is limited by the fact that these agents
increase triglyceride levels in the blood and liver. These undesired effects are caused by
an increase in transcription of genes controlling triglyceride synthesis, such as acetyl
CoA carboxylaseα (ACCα). We have demonstrated that a synthetic LXR agonist, T0901317 increases ACCα via both a direct mechanism involving the activation of
LXR/retinoid X receptor (RXR) heterodimers on the ACCα gene and by an indirect
mechanism involving the increased expression of sterol regulatory element binding
protein-1 (SREBP-1). SREBP-1 binds a site adjacent to the ACCα LXRE and enhances
the ability of LXR/RXR to activate ACCα transcription. We screened a number of
compounds for their ability to inhibit the stimulatory effects of T0-901317 on expression
of lipogenic genes in primary cultures of hepatocytes. We found that the bile acid,
chenodeoxycholic acid (CDCA), inhibited the T0-901317-induced increase in mRNA
abundance encoding ACCα, fatty acid synthase, and stearoyl CoA desaturase-1. CDCA
also blocked the stimulatory effects of T0-901317 on triglyceride secretion into the
culture medium. Results from transient transfection analyses identified two cis-acting
elements that mediated the inhibitory effects of CDCA on T0-901317-induced ACCα
transcription. One element bound LXR/RXR heterodimers and the other element bound
SREBP-1. Treatment with CDCA decreased the expression of mature, active SREBP-1
and decreased the binding of LXR/RXR heterodimers to the ACCα promoter. Further
studies demonstrated that the CDCA-mediated inhibition of ACCα transcription was
associated with an activation of extracellular signal-related kinase-1/2 (ERK1/2) and p38
mitogen activated protein kinase (p38MAPK) and that inhibitors of ERK1/2 and
p38MAPK abolished or substantially attenuated the inhibitory effect of CDCA on ACCα
expression. These results indicate that CDCA inhibits T0-901317-induced ACCα
expression by decreasing the transcriptional activity of LXR and SREBP-1 and that
ERK1/2 and p38MAPK are components of the signaling pathway mediating the
inhibitory effects of CDCA on ACCα expression and triglyceride secretion.

"Whatever we understand and enjoy in human products instantly becomes
ours, wherever they might have their origin."
- Rabindranath Tagore (1861-1941)
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Chapter 1
I) Introduction
Liver X receptors are ligand dependent transcription factors that belong to the
nuclear hormone receptor superfamily. LXRs modulate multiple cellular pathways
making it a very attractive drug target to prevent and cure a wide range of diseases. For
example, agonists of LXR prevent and decrease arterial plaque formation in experimental
models of cardiovascular disease and atherosclerosis. The anti-atherosclerotic effects of
LXR agonists are mediated by an increase in expression of genes involved in cholesterol
export and high density lipoprotein (HDL) formation. In rodent models of diabetes, an
LXR agonist, T0-901317, lowered plasma glucose levels and significantly improved
insulin sensitivity. Activation of LXR in mouse liver inhibits gluconeogenesis by
inhibiting the expression of peroxisome proliferator-activated receptor gamma
coactivator-1α (PGC-1α), phosphoenolpyruvate carboxykinase (PEPCK), and glucose-6phosphatase. In contrast, LXR agonists promote hepatic glucose utilization by increased
expression of glucokinase. Recently there is compelling evidence showing an important
link between cholesterol and Alzheimer's disease. High plasma levels of HDL have been
shown to have an inverse effect on Alzheimer's disease. This effect is primarily due to
the increase in ABCA1 by LXRs. LXR agonists applied to a variety of in vitro models,
including immortalized fibroblasts from Tangier patients, and primary embryonic mouse
neurons and Alzheimer disease mouse model (APP23 transgenic mice) caused a T0901317-dose-dependent decrease in amyloid beta secretion.
Currently, the therapeutic utility of LXR agonists is limited by the fact that these
agents also increase triglyceride levels in the blood and liver. These undesired effects are
caused by an increase in transcription of genes controlling triglyceride synthesis. I have
developed data demonstrating that the LXR agonist, T0-901317, increases the expression
of ACCα in chicken embryo hepatocytes (CEH). This result is consistent with previous
work from our laboratory that ACCα is a LXR target gene. Results from transient
transfection analyses indicated that the T0-901317 induction of ACCα mRNA is
mediated by two cis-acting elements on the ACCα promoter.
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We screened a number of compounds for their ability to inhibit the stimulatory
effects of the synthetic LXR agonist, T0-901317, on expression of lipogenic genes in
primary cultures of hepatocytes. We found that the primary bile acid, chenodeoxycholic
acid (CDCA), inhibited the T0-901317-induced increase in abundance of mRNAs
encoding acetyl CoA carboxylaseα (ACCα), fatty acid synthase, and stearoyl CoA
desaturase-1. Interestingly, CDCA enhanced the T0-901317-induced increase in
abundance of mRNA encoding ABCA1, a key protein involved in HDL formation. Thus,
CDCA may enhance the ability of T0-901317 to stimulate HDL formation while reducing
the effects of T0-901317 on triglyceride accumulation in the blood and liver.
Results from transient transfection analyses identified two cis-acting elements that
mediated the inhibitory effects of CDCA on T0-901317-induced ACCα transcription.
One element bound LXR/retinoid X receptor (RXR) heterodimers and the other element
bound sterol regulatory element binding protein-1 (SREBP-1). Treatment with CDCA
decreased the expression of mature, active SREBP-1, via a post translational mechanism.
Further studies demonstrated that the CDCA-mediated inhibition of ACCα transcription
was associated with an activation of extracellular signal-related kinase-1/2 (ERK1/2) and
p38 mitogen activated protein kinase (p38 MAPK). Specific inhibitors of ERK1/2 and
p38MAPK abolished or substantially attenuated the inhibitory effect of CDCA on ACCα
expression. These results indicate that CDCA inhibits ACCα transcription by decreasing
the activity of LXR and SREBP-1, and that ERK1/2 and p38MAPK are involved in
mediating this effect.

II) BACKGROUND
A) Acetyl CoA Carboxylase
1) Structure and function
Acetyl CoA carboxylase (ACC) catalyzes the ATP-dependent carboxylation of
acetyl CoA to malonyl CoA. This reaction is the first committed step in the fatty acid
synthesis pathway (67, 94). There are two isoforms of ACC that are encoded by different
genes. ACCα (260 kDa) is the principal isoform that is expressed in tissues that exhibit
high rates of fatty acid synthesis such as liver, adipose tissue and mammary gland.
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ACCβ (280 kDa) is the major isoform found in heart and skeletal muscle where it is
thought to primarily function in the regulation of β-oxidation of fatty acids (173).

2) Regulation of ACC
The levels of ACCα in the liver are dependent on nutritional and hormonal
regulation (13, 67). The effects of nutritional regulation on the ACCα concentration are
mediated primarily by changes in the rate of transcription of the ACCα gene (65). In
livers of starved chickens the rate of ACCα transcription is low. Consumption of a high
carbohydrate, low fat diet stimulates an 11-fold increase in ACCα transcription (65).
Several signaling pathways are involved in mediating the stimulatory effects of dietary
carbohydrate on ACC transcription in liver. Increased insulin secretion and glucose
metabolism are two important signals mediating this response. Another factor signaling
changes in carbohydrate status is the active form of thyroid hormone, 3, 5, 3'triiodothyronine (T3). Ingestion of a high carbohydrate meal stimulates a rapid increase
in the secretion of thyroxine from the thyroid gland and the conversion of thyroxine to T3
in extrathyroidal tissues (66). The resulting increase in T3 concentration in liver activates
the transcription of the genes for ACC. Ingestion of carbohydrate also increases the
levels of nuclear T3 receptors (TRs) in liver (23). This phenomenon may also contribute
to the stimulation of lipogenic gene transcription by dietary carbohydrate.
Diet-induced changes in ACCα transcription are mimicked in primary cultures of
chick embryo hepatocytes by manipulating the concentration of hormones and nutrients
in the culture medium. The addition of T3 to the culture medium stimulates a 7-fold
increase in ACCα transcription (66). Insulin has no effect on the transcription of ACCα,
but amplifies the increase in ACCα transcription caused by T3. Glucagon acting through
cAMP suppresses the induction of ACCα transcription caused by T3 and insulin (225).
The ACC gene is transcribed from two promoters, PI and PII, which result in
alternatively spliced mRNAs containing different 5’ noncoding regions (94). In rodents,
PI is active in white adipose tissue and regulated by dietary manipulation (121, 122). In
contrast PII is active in all tissues at a low level. PII promoter for ACCα is specifically
regulated by sterols through the action of the transcription factor Sp1 and the sterol
regulatory element binding proteins (SREBPs) (127). In contrast to the rodents, our
laboratory has shown that both PI and PII are regulated by nutrients and hormones in
3

chick hepatocytes and that the activity of PII accounts for a greater proportion of the
changes in total ACCα mRNA abundance than activity of PI (236).
Our laboratory has identified a unique regulatory element between -108 and -82bp
in the ACCα gene that confers T3 regulation on ACCα promoter 2 in chicken embryo
hepatocytes (CEH). This element stimulates transcription both in the absence and
presence of T3, with a greater stimulation observed in the presence of T3. The T3independent enhancer activity of this regulatory element was mediated by protein
complexes containing LXR•RXR heterodimers and the increase in enhancer activity in
the presence of T3 was mediated by protein complexes containing thyroid hormone
receptor (TR)•RXR heterodimers and LXR•RXR heterodimers (236). This regulatory
element is referred to as a composite thyroid hormone response element/liver X receptor
response element (T3RE/LXRE). Immediately downstream of the ACCα T3RE/LXRE is
a sterol regulatory element (SRE)
(-80 to -71 bp), that increased the ability of the ACCα-T3RE/LXRE to stimulate ACCα
transcription in the presence of T3. The stimulatory effect of the SRE-1 on ACCα
transcription was mediated by a direct interaction between SREBP-1 and TR. This
interaction facilitated the formation of a tetrameric complex comprised of SREBP1•SREBP-1/TR•RXR on the ACCα gene. The formation of this tetrameric complex
stabilized the binding of SREBP-1 to ACCα SRE-1. The binding of T3 to thyroid
hormone receptor (TR) enhanced tetrameric complex formation. T3 was also shown to
stimulate the production of the mature, transcriptionally active form of SREBP-1 in
hepatocytes. Thus multiple interactions between the TR and SREBP-1 signaling
pathways contribute to the stimulatory effects of T3 on ACCα transcription (226).

B) Sterol Regulatory Element Binding Protein

1) Structure and function
Sterol regulatory element binding proteins (SREBPs) belong to a large class of
transcription factors that contain a basic helix-loop-helix-leucine zipper domain (bHLHZIP). SREBPs are synthesized as 125 kDa membrane-bound precursors of ~1150 amino
4

acids that require cleavage by a two-step proteolytic process in order to release an Nterminal fragment that binds DNA and is transcriptionally active (22). Each SREBP
precursor is organized into three domains. The first domain is the N-terminal segment,
comprised of about 480 amino acids that contains the bHLH-ZIP and which binds DNA.
The second domain is composed of two hydrophobic transmembrane-spanning segments
interrupted by a short loop of about 30 amino acids that projects into the lumen of the
endoplasmic reticulum (ER). The third domain of 590 amino acids is the C-terminal
segment of the protein and plays a role in the regulation of cleavage (22, 149).
To date, three isoforms of SREBP have been identified. SREBP-1a and SREBP1c are produced from the same gene. They contain differences in their N-terminal region
due to the use of alternative promoters and first exons (73). SREBP-2 is derived from a
gene distinct from SREBP-1 (74). Most cells in culture express both SREBP-1a and
SREBP-2. SREBP-1c is the predominant form of SREBP-1 expressed in liver and
adipose tissue (182). In chickens, only one form of SREBP-1 has been identified and this
form more closely resembles the mammalian SREBP-1a (7).

2) Activation of SREBP via proteolytic processing
The precursor form of SREBP is anchored to the endoplasmic reticulum (ER). In
order for SREBP to enter the nucleus and function as a transcription factor, it must
undergo a cleavage resulting in the release of the N-terminal fragment from the
endoplasmic reticulum. Three proteins are required for SREBP processing. One is an
escort protein designated SREBP cleavage-activating protein (SCAP). The other two are
proteases, designated Site-1 protease (S1P) and Site-2 protease (S2P). SREBP is
synthesized and inserted into the membrane of the endoplasmic reticulum, where its Cterminal regulatory domain binds to the C-terminal domain of SCAP. SCAP is both an
escort for SREBPs and a sensor of sterols. When cells become depleted in cholesterol,
SCAP escorts SREBP from the ER to the Golgi, where S1P and S2P are present (41, 177,
178). In the Golgi, S1P, a membrane-bound serine protease, cleaves the SREBP in the
luminal loop between its two membrane-spanning segments, dividing the SREBP
molecule roughly in half. The N-terminal bHLH-Zip domain is then released from the
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membrane after a second cleavage by S2P, a membrane-bound zinc metalloproteinase.
The N-terminal fragment, referred to as mature SREBP, is transported into the nucleus,
where it activates transcription by binding nonpalindromic sterol response elements
(SREs) (93, 128) in the promoter/enhancer regions of genes involved in cholesterol and
triacylglycerol synthesis (41, 176).
When the cholesterol content of cells rises, SCAP senses the excess cholesterol
through its membranous sterol-sensing domain, causing a conformational change such
that the SCAP/SREBP complex is no longer incorporated into endoplasmic reticulum
transport vesicles. This results in SREBPs losing their access to S1P and S2P in the
Golgi. The active, N-terminal fragment is not released from the ER membrane, and
transcription of target genes is inhibited (70).
Recently, an endoplasmic reticulum protein was identified that binds to the sterolsensing domain of SCAP only in the presence of sterols. This protein, referred to as
insulin induced gene-1 (INSIG-1), is required for retention of the SCAP/SREBP complex
in the ER in the presence of sterols. Sterols induce binding of SCAP to INSIG-1, and this
interaction is correlated with the inhibition of SCAP exit from the ER. When sterol
levels in the cell are high, the sterols bind to SCAP and facilitate the binding of SCAP to
INSIG-1. The SCAP-INSIG-1 complex then binds to SREBP and facilitates retention of
SREBP in the ER. Interestingly, expression of INSIG-1 is dependent on the presence of
mature SREBP, and thus constitutes an autoregulatory loop in the regulation of mature
SREBP production (45, 80, 223). When sterol levels are high, mature SREBP levels are
decreased and hence INSIG-1 levels decrease. On the other hand, when sterol levels are
low, mature SREBP levels are increased which in turn increase the INSIG-1 gene
expression which in turn inhibit mature SREBP production.
Recently, a second ER protein, referred to as INSIG-2, has been identified that
functions in a manner similar to that of INSIG-1 except for two differences. First,
expression of INSIG-2 is not dependent on the presence of mature SREBP. Second,
INSIG-2 requires the presence of sterols in order to retain the SCAP-SREBP complex in
the ER (219, 220). Three point mutations in the sterol sensing domain of SCAP,
(L315F), (D443N) and (Y298C), prevent sterol-induced binding of SCAP to INSIG-1
and -2 and abolish feedback inhibition of SREBP processing by sterols (221). The
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combined actions of INSIG-1 and INSIG-2 may allow for fine-tuning of SREBP
processing under conditions of widely varying sterol demand and supply.

3) Regulation of transcription by SREBP
The SREBP target genes include enzymes of cholesterol biosynthesis such as
HMG-CoA reductase, HMG-CoA synthase, farnesyl diphosphate synthase, squalene
synthase, and SREBP-2. Each of these genes contains a SRE or SRE-like sequence in its
promoter. SREBPs also bind to regulatory sequences in the promoters of the genes
involved in the biosynthesis of triacylglycerols such as acetyl-CoA carboxylase, fatty
acid synthase, and stearoyl-CoA desaturase (41, 93, 128, 176).
Results of studies employing transgenic mice indicate SREBP-2 is more effective
in regulating genes involved in cholesterol synthesis, whereas SREBP-1 is more effective
in controlling genes involved in triacylglycerol synthesis. The mechanism for the
specificity of the two forms of SREBP is currently unknown. SREBP-1a is more
effective than SREBP-1c in modulating transcription due to the shorter acidic
transactivation domain of the latter protein (146, 184). In liver and adipose tissue
SREBP-1c binds to the promoters of several lipogenic enzyme genes and increases their
expression. In transgenic mice that lack the SREBP-1 gene, the effects of high
carbohydrate feeding on lipogenic enzyme expression are abolished (117, 184). Also, in
transgenic mice overexpressing SREBP-1c in the liver, rate of lipogenesis and lipogenic
enzyme expression are dramatically increased (71, 183).

4) Regulation of SREBP activity
a) Activation of SREBP transcription
Transcription of SREBP-1 but not SREBP-2, is dramatically increased by high
carbohydrate feeding. In rat and chick hepatocyte cultures, diet induced changes in
SREBP-1 transcription are mimicked by altering the concentration of insulin, T3 and
glucagon in the culture medium. Insulin and T3 increase SREBP-1 expression, whereas
glucagon has the opposite effect (48, 235).
LXR agonists have also been shown to stimulate SREBP-1 transcription. This
effect is mediated by a LXRE in the SREBP promoter. LXR agonist-induced activation
7

of SREBP-1c transcription is associated with an increase in mature SREBP-1c levels and
lipogenic enzyme expression (150, 228). A similar observation has been made in chick
hepatocytes. Thus, LXR agonists can stimulate lipogenic genes, at least in part, by
altering the expression of SREBP-1.

b) Inhibition of SREBP-1 expression
Long chain polyunsaturated fatty acids have been shown to suppress the insulininduced SREBP-1 expression in rat hepatocytes. This effect is mediated by a decrease in
transcription of SREBP-1 gene, as well as an enhanced turnover of the SREBP-1 mRNA
(145, 218). Previous work in our laboratory has shown hexanoate inhibits ACCα
transcription, in part, by repressing the ability of insulin and T3 to increase SREBP-1
mRNA abundance in chicken embryo hepatocytes. This effect disrupts the positive
interaction between SREBP-1 and T3 bound TR on the ACCα gene previously identified
by our laboratory (235). Data from our preliminary studies show that hexanoate
decreases the mRNA expression of SREBP-1. These data suggest that fatty acid
inhibition of SREBP-1 expression in rat and chicken hepatocytes may occur through a
similar mechanism. cAMP inhibits SREBP-1 expression in chicken embryo hepatocytes
via a mechanism not involving changes in SREBP-1 mRNA abundance (235).

5) Post translational regulation of SREBP activity
Sumoylation of SREBP-1 has been shown to control SREBP-1 activity. SUMO-1
is a protein responsible for posttranslational modification of many proteins and has a
remarkably similar secondary structure to ubiquitin. Most proteins are sumoylated by a
multi-step process. SUMO-1 target proteins include several transcription factors and
regulate protein function through changes in protein-protein interactions and by
stabilizing the target proteins. Recent work has shown that SREBP-1 and -2 have two
and one major sumoylation sites respectively. Sumoylation decreases the transcriptional
activity of both SREBP-1 and –2 resulting in the decrease of expression of their target
genes (68).
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SREBP-1 activity is also regulated by phosphorylation. Previous work has shown
that SREBPs are substrates for Erk1 and Erk2 in vitro. Phosphorylation of serine 117 of
SREBP-1a by ERK induces a conformational change resulting in an increase in
transcriptional activity of SREBP-1a (170). SREBP-1a, -1c, and -2 are ubiquitinated and
degraded by the 26S proteasome pathway. Phosphorylation of Thr426 and Ser430 in the
424TLTTPPPSD motif in SREBP-1a corresponds to Thr393 and Ser399 in SREBP-1c.
Phosphorylation of the TLTTPPPSD motif by Gsk3β promotes binding of the ubiquitin
ligase, SCFFbw7, which targets SREBP for 26S proteasomal degradation. Inhibition of
Gsk3β activity by LiCl or insulin promotes the accumulation of SREBP. Insulin inhibits
Gsk3β activity by increasing the Akt-mediated phosphorylation of Gsk3β at Ser9 (191),
(95). n-3 polyunsaturated fatty acids (PUFAs) decrease the mature, active form of
SREBP-1 in primary rat hepatocytes through 26S proteasome and Erk-dependent
pathways. Specific inhibitors of these pathways attenuate the inhibitory effect of PUFA
on mature SREBP-1 levels (15). The mechanisms by which Erk phosphorylation, and
26S proteasomal mediate degradation of mature SREBP-1 are yet to be identified.

C) Liver X Receptors
1) Structure and Function
Liver X receptors (LXRs) were first identified as orphan members of the nuclear
receptor superfamily (212). Two members of the LXR family have been identified:
LXRα (also known as RD-1) and LXRβ (also known as UR, NER, OR-1 and RIP15)
(196, 212). Both LXRα and LXRβ are involved in the control of cholesterol and fatty
acid metabolism (25),(126),(169),(166),(34),(106). The expression patterns of the two
LXR proteins differ significantly. LXRα in adult animals is predominantly expressed in
tissues that are known to play important roles in lipid metabolism. The highest levels are
found in the liver (hence the name liver X receptor), kidney, small intestine, spleen,
adipose tissue, pituitary and adrenals. In contrast, expression of LXRβ is much more
widespread; and it is found in almost every tissue examined, including liver and brain
(167),(33). As is the case with other non-steroid nuclear receptors, the majority of LXR
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proteins are localized in the nucleus and require heterodimerization with the retinoid X
receptor (RXR) in order to bind DNA and regulate transcription (82, 212).
Three structural domains comprise LXRs. An N-terminal domain contains a
strong transcriptional activation function (AF1) that is important for cell and target gene
specificity. A highly conserved DNA binding domain (DBD) is contained in the more
central region of the receptor and is characterized by two C4-type zinc fingers. The Cterminal region of the receptor contains the ligand binding domain (LBD), and a ligandregulated transcriptional activation function (AF2). This LXR domain also mediates the
recruitment of transcriptional co-regulatory proteins. The structural domains of LXR are
observed in other members of the nuclear hormone receptor superfamily (52, 130, 192).

2) Identification of ligands of LXR
A major breakthrough in elucidating the physiological role of the LXR was the
finding that oxysterols serve as their ligands. The best studied and the most potent
activators to date are a specific group of mono-oxidized derivatives of cholesterol that
include, 24(S)-hydroxycholesterol, 22(R)-hydroxycholesterol and 24(S) epoxycholesterol
(82, 212). All of the activators analyzed thus far are able to activate both LXRα and
LXRβ. The compounds elicit a response at concentrations observed in LXR target
tissues. 24(S), 25-epoxycholestrol, one of the most potent LXR ligands to be
characterized, is known to be present at concentrations of 1-5 μM in human and murine
liver where LXRα expression is the highest. 22(R)-hydroxycholesterol is found at
micromolar concentrations in the placenta, where LXRβ expression is high. Levels of
24(S)-hydroxycholesterol are high in the brain, adrenals and liver. The binding affinities
of these oxysterols (Kd = 70-900 nM) correlates with their ability to activate LXRmediated transcription in vivo (81-83, 112).
Fluorescence polarization-based screening assays have led to the identification of
non-steroidal LXR ligands that may be used as drugs in preventing and treating
atherosclerosis. In this assay, the recruitment of a rhodamine-labeled coactivator peptide
fragment to LXR is used to assess the binding of ligand to LXR. This coactivator peptide
fragment contains a LXXLL motif, (where L is leucine and X is any amino acid) that has
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been shown to interact with LXR in an agonist-dependent manner. Screening a chemical
library using this assay has led to the identification of T0-314407 (N-methyl-N-[4-(2, 2,
2-trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl] benzene sulfonamide). A
derivative of T0-314407 that exhibited enhanced selectivity was developed by structureactivity relationship studies. This compound was referred to as T0-901317 (N-(2,2,2trifluoro-ethyl)-N-[4-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl]benzenesulfonamide). T0-901317 also exhibited a greater potency than endogenous
oxysterol ligands in stimulating transcription (49, 82, 112, 179).

3) Biological Actions of LXR
LXR•RXR heterodimers regulate target genes by binding to specific DNA
sequences referred to as LXR response elements (LXREs). LXREs are usually
comprised of a direct repeat of two hexanucleotide half sites separated by a 4 bp spacer
(212). In addition to being activated by oxysterols, LXR•RXR heterodimers have been
shown to be activated by ligands of RXR such as 9-cis retinoic acid (9-cis RA) (6, 107).
LXR agonists stimulate multiple processes controlling cholesterol export from the
body. For example, LXR agonists cause an increase in expression of genes encoding
apolipoprotein E (apo E) and cholesterol transporters ABCA1 and ABCG1 (125). Apo E,
ABCA1 and ABCG1 are involved in cholesterol efflux to HDL, a critical component of
the reverse cholesterol transport pathway (54, 111, 123, 169). In liver, LXR agonists also
activate the transcription of cholesterol 7 alpha hydroxylase (CYP7A1), which encodes
the pace setting enzyme catalyzing the conversion of cholesterol to bile acids (150). Bile
acid formation is the primary pathway of cholesterol excretion from the body. LXR
activation also increases expression of hepatic transporters involved in biliary cholesterol
excretion such as ABCG5 and ABCG8. The oxysterol mediated increase in expression of
ABCA1, ABCG5 and ABCG8 in the small intestine reduces the efficiency of cholesterol
absorption by accelerating cholesterol efflux into the intestinal lumen (12). Another
protein induced by LXR agonists is cholesterol ester transfer protein (CETP). CETP
catalyzes the transfer of cholesterol ester from HDL to chylomicrons and very low
density lipoproteins (VLDL), thus facilitating cholesterol transport to the liver. The
mechanism for the effects of LXR agonists on transcription of genes involved in
cholesterol export is mediated by the activation of LXR•RXR heterodimers bound to the
11

promoter/regulatory region (133). The effects of LXR agonists on processes controlling
cholesterol export result in a reduction in blood cholesterol levels and increase in HDL
formation. Interestingly, administration of GW3965, another synthetic LXR agonist, has
been shown to not only prevent but also reverse atherosclerotic lesions in the aorta of
mice lacking the LDL receptor and apo E gene (87).
In addition to controlling cholesterol metabolism, LXR regulates the de novo
synthesis of fatty acids. LXR agonists increase the expression of SREBP-1c (38, 228), a
transcription factor that stimulates transcription of various lipogenic genes including
ACCα, FAS and stearoyl CoA desaturase (SCD) (42, 90, 144). Thus LXR agonists may
stimulate transcription of lipogenic genes via an indirect mechanism involving the
activation of SREBP-1 expression. LXR agonists may also stimulate lipogenesis via a
direct mechanism as LXREs have also been identified in the genes for ACCα, FAS and
SCD. Increased lipogenesis caused by LXR agonists results in the development of fatty
liver. This phenomenon has limited the use of these agents for the treatment and
prevention of atherosclerosis.
A second potent and selective LXR agonist identified by fluorescence polarization
screening is GW3965. Oral administration of the synthetic LXR agonist, T0901317, to
mice lacking the LDL receptor or apolipoprotein E stimulates an increase in blood HDL
levels and reverses the formation of atherosclerotic lesions in the aorta (194), (87). Oral
administration of GW3965 to mice increased plasma HDL concentration (87). Recently,
another synthetic ligand for LXR, termed LN6500, has been identified, that will be
discussed later in this section (2). As T0-901317 is commercially available, we are using
this compound in our studies analyzing the regulation of ACCα by the LXR pathway.
The role of LXR agonists in glucose homeostasis has been studied in rodent
models of diabetes. T0-901317 lowered plasma glucose level in both db/db and Zucker
diabetic fatty (ZDF) rat models in a dose dependent manner. In the fa/fa insulin-resistant
rat model, T0-901317 significantly improved insulin sensitivity. The low plasma glucose
levels were due to a dramatic inhibition of PEPCK mRNA transcription. Further studies
in primary hepatocytes have shown that hepatic activation of LXRs is sufficient to
mediate the inhibition of gluconeogenic pathway (26).
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Moreover, GW3965 improves glucose tolerance in a murine model of dietinduced obesity and insulin resistance. Activation of LXR in mouse liver inhibits
gluconeogenic pathway by inhibiting the expression of peroxisome proliferator-activated
receptor gamma coactivator-1α (PGC-1α), phosphoenolpyruvate carboxykinase
(PEPCK), and glucose-6-phosphatase. In contrast, LXR agonists promote hepatic
glucose utilization by increased expression of glucokinase. Activation of LXR in adipose
tissue, increases transcription of the insulin-sensitive glucose transporter, GLUT4, which
is a direct transcriptional target for the LXR•RXR heterodimers. In LXR null cells and
intact animals, the ability of LXR agonists to induce GLUT4 expression is abolished
(105). These results suggest a major role for LXRs in the coordination of lipid and
glucose metabolism.
Recently there is compelling evidence showing an important link between
cholesterol and Alzheimer's disease. Vascular risk factors such as high total plasma
cholesterol, particularly low density lipoprotein (LDL) cholesterol, influence the
progression or the incidence of Alzheimer's disease (21, 96, 97, 114, 213). In contrast,
plasma high density lipoprotein (HDL) cholesterol are inversely associated with
cardiovascular disease (92) and Alzheimer's disease (14, 135). Oxysterols decrease
amyloid beta (A beta) secretion in vitro. This effect is primarily due to the increase in
ABCA1 by LXRs. T0-901317 applied to a variety of in vitro models, including
immortalized fibroblasts from Tangier patients, and primary embryonic mouse neurons
and Alzheimer disease mouse model (APP23 transgenic mice) caused a concentrationdependent decrease in A beta secretion (101).

4) Regulation of LXR activity
Several distinct pathways have been identified that modulate LXR transcription
activity. One such pathway involves small heterodimer partner (SHP), an unusual
member of the nuclear hormone receptor superfamily. SHP lacks the typical DNA
binding domain observed in most nuclear hormone receptors. SHP has been shown to
interact with LXR and other nuclear hormone receptors. In transient transfection assays,
overexpression of SHP inhibits LXR activation of ABCA1 transcription. Bile acids have
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been shown to stimulate SHP expression in human intestinal cell lines. This phenomenon
has been proposed as a mechanism for the inhibitory effects of bile acids on the
expression of the LXR target, ABCG1 (20).
Another mechanism by which LXR activity is inhibited is by competition for the
binding of oxysterols to the receptor. Many compounds antagonize the binding of LXR
agonists. For example, polyunsaturated fatty acids (PUFAs) antagonize the binding of
oxysterols to LXRα in hepatoma cells with arachidonic acid being the most potent,
followed by linoleic and oleic acids, whereas saturated fatty acids have no effect. PUFAs
also interfere with LXR•RXR binding to LXREs. PUFAs are natural agonists for
peroxisome proliferator activated nuclear receptors (PPARs). Ligand-activated PPAR
induces transcription of LXRα gene through a PPAR response element (145, 229). Thus
PUFAs may potentially induce LXRα levels in cells while inhibiting LXRα binding of
activating ligands such as oxysterols. Evidence that PUFAs are physiological regulators
of LXR signaling is currently lacking.
Recently, the hypolipidemic agent, fenofibrate, has been shown to repress LXRactivation of lipogenic gene expression in hepatocytes. Fenofibrate binds directly to the
LXR ligand binding domain, and displaces a naturally occurring LXR ligand.
Interestingly, the antagonistic effects of fenofibrate on LXR signaling are gene specific.
Fenofibrate inhibits LXR activation of lipogenic genes (ACCα, FAS, SREBP), but has no
effect on LXR activation of ABCA1. Fenofibrate could induce distinct structural
changes in LXR that influence its ability to interact with other proteins, such as
transcription factors residing at selective target gene promoters or with coactivators or
corepressors that are critical for target gene regulation (47, 147, 197).
Data from our laboratory have shown that bile acids (chenodeoxycholic acid)
inhibit the T0-901317-induced expression of lipogenic genes. Interestingly,
chenodeoxycholic acid enhances T0-901317-induced expression of ABCA1. Thus, the
action of CDCA on LXR-induced gene expression is similar to that of fenofibrate in that
it is gene-specific. Currently, there is no evidence that CDCA or metabolites of CDCA
directly interact with LXR.
Another protein, PGC-1α has been shown to act as a coactivator for the LXRα.
More will be discussed about PGC-1α and LXR interactions later in this Chapter.
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Previous work has shown that the selective, potent and orally active LXR agonist,
GW4064, enhances the recruitment of SRC-1 to human LXRα in vitro (51, 76). Studies
have shown that LXRs interact with corepressors such as N-CoR (nuclear receptor
corepressor) and SMRT (silent mediator of retinoic acid receptor and thyroid receptor), in
the absence of LXR agonists and that ectopic expression of N-CoR represses
transcription directed by LXR. Chromatin immunoprecipitation (ChIP) experiments have
demonstrated that N-CoR is recruited to endogenous LXR target genes and that addition
of LXR agonists releases N-CoR (72, 203). Thus, to develop LXR ligands as drugs for
the treatment of atherosclerosis, partial, selective activators of LXRs are needed that
induce cholesterol efflux in macrophages but do not induce fatty acid synthesis in liver.
Among the currently known ligands for LXRs, some compounds, such as the
T0901317, have a purely agonistic activity, whereas others, such as GW3965, have been
reported to be more selective in their activation of LXR function (162, 179). Based on
structural data, it has been predicted that cofactor interactions induced by T0901317 and
a natural ligand would differ from each other (211). For drug development, partial and
selective agonists are desired, which activate the target receptors in a tissue-specific
manner. For example, tamoxifen and raloxifen have been shown to activate the estrogen
receptor in a tissue-specific manner (134). Responses to raloxifen and tamoxifen are
sensitive to the amount of coactivators and corepressors in a cell. Thus availability or
changes of coactivators or corepressors are responsible for variable degrees of agonism or
antagonism of these agents. These studies have led to the hypothesis that relative
availability of corepressors and coactivators in a cell determines the agonistic or
antagonistic behavior of partial agonists (186). According to the model, a variety of
conformations can be adopted by the receptor between the two extremes of a purely
antagonistic state and a purely agonistic state (187). Partial agonists would induce
conformations that are to be placed in intermediate positions between the two extreme
states.
The different conformations that LXRα can adopt goes beyond a linear scale. For
example, GW3965 increases binding of LXRα to coactivators comparably to T0901317,
but there is a dramatic difference on corepressor binding. On the other hand, GW3965
and LN6500 have similar effects on corepressor binding, but LN6500 increases
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coactivator binding more than that of GW3965. Thus, the hypothesis that availability of
corepressors and coactivators in a cell determines the agonistic or antagonistic behavior of
partial agonists, can be modified as follows. In addition to the two extremes on the linear
scale of pure agonists and pure antagonists the following conformations are also possible
(a) induction of corepressor and coactivator binding simultaneously; (b) partial induction
of coactivator binding without induction of corepressor binding; (c) partial induction of
both coactivator and repressor binding; and (d) inhibition of the binding of any cofactor,
that results in derepression. This phenomenon described in (d) has been demonstrated in
LXR-knockout mice (203).
The fundamental problem for using LXR pathway as drug targets is that in
addition to preventing the formation of atherosclerotic plaque by increasing HDL, LXR
agonists increase serum and liver triglyceride levels. Recently, GW3965 has been shown
to have a weaker effect on increase in triglyceride levels in mice than T0901317 (136).
This provides a good example of partial agonism as described above. Moreover, LN6500
has a weaker agonistic property than GW3965 (2). These observations suggest
alterations in coactivator or corepressor recruitment to LXR is a possible mechanism
controlling LXR transcriptional activity. T0-901317 and bile acids may regulate ACCα
transcription in hepatocytes by modulating the recruitment of coactivators and
corepressors to the ACCα gene.

D) Regulation of gene expression by bile acids
Bile acids, derived from cholesterol, are physiologically important amphipathic
molecules that perform several functions in lipid physiology. First, their synthesis
provides a disposal mechanism to counterbalance cholesterol synthesis and allow
homeostasis to be achieved. Second, their detergent actions are essential in the intestine
for the uptake of hydrophobic nutrients such as triacylglycerols and fat-soluble vitamins
and in the liver for the solubilization of metabolites such as bilirubin. Third,
intermediates and end products of the bile acid pathway regulate the expression of genes
involved in the synthesis of cholesterol, fatty acids, and bile acids themselves.
Cholesterol is oxidized to oxysterols that, in turn, increase expression of bile acid
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synthesis via LXR-mediated stimulation of cholesterol 7 alpha hydroxylase (CYP7A1),
which catalyzes the first and rate-limiting step in the classical bile acid synthetic
pathway, transcription in liver. To prevent the accumulation of potentially harmful levels
of bile acids, a feedback regulatory system that controls expression of CYP7A1 has
evolved. This system is initiated by the binding of bile acids to the farnesoid X receptor
(FXR), a member of the nuclear hormone receptor superfamily (56). Chenodeoxycholic
acid (CDCA) is the most potent natural ligand of FXR (19).

1) Structure and function of bile acids
There are several bile acids that function differently in a physiological context.
This strongly suggests that diversity of the side chains that lead to minor structural
differences of bile acids may lead to their specificity of action. For example, CDCA is
the most potent physiological ligand of FXR, but its 7β-epimer, ursodeoxycholic acid
(UDCA), has no effect on CYP7A1 in vivo and does not activate FXR (129, 148, 189).
Relative hydrophobicities of bile acids are a primary determinant of the biological
properties (175). As bile acids function as detergents to solubilize fat, it has been
reported that hydrophobic bile acids have a greater capacity to perturb the structure and
partly digest cell membranes (175, 202). Powell et. al. have determined the
hydrophobicity of different bile acids arranged in decreasing order of hydrophobicity as
follows; DCA>CDCA>HDCA>UDCA>CA (154). DCA and CDCA induce apoptosis
very rapidly in colon cancer cell lines via induction of protein kinase-C (PKC) and
activator protein-1 (AP-1) (159). However, moderately hydrophobic bile acids such as
HDCA also induce apoptosis, although at later time points (154). In contrast,
ursodeoxycholic acid (UDCA), a less hydrophobic stereoisomer of CDCA, inhibits
proliferation in colon cancer cell lines (64, 77). Hydrophobicity of bile acids facilitates
solubilization and crossing the cell membrane. Hepatocytes contain transmembrane bile
acid transport proteins and bile acid nuclear receptors, thus elevated bile acid levels result
in the activation of signaling pathways by binding directly to intracellular components
(129, 148). These examples suggest that one of the major determinants of bile acid
action and specificity is a measure of its hydrophobicity.
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2) Bile acids and gene regulation
Bile acids decrease expression of the CYP7A1 gene through multiple pathways.
One pathway involves the induction of the repressor, short heterodimeric partner (SHP),
by ligand-activated FXR (56, 124). Increased SHP levels inhibit the CYP7A1 promoter
via interaction with the positive acting transcription factor, LRH. In support of this
regulatory pathway, FXR knockout mice exhibit markedly reduced levels of SHP and
bile acid regulation of CYP7A1. Recent studies have shown that bile acids also inhibit
transcription by causing dissociation of coactivators from the promoter of genes (89).
For a long time bile acids have been shown to have an inverse correlation with
triglyceride levels. For example, humans with cholesterol gallstones treated with the bile
acid chenodeoxycholic acid (CDCA) has been shown to reduce hypertriglyceridemia (5,
10, 28). Disruption in the sterol 27-hydroxylase gene in mice leads to a decrease in
hepatic bile acid pool size that is associated with an increase in CYP7A activity and an
increase in SREBP-1 and SREBP-2 expression that is associated with an increase in
cholesterol synthesis and lipogenic gene expression (168). Mice lacking FXR exhibit
elevated levels of serum and hepatic triacylglycerol and cholesterol suggesting a role for
FXR in maintaining lipid homeostasis (185, 207). Disruption of the CYP7A1 gene in
mice causes a reduction in bile acid synthesis and bile acid pool size that is associated
with hypertriglyceridemia and treatment of these mice with a synthetic FXR agonist
causes a reduction of plasma triacylglycerols (158). Treatment of wild type mice with a
synthetic FXR agonist causes a reduction in hepatic SREBP-1 levels (207).
Recently, a novel G-protein coupled receptor (GPCR) has been identified that is
referred to as TGR5. TGR5 functions as a cell surface receptor that binds bile acids as
agonists. The primary structure of the TGR5 receptors and their responsiveness to bile
acids are highly conserved in human, bovine, rabbit, rat, and mouse. TGR5 mRNA is
present in the placenta, spleen, and monocytes/macrophages, whereas the nuclear
receptors are mainly expressed in the liver, kidney, and intestine (91, 129, 148).
Treatment of CHO cells that express TGR5 increased ERK and cAMP production (91).
An increase in cAMP levels as a second messenger is a classic response of GPCRs.

18

Moreover, NIH 3T3 murine fibroblasts expressing human muscarinic acetylcholine
receptors GPCRs increase the activity of ERK5, p38α, p38γ, and p38δ, that results in the
activation of the c-jun promoter (131).
Another pathway involves Kupffer cells that act as sensors of concentration of
bile acids in the liver via enterohepatic circulation (138). Bile acids increase the
expression of inflammatory cytokines such as tumor necrosis factor-α (TNFα) and
interleukin (IL-1β) that are subsequently secreted into the sinusoids as a result of
interaction with macrophages. These cytokines are recognized by high affinity receptors
on hepatic parenchymal cells, that activate protein kinase-C (PKC) (152) and c-jun Nterminal kinase (JNK) to inhibit expression of CYP7A1 (36, 138). Activation of PKC
has been shown to increase Mg2+ accumulation in hepatocytes via ERK and p38 MAPK
(199).
In addition to activating PKC, bile acids modulate gene expression signaling
cascades such as p53 (160), ERK and p38 (159, 161), phosphatidylinositol 3-kinase
(PI3K) (174), and the activator protein-1 (AP-1) transcription factor (159). CDCA
increases low density lipoprotein receptor (LDLr) gene expression via ERK activationmediated stabilization of LDLr mRNA via activating SHP (140). These authors reported
that ursodeoxycholic acid (UDCA) had no effect on LDLr and SHP mRNA. These
results suggested that the structural difference between CDCA and UDCA, specifically
the 7β-hydroxy epimer of CDCA, is critical for the activation of ERK and binding to
FXR (129, 148). Lithocholic acid (LCA), a weak activator of FXR, is a potent inducer of
LDLr via a robust activation of ERK. However, UDCA had no effect on the activation of
ERK (18). Octyl β-D-glucopyranoside, a non-ionic and non-cytolytic membrane
detergent had no effect on ERK activity (132). These results provide further evidence
that bile acids activate MAP kinases in a specific manner, not by their detergent effects,
but by specific side chain residues and three-dimensional structure.
Administration of bile acids increases energy expenditure in brown adipose tissue,
preventing obesity and insulin resistance in mice. This effect is mediated by an induction
of the cyclic-AMP-dependent thyroid hormone activating enzyme type 2 iodothyronine
deiodinase (D2). Treatment of brown adipocytes and human skeletal myocytes with bile
acids increases D2 activity and oxygen consumption. These effects are independent of
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FXR, and are mediated by increased cAMP production from the binding of bile acids
with TGR5 (206).
Recently, it has been shown that increased bile acid levels accelerate liver
regeneration, and decreased bile acid levels inhibit liver regrowth. This finding is
supported by the fact that FXR null mice inhibit liver regeneration. Therefore FXR, and
possibly other nuclear receptors, may promote homeostasis not only by regulating
expression of appropriate metabolic target genes but also by driving homeotrophic liver
growth (75). The effects of bile acids on liver regeneration can be further accounted for
by the fact that taurochenodeoxycholic acid (TCDCA), but not glycochenodeoxycholic
acid (GCDCA), activates phosphatidylinositol 3-kinase (PI3K)-mediated survival
pathway in isolated, perfused rat livers. TCDCA moderately induced hepatic injury by
stimulating apoptosis as opposed to GCDCA, that causes a more severe liver injury. It
has been shown that TCDCA increases the PI3K pathway more robustly than GCDCA,
thus accounting for the relative moderate effects of TCDCA on liver injury. Inhibitors of
the PI3 kinase pathway, such as wortmannin, reversed the effects of TCDCA and
GCDCA on liver injury, in that TCDCA resulted in a more severe liver injury and
GCDCA had a far lesser injury. These results showed that TCDCA block its toxic effect
in intact liver, by activating the PI3K dependent survival pathway (174). Another recent
report showed that a relatively hydrophilic bile acid UDCA, protects reperfusion injury of
the heart by activating the PI3K pathway (164). These findings suggest a protective, or
growth promoting role of bile acids. Physiologically, the growth promoting effects of
some bile acids may act to oppose the pro-apoptotic effects of more hydrophobic bile
acids.

3) Bile acids and fibroblast growth factor-19 (FGF-19)
Another pathway mediating bile acid regulation of CYP7A1 expression involves
the fibroblast growth factor 19 (FGF-19). FGF-19 is a member of the fibroblast growth
factor (FGF) family of secreted signaling molecules. FGF-19 is a high affinity ligand for
its receptor, fibroblast growth factor receptor 4 (FGFR4) and is the first member of the
FGF family to show exclusive binding to FGFR4. FGFR4 belongs to the receptor
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tyrosine kinase family of receptors. Bile acids increase the expression of FGF-19 in
human hepatocytes by binding FXR on the FGF-19 gene promoter. Increased FGF-19
levels, in turn, inhibit transcription of CYP7A1 via a mechanism involving the activation
of Jun-N terminal kinase (JNK) signaling pathway (60, 69, 217, 233).
In support of a role of FGF-19 in bile acid regulation of CYP7A1, FGFR4
knockout mice have an elevated bile acid excretion and expression of CYP7A1 (232). In
contrast, transgenic mice expressing a constitutively active form of FGFR4 have
increased JNK activity, decreased CYP7A1 expression, and a reduced bile acid pool size
(231). Transgenic mice overexpressing FGF-19 showed a decrease in fat mass and
increased energy expenditure. These animals overexpressing FGF-19 were resistant to
high fat diet, in that they did not develop obesity or diabetes. Expression of acetyl CoA
carboxylase 2, malic enzyme and stearoyl CoA desaturase in the liver were decreased
along with a decrease in liver triglyceride levels in these animals (198). In humans
Paraoxonase-1 (PON1), an enzyme that metabolizes organophosphate insecticides is
secreted by the liver and transported in the blood complexed to HDL. Bile acids inhibit
the expression of PON1 via increase of FGF-19 (181).
Recently, it has been demonstrated that expression of FGF15, the mouse ortholog
of human FGF19, is induced by FXR agonists in small intestine. FGF15 mediated
inhibition of hepatic bile acid synthesis involves both FGFR4 and SHP (78). We have
shown that bile acids increase FGF-19 mRNA expression in chicken embryo hepatocytes.
Work from our lab by Sushant Bhatnagar has shown that recombinant human FGF-19
inhibits insulin-induced expression of glucokinase and lipogenic genes such as ACC1 and
SCD in primary rat hepatocytes. We hypothesize that inhibition of T0-901317-induced
lipogenic gene expression in chick hepatocytes is mediated by increased FGF-19
expression.
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E) Peroxisome gamma coactivator -1 alpha (PGC-1α)
1) Structure and function
PGC-1α belongs to a small family of transcriptional coactivators that includes
PGC-1β and PGC-1-related coactivator. PGC-1α was first identified as a protein that
interacts with the nuclear hormone receptor PPARγ, that is the regulator of adipocyte
differentiation (157). From structure-function analysis of PGC-1α it has been
demonstrated that the N terminus of the protein consists of a transcriptional activation
domain that includes the nuclear hormone receptor-interacting motif (LXXLL). This
motif mediates ligand-dependent interaction of coactivators with nuclear hormone
receptors. The C-terminal region of PGC-1α consists of an RNA-binding motif (RMM)
and a serine-arginine-rich (RS) domain (4, 62, 102, 119). Transcriptional coactivators are
recruited to particular DNA sequences in promoters of genes through direct interaction
with transcription factors. The LXXLL motif of PGC-1α has been shown to mediate
ligand-dependent interaction with nuclear receptors such as estrogen receptor (ER) (195),
PPARα (200), RXRα (39), and glucocorticoid receptor (GR) (98).

2) PGC-1α and gene regulation
PGC-1α has been shown to be a coactivator for LXRα. In transient transfection
studies, PGC-1α potentiates the LXR-mediated autoregulation and transactivation of the
LXRα promoter via the LXRE on the cholesteryl ester transfer-protein (CETP) gene
promoter in a ligand-dependent manner. As described above, the LXXLL motif of PGC1α is located in the vicinity of the binding region for a putative repressor that will be
described later in this section. The repressor sequesters PGC-1α from PPARα and the
glucocorticoid receptor. However, this repressor does not interfere with PGC-1αmediated coactivation of LXR-dependent gene transcription (142). Previous reports have
shown that p38 MAPK phosphorylates PGC-1α on Thr262, Ser265, and Thr298.
Phosphorylation of PGC-1α on these residues results in increased stability and half-life of
the protein (156). Inhibition of p38 MAP kinase activity had only a moderate inhibitory
effect on LXR coactivation by PGC-1α. Thus PGC-1α has been established as a bona
fide LXR coactivator and suggests the involvement of distinct motifs of PGC-1α and/or
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additional cofactors in the modulation of LXR and PPARα transcriptional activities
(142). Interestingly, HNF4 also interacts with this motif of PGC-1α in the absence of an
agonist, suggesting that this nuclear hormone receptor is in an active conformation even
without the addition of exogenous ligand (227).
Non-LXXLL motifs of PGC-1α also mediate interaction with transcription
factors. For example, a region between amino acids 200 and 400 interacts with PPARγ
(157) and NRF-1 (216) and a region between amino acids 400 to 500 interacts with
MEF2-C (137). Most coactivators increase transcriptional activity by either intrinsic
chromatin remodeling activity, or by recruiting other proteins that have intrinsic
chromatin remodeling activity (53, 139, 190). PGC-1α lacks significant amino acid
sequence homology to other transcriptional coactivator families and it does not possess
intrinsic histone acetyl transferase (HAT) activity. However, the N-terminal domain of
PGC-1α recruits proteins that contain HAT activity, such as SRC-1 and CREB binding
protein CBP/p300 (155). In addition, PGC-1α is also present in a complex that contains
RNA polymerase II.
Interestingly, the binding of SRC-1 and CBP/p300 to the N-terminus of PGC-1α
is dependent upon docking of transcription factors such PPARγ and NRF-1 to the amino
acids 200-400 region of PGC-1α (155). This suggests that PGC-1α is in a relatively
inactive state when not bound to a transcription factor. However, when a transcription
factor binds to PGC-1α, it is activated, and results in a conformation change that recruits
SRC-1 and CBP/p300 into the complex. Thus, transcription factor docking switches on
the activity of PGC-1α. Whether this phenomenon of transcriptional activation via a
transcription factor docking event is a common feature of coactivators remains to be
determined. Transcription factors are targets of multiple signal transduction pathways,
but there is evidence to suggest that coactivators can also be targets of these signaling
pathways in response to hormones, growth factors and ligands. For example,
transcriptional activity of CBP is increased in response to calcium signaling through
calmodulin kinase IV (29). In addition, SRC-1 has been shown to be a target of cAMP
signaling through protein kinase A PKA (172). Therefore, regulation of transcriptional
coactivator function provides a target to integrate different responses to specific signals
across multiple transcription factors.
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As discussed previously, p38 MAPK phosphorylates PGC-1α at three residues
Thr262, Ser265, and Thr298 (156). Phosphorylation of PGC-1α on those residues leads
to increased stability and half-life of PGC-1α. It is interesting that these
phosphorylations occur in a region previously shown to play a regulatory role in PGC-1α
binding to transcription factors. It is unclear whether the p38 MAPK-mediated
phosphorylations affect transcription factor docking or the recruitment of other
coactivator proteins to the PGC-1α complex. It is also unclear as to how these phosphoamino acids change protein stability.
Activation of p38 MAPK leads to an increase in transcriptional activity of PGC1α. In the absence of nuclear hormone receptor, PGC-1α associates with a strong
transcriptional repressor, referred to as p160 myb binding protein (p160MYB), that keeps
PGC-1α in an inactive state. It is unclear whether p160myb by itself is a transcriptional
repressor, or whether it recruits the binding of another repressor on the promoter.
Activation of p38 MAPK phosphorylates PGC-1α that removes p160myb and facilitates
the association of PGC-1α with the nuclear hormone receptor at the transcription site (43,
99). Binding to the nuclear hormone receptor causes a conformational change on PGC1α that helps to stabilize the active state (155). Interestingly, transcriptional activity of
PPARα associated with PGC-1α can be activated via the p38 MAPK pathway (9).
Hepatic nuclear factor-4α (HNF-4α) and PGC-1α are key activators of hepatic
gluconeogenic enzymes such as phosphoenolpyruvate carboxykinase (PEPCK) and
Glucose-6-Phosphatase (G6Pase). These genes are activated during fasting and inhibited
during the fed state. SREBP-1a and -1c inhibited PEPCK promoter activity that was
induced by HNF-4α. Electrophoretic mobility shift assays showed that SREBP-1 did not
bind to the PEPCK promoter, and that the inhibitory effect was more potent in SREBP-1a
than SREBP-1c. This inhibitory effect was abolished by deletion of the amino-terminal
transactivation domain of SREBP-1. SREBP-1 competitively inhibits PGC-1α
recruitment, that is a fundamental requirement for HNF-4α activation. Transgenic mice
overexpressing SREBP-1a and -1c showed an inhibition of hepatic PEPCK and G6Pase
mRNA abundance. These results identify a novel role of SREBP-1 as an inhibitor of
gluconeogenic genes by inhibiting PGC-1α recruitment to HNF-4α (222).
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F) Peroxisome proliferator activated receptor gamma coactivator
-1 beta (PGC-1β)
PGC-1β is a transcriptional coactivator that has been recently identified as a close
member of PGC-1α. The biological activities of PGC-1β are currently unknown (102,
118). The tissue distribution of PGC-1β is similar to that of PGC-1α. However, they are
differentially regulated during development and in response to changes in nutritional
status (88, 118). Recently it has been shown that high fat feeding increases PGC-1β and
SREBP-1a and -1c. PGC-1β has been shown to be a coactivator of SREBP and LXR.
This increase in SREBP-1 and LXR activity increases de novo lipogenesis and
lipoprotein secretion. PGC-1β coactivation of SREBP and LXR by high fat leads to
hypertriglyceridemia and hypercholesterolemia (120).

G) Mitogen activated protein kinases
Mitogen activated protein kinases (MAPKs) consist of a family of protein kinases
that are conserved across species from unicellular organisms to complex organisms
including humans. Protein kinases are enzymes that covalently attach phosphate to Ser,
Thr and Tyr residues on other proteins in the cell. MAPKs phosphorylate Ser and Thr
residues on target proteins that are substrates, and modulate multiple cellular processes
such as gene regulation, mitosis, metabolism and apoptosis. The phosphorylation of
substrate proteins by MAPKs functions as a molecular switch to turn on or turn off the
activity of the target protein that ultimately alter cellular processes. There are several
substrates of MAPKs that modulate multiple functions such as other protein kinases,
transcription factors and phospholipases. Protein phophatases remove the phosphate
attached by MAPKs to inactivate the substrate proteins (165, 209).
MAPKs are part of a signaling cascade comprised of three kinases that are
regulated by phosphorylation. MAPKs are substrates for MAPK kinases (MKKs) that
phosphorylate and activate MAPKs. Specific phosphatases of the MAPKs, remove the
phosphate from the MAPKs and render them inactive. MKKs in turn, are phosphorylated
and activated by MAPK kinase kinases (MKKKs). In multicellular organisms, there are
three conserved and well characterized MAPK families. These include the extracellular
signal-regulated kinases ERK1 and ERK2 (16, 17), the c-Jun N-terminal kinases JNK-1, 25

2 and -3 (63, 104), and p38 MAPKs p38α, p38β, p38γ and p38δ (84, 85, 108, 116, 188).
Recently a fourth MAPK, ERK5 has been identified and is being studied (237).
Additional proteins kinases have been identified during sequencing the human and mouse
genomes that may function as MAPKs, one of them being ERK7, but very little is known
about this protein (1).

1) ERK
Mammalian ERK1/2 MAPKs are referred to as the classical mitogen kinase
cascade, consisting of the MAPKKKs A-Raf, B-Raf, and Raf-1, the MAPKKs MEK1 and
MEK2, and the MAPKs ERK1 and ERK2. ERK1 (44 kD) and -2 (42 kD) have 85%
amino acid identity and are expressed in almost all tissues; however, their relative
distribution in tissues differ widely (31). Both ERK1/2 are activated by a vast number of
ligands and cellular processes with some cell type specificity. Activators of ERK1/2
include serum, growth factors, phorbol esters and to a lesser extent by ligands of the
heterotrimeric G protein-coupled receptors, cytokines and osmotic stress (115). These
agents and events activate ERK pathway by activating receptor tyrosine kinases (RTKs)
on the cell surface and G protein-coupled receptors. Activated RTKs in turn, activate the
Raf/MEK/ERK cascade through different isoforms of the small GTP-binding protein Ras
(24, 214).
ERK1/2 are distributed in almost all cells in the inactive, unphosphorylated state,
but upon activation, a significant population of ERK1/2 accumulates in the nucleus (30,
55, 113). The mechanism of nuclear accumulation of ERK1/2 are unclear; however,
phosphorylation, dimerization, nuclear retention and release from cytoplasmic anchors
are suggested in mediating the effect (153). Since ERK1/2 pathway has been shown to
be a key regulator of cellular proliferation, chemical inhibitors of the ERK pathway are
being tested in clinical trials as potential anticancer agents (100). Two structurally
unrelated compounds, U0126 (44) and PD98059 (3, 40), are commonly used to
specifically inhibit the ERK1/2 pathway in cell culture. The use of these compounds has
been widely validated in the literature in various cell culture systems. Both these
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compounds are noncompetitive inhibitors of MEK1/2/5 and inhibit phosphorylation and
activation of ERK1/2/5 (8).

2) Transcriptional regulation by ERK
ERK1/2 increases the phosphorylation and activation of several downstream
MAPK-activated protein kinases referred to as p90 ribosomal S6 kinases (RSKs)
proteins. The RSK family consists of four human isoforms that share 70% amino acid
similarity. RSK like proteins have also been identified in other species such as
Drosophila, Xenopus, chicken and yeast. These proteins are Ser/Thr kinases that
modulate the activity of target proteins (46, 86, 204).
Activation of the ERK pathway facilitates the interaction between RSK1 and the
transcriptional coactivator CREB-binding protein (CBP) (141). CBP and its paralog p300
facilitate complex formation between different components of the basal transcriptional
machinery. RSK1 interaction with CBP was found to modulate its function, but the exact
outcome of this interaction remains to be determined. Binding of phospho-p90RSK (Pp90RSK) to CBP mediated transcription inhibition of cAMP-responsive genes via the
cAMP-inducible factor CREB. In contrast, formation of the P-p90RSK-CBP complex
was required for increase in transcription of Ras-responsive genes (141, 205).
Interestingly, CBP and p300 have been shown to associate with several transcription
factors also known to be RSK1 and RSK2 substrates, such as c-Fos, c-Jun, ER81, and
NF-κB, suggesting that RSK1 binding to CBP may provide a second mechanism of
transcriptional control (171). It is interesting to note that although both ERK and RSK
accumulate in the nucleus upon activation, it is unclear whether ERK1/2 directly
modulates the activity of proteins. All data so far suggest that RSK proteins mediate the
effects of ERK on target proteins.
Deoxycholic acid (DCA), lithocholic acid (LCA) and CDCA, but not
ursodeoxycholic acid (UDCA), increase the mRNA abundance of the LDL receptor, even
in the presence of a potent inhibitor of the LDL receptor, 25-hydroxycholesterol.
Surprisingly, this increase of the LDL receptor mRNA is not mediated by FXR. CDCA
increased the phosphorylated, active form of ERK, and inhibition of ERK activity by
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U0126 abolished the CDCA-mediated increase of LDL receptor. Thus, CDCA-mediated
increase of ERK stabilizes LDL receptor mRNA and the ERK inhibitor accelerates its
turnover (140).
As discussed previously, ERK has been shown to mediate lipogenic gene
inhibition by inhibiting the mature, transcriptionally active form of SREBP-1 (15). This
is another example by which ERK can inhibit gene transcription. Our studies have
shown that activation of ERK mediates inhibitory effects of CDCA on ACCα mRNA
expression.

3) p38 MAP kinase
The p38 MAPK module consists of the four known p38 isoforms (α, β, γ, and δ),
several MAPKKKs, including MEKKs 1 to 4, the MAPKKs MKK3 and MKK6 (103).
Most stimuli or agents that stimulate JNK pathway also stimulate p38 MAPK. The
functional role of p38 MAPK has largely been determined by using the anti-inflammatory
drug SB203580 (110). SB203580 inhibits p38α, β and β2 (not γ and δ) by competing
with the substrate, ATP (57, 230). While SB203580 inhibits p38 activity, it does not
significantly affect the activation of p38. SB203580 does not inhibit PKA, PKC, MEKs,
MEKKs or ERK and JNK MAPKs (35, 50, 230).
p38 is present in both the nucleus and cytoplasm of cells. The subcellular
localization of p38 MAPK kinase upon cellular stimuli is unclear. On one hand, upon
receiving activation stimuli, p38 MAPK translocates from the cytoplasm to the nucleus
(163), and on the other, active p38 MAPK is also present in the cytoplasm of stimulated
cells (11). p38 MAPK activation in macrophages, neutrophils, and T cells by numerous
extracellular modulators of inflammation mediates normal immune and inflammatory
responses (143). p38 MAPK phosphorylates several cellular targets, including the
transcription factors ATF1 and -2, MEF2A, Sap-1, Elk-1, NF-κB, Ets-1, and p53 (103).

4) Transcriptional regulation by p38 MAPK
Mitogen- and stress-activated kinases 1 and 2 (MSK1 and MSK2) are
downstream substrates of both ERK1/2 and p38α and p38β MAPK. MSKs are
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predominantly located in the nucleus in the inactive state as they contain a C-terminal
nuclear localization signal (NLS). MSK1 and MSK2 phosphorylate and activate CREB
on ser133 in vitro with a significantly lower Km than that of RSK1 and MK2 (37, 151).
This data has been confirmed by data that showed the involvement of MSK1 and -2 in
CREB phosphorylation with different inhibitors (58, 109). MSK1 has been shown to
mediate NF-κB-dependent transcription by phosphorylating the NF-κB isoform p65 on
Ser276 (201). MSK1 has also been shown to phosphorylate and activate other
transcription factors such as ER81 (79) and STAT3 (210, 234).
Hepatic gluconeogenesis is essential for maintaining blood glucose levels during
fasting and is the major contributor to postprandial and fasting hyperglycemia in diabetes.
Glucagon, elevated in the blood during fasting and diabetes increases gluconeogenesis.
Glucagon activates p38 MAPK in primary hepatocytes. Mice treated with the p38
MAPK inhibitor SB203580 reduced fasting plasma glucose levels. Inhibition of p38
MAPK inhibited gluconeogenesis by decreasing the mRNA abundance of gluconeogenic
genes such as phosphoenolpyruvate carboxykinase and glucose-6-phosphatase. PGC-1α
and CREB have been shown to mediate hepatic gluconeogenesis. Inhibition of p38
MAPK decreased PGC-1α and CREB. These results have established a role for p38
MAPK in cAMP-dependent activation of genes involved in gluconeogenesis (27).
Recently, it has been shown that polyunsaturated fatty acids such as arachidonic
acid inhibit the insulin-induced abundance of glucose-6-phosphate dehydrogenase
(G6PD) mRNA in hepatocytes. Arachidonic acid increases phosphorylation and
activation of p38 MAPK that phosphorylates Ser307 residue of insulin receptor substrate
(IRS-1) and inhibits the activity. This inhibition of IRS-1 inhibits activation of phosphorAkt and inhibits insulin signaling (193). As G6PD is a lipogenic gene, this report
suggests a link between activation of p38 MAPK and inhibition of lipogenic genes. Our
data shows that CDCA inhibits ACCα mRNA abundance at least in part, by increasing
the phosphorylation and activation of p38 MAPK.
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5) JNK
Three members have been identified that are referred to as JNK1, JNK2, and
JNK3 (also known as SAPKγ, SAPKα, and SAPKβ, respectively) that are ubiquitously
expressed. Activators of JNK include cytokines, UV irradiation, growth factor
deprivation, DNA-damaging agents, and, to a lesser extent, growth factors, serum and
some G protein-coupled receptors (103). The MAPKKs that phosphorylates and activates
JNK are referred to as MEK4 and MEK7, which are themselves phosphorylated and
activated by several MAPKKKs, that include MEKK1-4, MLK2 and -3 (103). JNKs
relocalize from the cytoplasm to the nucleus following activation (103). The best known
substrate for JNKs is the transcription factor c-Jun. Phosphorylation of c-Jun on ser63
and ser73 by JNK leads to increased c-Jun-dependent transcription (208). Several other
transcription factors have been shown to be phosphorylated by the JNKs, such as ATF-2,
NF-ATc1, HSF-1, and STAT3 (31, 103). It is interesting to note that although some
cytoplasmic targets of JNK are known, the fact that activated JNK does not exhibit
exclusive nuclear localization suggests that many other cytoplasmic substrates remain to
be identified. Interestingly, JNK-activated MKs are unknown.
As discussed above, FGF-19 activates JNK that results in feedback inhibition of
CYP7A. Transcription regulation by JNK has been discussed in Section D 2). Our data
shows that CDCA increases the phosphorylation and activation of JNK in primary
hepatocytes.

H) AMP-activated protein kinase
When cellular AMP:ATP ratio increases, AMP activates a wide range of cellular
processes by binding to AMP-activated protein kinase (AMPK) that activates pathways
that generate ATP while inhibiting pathways that utilize ATP (59). AMP causes an
allosteric activation of AMPK. Binding of AMP makes AMPK a better substrate for
upstream kinases, that phosphorylates AMPK at Thr172. Binding of AMP to AMPK also
inhibits dephosphorylation of Thr172 by phosphatases (59). AMPK is phosphorylated
and activated by its upstream protein kinase, referred to as LKB1 (61, 180, 215).
Phosphorylated and activated AMPK (P-AMPK) inhibits fatty acid synthesis and
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cholesterol biosynthesis and activates catabolic pathways such as fatty acid oxidation,
glucose uptake and glycolysis (59). P-AMPK inhibits lipogenesis by inhibiting SREBP-1
(238). P-AMPK also inhibits the coactivator p300 by phosphorylating the protein at
(Ser89), and inhibiting the binding to nuclear hormone receptors (224). P-AMPK also
phosphorylates and inactivates ACC at Ser79. Phosphorylation of ACC at this residue is
a direct measure of AMPK activity (32, 59).
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ABSTRACT
In avians and mammals, agonists of the liver X receptor (LXR) increase the
expression of enzymes comprising the fatty acid synthesis pathway. Here, we investigate
the mechanism by which the synthetic LXR agonist, T0-901317, increases the
transcription of the acetyl-CoA carboxylase-α (ACCα) gene in chick embryo hepatocyte
cultures. Transfection analyses demonstrate that activation of ACCα transcription by T0901317 is mediated by a cis-acting regulatory unit (-101 to -71 bp) that is comprised of a
LXR response element (LXRE) and a sterol regulatory element (SRE). The SRE
enhances the ability of the LXRE to activate ACCα transcription in the presence of T0901317. Treating hepatocytes with T0-901317 increases the concentration of mature
sterol regulatory element-binding protein-1 (SREBP-1) in the nucleus and the acetylation
of histone H3 and histone H4 at the ACCα LXR response unit. These results indicate
that T0-901317 increases hepatic ACCα transcription by directly activating LXR•
retinoid X receptor (RXR) heterodimers and by increasing the activity of an accessory
transcription factor (SREBP-1) that enhances ligand-induced-LXR•RXR activity. We
also show that T0-901317 treatment decreases LXR•RXR binding and increases nuclear
T3 receptor•RXR binding to the ACCα LXRE. We propose that changes in the binding
of nuclear receptor complexes to the ACCα LXRE limit the activation of ACCα
transcription by T0-901317.

Supplementary keywords: fatty acid synthesis, liver, sterol regulatory element binding
protein, LXR, chicken, histone acetylation
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INTRODUCTION
The first committed step of the fatty acid synthesis pathway is the ATP-dependent
carboxylation of acetyl-CoA to form malonyl-CoA. This reaction, catalyzed by acetylCoA carboxylase-α (ACCα), constitutes a key control point in the synthesis of longchain fatty acids from carbohydrate (1, 2). Malonyl-CoA serves as a donor of C2 units
for the synthesis of palmitate catalyzed by fatty acid synthase. Malonyl-CoA is also a
substrate of specific elongases involved in the chain elongation of fatty acids to very
long-chain fatty acids (3). The essential role of ACCα in lipid biosynthesis has been
confirmed by studies demonstrating that knockout of the ACCα gene disrupts embryonic
development prior to day 7.5 (4).
In lipogenic tissues of avians and mammals, transcription of the ACCα gene is
regulated by nutritional and hormonal factors. For example, ACCα transcription is low
in livers of starved chicks, feeding a high-carbohydrate, low-fat diet stimulates an 11-fold
increase in ACCα transcription (5). Diet-induced changes in ACCα transcription are
mimicked in primary cultures of chick embryo hepatocytes by manipulating the
concentrations of hormones and nutrients in the culture medium (6). Incubating chick
embryo hepatocytes with the active form of thyroid hormone, 3,5’,3-triiodothyronine
(T3), stimulates a 5 to 7-fold increase in ACCα transcription. The mechanism by which
T3 increases ACCα transcription involves multiple processes. First, T3 interacts with the
nuclear T3 receptor (TR) bound to a T3 response element (T3RE) on the more
downstream promoter (promoter 2) of the ACCα gene (7). This T3RE (-101 to -86 bp) is
comprised of two hexameric half-sites arranged as direct repeats with 4 bp separating the
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half-sites (DR-4 element). Second, T3 treatment increases the binding of TR•retinoid X
receptor (RXR) heterodimers to the ACCα T3RE. The mechanism for this effect has not
yet been defined. Third, T3 treatment increases the binding of sterol regulatory elementbinding protein-1 (SREBP-1) to a sterol regulatory element (SRE) (-80 to -71 bp) located
immediately downstream of the ACCα T3RE (8). SREBP-1 directly interacts with
TR•RXR heterodimers and enhances the ability of this complex to activate ACCα
transcription in the presence of T3 (9).
In our studies analyzing the regulation of ACCα transcription by T3, we observed
that the ACCα T3RE not only bound protein complexes containing TR•RXR
heterodimers but also bound protein complexes containing liver X receptor (LXR)•RXR
heterodimers (7). LXRs are nuclear hormone receptors that are bound and activated by
naturally occurring oxysterols (10, 11). Two isoforms of LXR, designated LXRα and
LXRβ, have been identified in avians and mammals. LXRβ is expressed in a wide
variety of tissues, whereas LXRα is selectively expressed in liver, adipose tissue,
intestine, and macrophages (12, 13). LXRs play a key role in regulating cholesterol
excretion by mediating the stimulatory effects of oxysterols on the transcription of genes
involved in reverse cholesterol transport and bile acid synthesis. For example, naturally
occurring oxysterols and synthetic, non steroidal LXR agonists activate the transcription
of a battery of genes involved in cholesterol efflux (ABCA1, ABCG1, ABCG5, and
ABCG8), cholesterol clearance (cholesterol ester transfer protein and apolipoprotein E),
and cholesterol catabolism (cholesterol 7α-hydroxylase) (14-16). For each of these
genes, regulation of transcription by LXR agonists is conferred by a LXR response
element (LXRE) that binds LXR•RXR heterodimers. Because oxysterols are produced in
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proportion to cellular cholesterol content, LXRs have been proposed to function as
sensors in a feed-forward pathway that stimulates reverse cholesterol transport and
cholesterol excretion in response to high cholesterol levels in the diet. Consistent with
this proposal, mice lacking the LXRα and/or LXRβ gene exhibit diminished cholesterol
excretion and elevated cholesterol levels in the blood and liver when fed a highcholesterol diet (17, 18).
The ability of LXR agonists to activate genes involved in cholesterol excretion has
led to an evaluation of the atheroprotective properties of these compounds in murine
models of atherosclerosis. Oral administration of the synthetic LXR ligand/agonist,
T0901317, to mice lacking the LDL receptor or apolipoprotein E causes an increase in
blood HDL levels and reverses the formation of atherosclerotic lesions in the aorta (19,
20). These exciting findings are tempered by the observation that treatment with
T0901317 also causes hypertriglyceridemia and the development of a fatty liver in
rodents and chickens (21-24). These undesired effects of T0901317 are caused by
alterations in the expression of enzymes comprising the fatty acid synthesis pathway. For
example, T0-901317 treatment increases the hepatic expression of the mRNAs encoding
ACCα, fatty acid synthase (FAS), ATP-citrate lyase (ATP-CL), and stearoyl-CoA
desaturase-1 (SCD1) (23-25). The aim of the present study is to determine the
mechanism by which T0-901317 regulates the expression of ACCα in avian liver. We
show that T0-901317 acts directly on the liver to increase the expression of ACCα and
that the extent of this effect is modulated by the presence of insulin and T3. We further
show that T0-901317 increases ACCα transcription by activating LXR•RXR
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heterodimers bound to the ACCα gene and that SREBP-1 interacts with LXR•RXR to
enhance the stimulatory effects of T0-901317 on ACCα transcription.

EXPERIMENTAL PROCEDURES
Cell culture and analytical assays
Hepatocytes were isolated from livers of 19-day-old chick embryos as previously
described (26). Cells were incubated in serum-free Waymouth's medium MD752/1
containing penicillin (60 μg/ml) and streptomycin (100 μg/ml) on untreated petri dishes
at 40°C in a humidified atmosphere of 5% CO2 and 95% air. Hormone and other
additions were as described in the legends of figures. The triacylglycerol concentration
of the culture medium was measured using an enzymatic kit (Sigma).

Isolation of RNA and quantitation of mRNA levels
Medium was removed and RNA was extracted from hepatocytes by the
guanidium thiocyanate/phenol/chloroform method (27). Total RNA (15 µg) was
separated by size in 0.9% agarose, 0.7 M formaldehyde gels, and then transferred to a
Nytran membrane (Schleicher & Schuell) using a Vacuum blotting apparatus (Pharmacia
Biotechnology). The RNA was crosslinked to the membrane by UV and baked at 80°C
for 30-60 min. RNA blots were hybridized with 32P-labeled DNA probes labeled by
random priming (28). Hybridization and washes were as described (29). Membranes
were subjected to storage phosphor autoradiography. Hybridization signals were
quantified using ImageQuant software (Molecular Dynamics). cDNAs for chicken
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ACCα (5), FAS (30), SCD1 (31), SREBP-1 (32), ATP-CL (33), ABCA1 (23), LXR (34),
and malic enzyme (35) have been described.

Plasmids
Reporter plasmids are named by designating the 5' and 3' ends of the ACCα DNA
fragment relative to the transcription start site of promoter 2. A series of 5' deletions and
3' deletions of ACCα promoter 2 in the context of p[ACC-2054/+274]CAT have been
previously described (7). An ACCα promoter construct containing a mutation of the
SRE between -79 and -72 bp in the context of p[ACC-108/+274]CAT has been
previously described in (9). p[ACC-108/-66]TKCAT, p[ACC-84/-66]TKCAT and
pTKCAT constructs containing mutations in the -108 to -66 bp ACCα fragment are
described in (9).

Transient transfection
Chick embryo hepatocytes were transfected as described in Zhang et al (7).
Briefly, cells were isolated and incubated on 60 mm petri dishes. At 6 h of incubation,
the medium was replaced with one containing 10 μg of lipofectin (Invitrogen), 1.5 μg of
p[ACC-2054/+274]CAT or an equimolar amount of another reporter plasmid and
pBluescript KS(+) to bring the total amount of transfected DNA to 1.5 μg per plate. At
18 h of incubation, the transfection medium was replaced with fresh medium with or
without T0-901317 (6 μM). At 66 h of incubation, chick embryo hepatocytes were
harvested, and cell extracts were prepared as described in (36). CAT activity (37) and
protein (38) were assayed by the indicated methods.
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Western blot analysis
Nuclear extracts were prepared from chick embryo hepatocytes as described (9).
The proteins of the nuclear extract were subjected to electrophoresis in 10% SDSpolyacrylamide gels and then transferred to polyvinylidene difluoride membranes
(Millipore) using an electroblotting apparatus (Bio-Rad Laboratories, Hercules, CA).
Immunoblot analysis was carried using a mouse monoclonal antibody against SREBP-1
(IgG-2A4) (American Type Culture Collection, Manassas, VA). Antibody/protein
complexes on blots were detected using enhanced chemiluminescence (Amersham
Biosciences). Chemiluminescence on the blots was visualized using a FluorChem 8000
imager (Alpha Innotech Corporation) and signals for mature form of SREBP-1 were
quantified using FluorChem V200 software.

Gel mobility shift analysis
Nuclear extracts were prepared from hepatocytes incubated with or without T0901317 (9). A double-stranded oligonucleotide containing the ACCα LXRE/T3RE (-108
to -82 bp relative to the transcription initiation site of ACCα promoter 2) was labeled by
filling in overhanging 5’-ends using Klenow fragment of E. coli DNA polymerase in the
presence of [α-32P] dCTP. Binding reactions were carried out as previously described
(7). DNA and DNA-protein complexes were resolved on 6% nondenaturing
polyacrylamide gels at 4 ºC in 50 mM Tris (pH 8.8) and 50 mM glycine. Following
electrophoresis, the gels were dried and subjected to storage phosphor autoradiography.

59

Histone acetylation
The extent of histone acetylation on ACCα promoter 2 was measured using a
chromatin immunoprecipitation (ChIP) assay. The procedure for this assay was the same
as that described by Yin et al. (39). Chromatin immunoprecipitations were carried out
with antibodies against acetyl-histone H3 (06-599) and acetyl-histone H4 (06-866)
(Upstate Biotechnology). Precipitated DNA was analyzed in PCR reactions using Taq
DNA polymerase (New England Biolabs) and primers specific for the ACCα and malic
enzyme promoters. The cycling parameters were: 1 cycle of 95°C for 4 min, 30 cycles of
95°C for 1 min, 61°C for 1 min, 72°C for 1 min, and 1 cycle of 72°C for 10 min. The
forward primer of the ACCα gene was 5’-TCCCCTCCGTCAGCAGCCAATGGG-3’;
the reverse primer was 5’-ATCCCCGGTCCCGCCCTCGGCTCC-3’. The forward
primer of the SCD1 gene was 5’-AGCGAACAGCAGATTGCGGCAG-3’; the reverse
primer was 5’-TCTCGGCGTGCCAGAAGGGAGGT-3’. Amplified products were
subjected to electrophoresis in 2% agarose gels and visualized by ethidium bromide
staining.

Statistical methods
Data were subjected to analysis of variance, and statistical comparisons were
made with Dunnett’s test or Student’s t-test. Statistical significance is defined as P <
0.05.

RESULTS

60

LXR activation increases the expression of ACCα in primary cultures of chick
embryo hepatocytes
Oral administration of T0-901317 to chickens and rats causes a 2- to 3-fold
increase in hepatic ACCα mRNA levels (23, 24). To investigate whether this
phenomenon was due to a direct effect of T0-901317 n the liver, we determined whether
T0-901317 regulated the expression of ACCα in primary cultures of chick embryo
hepatocytes. Incubating hepatocytes with T0-901317 in the absence of other hormones
for 24 h caused a 2.4-fold increase in the abundance of ACCα mRNA (Fig. 1).
Treatment with the RXR agonist, 9-cis retinoic acid, had no effect on ACCα mRNA
abundance in the absence or presence of T0-901317. Thus, LXR agonists but not RXR
agonists regulate ACCα expression in hepatocytes in culture.
In chick embryo hepatocytes, insulin has no effect by itself but amplifies the
increase in ACCα transcription caused by T3 (6). This observation prompted us to
investigate whether insulin modified the effects of T0-901317 on ACCα expression.
Incubating hepatocytes with T0-901317 stimulated a greater increase in ACCα mRNA
abundance in the presence of insulin (3.5-fold) than in the absence of insulin (2.4-fold)
(Fig. 1). Thus, as observed for T3 regulation of ACCα, insulin enhances the stimulatory
effects of T0-901317 on ACCα expression.
In previous work, we showed that both TR and LXR bind the ACCα T3RE as
heterodimers with RXR (7). This observation raised the possibility that a common cisacting regulatory sequence is involved in mediating the effects of T0-901317 and T3 on
ACCα transcription. As a first step in investigating this possibility, we determined the
effects of T0-901317 on the expression of ACCα in the presence of T3. Incubating
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hepatocytes with T3 and insulin caused a 4.6-fold increase in the abundance ACCα
mRNA abundance (Fig. 1). Addition of T0-901317 in the presence of T3 and insulin
caused a further increase in ACCα mRNA abundance, however the magnitude of this
effect (39%) was substantially smaller than the effect of T0-901317 on ACCα expression
in the presence of insulin alone (350%). Addition of T0-901317 in the presence of T3,
insulin, and 9-cis retinoic acid had no effect on ACCα mRNA abundance. The nonadditive effects of T0-901317 and T3 on ACCα mRNA abundance support the proposal
that a common cis-acting sequence(s) mediates the actions of T0-901317 and T3 on
ACCα transcription.
We also investigated the effects of T0-901317 on the expression of other
lipogenic enzymes. In hepatocytes incubated in the absence and presence of insulin,
addition of T0-901317 to the culture medium increased the abundance of mRNAs
encoding FAS, SCD1, and ATP-CL (Fig. 1). T0-901317-induced expression of FAS,
SCD1, and ATP-CL was higher in the presence of insulin than in the absence of insulin.
In hepatocytes incubated with T3 and insulin, addition of T0-901317 had little or no
effect on the abundance of mRNA encoding FAS, SCD1, and ATP-CL. Incubating
hepatocytes with 9-cis retinoic acid in the absence or presence of T0-901317 had no
effect on FAS, SCD1, and ATP-CL mRNA levels. Thus, regulation of expression of
FAS, SCD1, and ATP-CL by agonists of LXR and RXR is similar to that of ACCα.
In contrast to ACCα, FAS, SCD1, and ATP-CL, the ability of T0-901317 to
increase the expression of malic enzyme (ME) was substantially lower than that of T3.
Treatment with T0-901317 and insulin caused a 2.9-fold increase in ME mRNA
abundance, whereas treatment with T3 and insulin caused a 35-fold increase in ME
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mRNA abundance (Fig. 1). These observations are consistent with previous work
demonstrating that the major T3RE mediating T3 regulation of malic enzyme
transcription lacks the ability to bind LXR•RXR heterodimers (7).
To determine whether the T0-901317-induced increase in lipogenic enzyme
expression was associated with an elevation in triacylglycerol production, the
triacylglycerol concentration in the culture medium was monitored in hepatocytes treated
with or with or without T0-901317. The triacylglycerol concentration of the culture
medium increased progressively during a 48 h incubation period (Fig. 2). The extent of
the increase in triacylglycerol concentration was higher in cells treated with T0-901317
relative to cells not receiving T0-901317. An elevation in hepatic lipogenic enzyme
expression and triacylglycerol secretion likely contributes to the hypertriglyceridemia
observed in animals treated with T0-901317 (21, 22, 24).

Identification of a LXR response unit that mediates the effects of T0-901317 on
ACCα transcription
Previous studies have shown that T3 regulation of ACCα transcription is
mediated by a 23 bp region (-101 to -71 bp) in promoter 2 of the ACCα gene (7). This
region contains a DR-4 element (-101 to -86 bp) that binds heterodimers comprised of
TR•RXR and LXR•RXR and a SRE (-82 to -71 bp) that binds SREBP-1. To determine
the role of these sequences and other sequences in ACCα gene in mediating the
stimulatory effects of T0-901317 on ACCα transcription, transient transfection
experiments were performed using reporter constructs containing portions of ACCα
promoter 2 linked to the chloramphenicol acetyltransferase (CAT) gene. In chick embryo
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hepatocytes transfected with a reporter construct containing 2054 bp of 5’-flanking DNA,
T0-901317 caused a 2.9-fold increase in promoter activity (Fig. 3). 5’-Deletion of ACCα
sequences to -391, -136, and -108 bp had no effect on T0-901317 responsiveness.
Deletion of ACCα sequences containing the DR-4 element (-108 to -84 bp) abolished the
stimulatory effect of T0-901317 on ACCα transcription. Further deletion to -41 bp had
no effect on T0-901317 responsiveness. Mutation of the SRE (-80 to -71 bp) in the
context of 108 bp of 5’-flanking DNA caused a 49% reduction in T0-901317
responsiveness. These results indicate that the DR-4 element (LXRE) is required for T0901317 regulation of ACCα transcription and that the SRE enhances the ability of the
LXRE to activate ACCα transcription in the presence of T0-901317.
To determine whether the functional interaction between the ACCα LXRE and
SRE required the presence of additional cis-acting sequences, hepatocytes were
transfected with constructs containing fragments of the ACCα gene linked to the minimal
promoter of the herpes simplex virus thymidine kinase (TK) gene. The TK promoter
alone was unresponsive to T0-901317 (Fig. 4). When a DNA fragment containing both
the ACCα LXRE and ACCα SRE (-108 to -66 bp) was linked to the TK promoter,
treatment with T0-901317 caused a 5.5-fold increase in promoter activity. Mutation of
the ACCα SRE in the context of the ACCα -108 to -66 bp fragment caused a 49%
decrease in T0-901317 responsiveness. When a DNA fragment containing the ACCα
SRE alone (-84 to -66 bp) was appended to the TK promoter, T0-901317 treatment had
no effect on promoter activity. These data demonstrate that the ACCα SRE can function
alone to enhance T0-901317 regulation conferred by the ACCα LXRE. Thus, a region of
the ACCα gene containing a LXRE and a SRE is responsible for mediating the effects of
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T0-901317 on ACCα promoter 2 activity. We refer to this region as the ACCα liver X
receptor response unit (LXRU).

LXR activation increases the abundance of mature SREBP-1 in chick embryo
hepatocytes
In our studies analyzing the regulation of the ACCα gene by T3, we showed that
T3 treatment increased the abundance of the mature, active form of SREBP-1 in chick
embryo hepatocytes and that this effect contributed to the activation of ACCα
transcription by T3 (8). This observation prompted us to ask whether T0-901317
regulated SREBP-1 levels in chick embryo hepatocyte cultures. The time course of the
effects of T0-901317 on the abundance of mature SREBP-1 protein, SREBP-1 mRNA,
and ACCα mRNA was determined in hepatocytes cultured in the presence of insulin.
Treatment with T0-901317 for 6 h caused an 1.5-fold increase in mature SREBP-1
concentration (Fig. 5). A larger increase in mature SREBP-1 concentration (2.2-fold)
was observed after 24 h of treatment with T0-901317. In contrast to the time course for
mature SREBP-1, the T0-901317-induced stimulation of ACCα mRNA levels occurred
at a later time point (between 24 and 48 of treatment). This observation is consistent with
the proposal that alterations in SREBP-1 levels play a role in mediating the regulation of
ACCα transcription by T0-901317. Treatment with T0-901317 increased in the
abundance of SREBP-1 mRNA and this effect was maximal (1.9 to 2.1-fold) at or before
2 h of incubation. Thus, T0-901317-induced changes in mature SREBP-1 concentration
appear to be mediated by a pretranslational mechanism.
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LXR activation modulates the binding of nuclear receptor complexes to the ACCα
LXRE/T3RE
In previous work, we showed that the ACCα LXRE/T3RE (-101 to -86 bp) bound
four protein complexes in nuclear extracts prepared from chick embryo hepatocytes (7).
Three of these complexes (designated complexes 1, 2 and 3) contained LXR•RXR
heterodimers, whereas the fourth complex (designated complex 4) contained TR•RXR
heterodimers. In the absence of nuclear receptor agonists, complexes 1 and 2 were the
predominant complexes that bound to the ACCα LXRE/T3RE. T3 treatment caused a
marked reduction in the binding of complexes 1 and 2 and an increase in the binding of
complexes 3 and 4. These findings have led us to propose that changes in the binding of
nuclear receptor complexes to the ACCα T3RE/LXRE play a role in mediating the
activation of ACCα transcription by T3. In the present study, we wanted to determine
whether treatment with LXR agonists also modulated the binding of nuclear receptor
complexes to the ACCα LXRE/T3RE. Gel mobility shift assays were performed using
nuclear extracts from chick embryo hepatocytes treated with or without T0-901317. As
reported previously, a DNA probe containing the ACCα LXRE/T3RE bound to
complex 1, complex 2, and complex 4 in nuclear extracts from hepatocytes incubated in
the absence of nuclear receptor agonists (Fig. 6). The binding activity of complex 1 and
complex 2 was substantially greater than that of complex 4. Complex 3 binding activity
was not detected in the absence of T0-901317 treatment. Incubating hepatocytes with
T0-901317 had no effect on the binding activity of complexes 1 and 3. In contrast,
T0-901317 treatment decreased the binding activity of complex 2 after 6, 12, and 24 h of
treatment. Between 24 and 48 h of T0-901317 treatment, the binding activity of complex
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2 increased to a level that was similar to that of cells not treated with T0-901317.
Treatment with T0-901317 also regulated the binding activity of complex 4. Incubating
hepatocytes with T0-901317 had no effect on complex 4 binding activity after 2, 6, and
12 h of treatment but increased complex 4 binding activity between 24 and 48h of
treatment. These data indicate that T0-901317 has opposing effects on the binding of
LXR•RXR and TR•RXR complexes to the ACCα LXRE/T3RE.

The effect of LXR activation on histone acetylation of the ACCα gene
The T0-901317-induced increase in ACCα transcription may be mediated in
whole or in part by alterations in histone acetylation. Previous studies have shown that
the activation of LXR•RXR heterodimers by LXR ligands/agonists triggers the
recruitment of coactivator complexes containing histone acetyltransferase (HAT) activity
(40, 41). Increased histone acetylation causes a chromatin decondensation that enhances
the accessibility of the basal transcriptional machinery and other transcription factors to
the target promoter. To investigate the role of histone acetylation in mediating the
activation of ACCα transcription by T0-901317, ChIP experiments were performed in
chick embryo hepatocytes incubated in the absence or presence of T0-901317.
Hepatocytes were treated with 1% formaldehyde to cross-link DNA to associated
proteins. Protein-DNA complexes were immunoprecipitated with an antibody against
acetylated histone H3 or an antibody against acetylated histone H4. Immunoprecipitated
DNA was analyzed by PCR using primers that flanked the ACCα LXRU. In hepatocytes
incubated in the absence of T0-901317, acetylation of histone H3 and histone H4 was
detected at the ACCα LXRU. Addition of T0-901317 to the culture medium stimulated a
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rapid increase (≤ 2 h) in the acetylation of histone H3 and H4 (Fig. 7, Table 1). Histone
acetylation remained elevated for 6 h of T0-901317 treatment and then declined between
6 and 24 h of T0-901317 treatment. These results support the proposal that an elevation
in histone acetylation plays a role in mediating the effects of T0-901317 on ACCα
transcription.
We also used ChIP to assess the effects of T0-901317 treatment on histone
acetylation in a uncharacterized region of the SCD1 promoter using a primer set that
amplified SCD1 sequences between -369 and -127 bp. In contrast to the data for the
ACCα gene, treatment with T0-901317 had no effect on histone acetylation at this region
of the SCD1 gene (Fig. 7). This observation indicates that the effects of T0-901317 on
histone acetylation are sequence specific.

DISCUSSION
In previous work analyzing the effects of T3 on ACCα transcription in avian
hepatocytes, we identified a T3RE that conferred T3 regulation on ACCα promoter 2 (7).
Interestingly, this T3RE not only bound protein complexes containing TR•RXR
heterodimers but also bound protein complexes containing LXR•RXR heterodimers. In
the present report, we provide functional evidence that LXR•RXR heterodimers regulate
ACCα transcription. A specific ligand/agonist of LXR (T0-901317) activates ACCα
transcription and this effect is mediated by the LXRE/T3RE in ACCα promoter 2. We
also demonstrate that SREBP-1 is an accessory factor that enhances the ability of
LXR•RXR to increase ACCα transcription in the presence of T0-901317 and that LXR
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activation by T0-901317 increases the concentration of mature, active form of SREBP-1
in chick embryo hepatocytes.
How does SREBP-1 enhance the stimulatory effects of T0-901317 on ACCα
transcription? One possibility is that SREBP-1 facilitates the recruitment of coactivators
to T0-901317-bound LXR•RXR complexes. LXRα, LXRβ, and SREBP-1 interact with
several coactivator proteins including CREB-binding protein (CBP) and the
TRAP/ARC/DRIP complex (40-45). We postulate that the presence of SREBP-1 on
ACCα promoter 2 provides additional coactivator interaction sites that stabilize the
binding of CBP, TRAP/ARC/DRIP, and other coactivators to T0-901317-bound
LXR•RXR. In support of this model, SREBP-1 and nuclear hormone receptors interact
with separate peptide sequences on CBP and separate subunits of the TRAP/ARC/DRIP
complex (46-49).
SREBP-1 also enhances the ability of TR•RXR to activate ACCα transcription in
the presence of T3 (9). In analyzing the mechanism mediating this effect, we showed
that SREBP-1 physically interacted with TR and that binding of T3 to TR enhanced this
interaction. We postulated that SREBP-1•SREBP-1 homodimers formed a tetrameric
complex with TR•RXR heterodimers and that tetrameric complex formation enhanced
the recruitment of coactivators to ACCα promoter 2. We also showed in these studies
that LXR•RXR heterodimers do not physically interact with SREBP-1. Thus, in contrast
to the mechanism by which SREBP-1 enhances TR•RXR activity, direct interactions
between SREBP-1 and LXR•RXR do not play a role in mediating the stimulatory effects
of SREBP-1 on LXR•RXR activity.
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The mechanism by which LXR agonists regulate transcription has been analyzed
for other lipogenic genes. In human hepatoma cells, T0-901317 activation of FAS
transcription is mediated by a single LXRE in the FAS promoter (50). In primary rat
hepatocyte cultures, the T0-901317-induced increase in SREBP-1c transcription is
mediated by two LXREs in the SREBP-1c promoter (51, 52). Both the FAS promoter
and the SREBP-1c promoter contain one or more SREs that are located approximately
110 to 540 bp downstream of the LXRE(s). In cells that express physiological levels of
LXR, these SREs enhance basal transcription but have little or no effect on the regulation
of transcription by T0-901317. In contrast to these findings, the SRE in ACCα promoter
2 enhances T0-901317 regulation of transcription but has no effect on basal transcription
(Figs. 3 and 4). These gene-specific differences in SRE activity may be due to variations
in the proximity of the SRE relative to the LXRE and other cis-acting regulatory
sequences. For example, the close association of the SRE with the LXRE/T3RE in
ACCα promoter 2 may facilitate interactions between LXR•RXR and SREBP-1 and the
ability of SREBP-1 to enhance T0-901317 responsiveness, whereas the wide separation
of the SREs and LXREs in the FAS and SREBP-1c promoters may impede interactions
between LXR•RXR and SREBP-1 and the ability of SREBP-1 to enhance T0-901317
responsiveness. Previous studies have shown that the SREs in the FAS and SREBP-1c
promoters are closely linked to a binding site for nuclear factor-Y (NF-Y) and that
SREBP-1 activity is dependent on interactions between SREBP-1 and NF-Y (51-54).
These interactions enhance the ability of SREBP-1 to stimulate basal transcription. In
contrast, the SRE in ACCα promoter 2 is not closely associated with binding sites for

70

NF-Y. The lack of interaction of SREBP-1 with NF-Y on ACCα promoter 2 may
explain why the ACCα SRE is not effective in modulating basal transcription.
Another finding of the present study is that LXR plays a permissive role in
mediating the actions of insulin on ACCα transcription in chick embryo hepatocytes.
Insulin stimulates ACCα expression in the presence of T0-901317 but has no effect on
ACCα expression in the absence of T0-901317 (Fig. 1). In rat hepatocytes, insulin
enhances the ability of T0-901317 to increase mature SREBP-1 concentration due to a
stimulatory effect of insulin on the processing of precursor SREBP-1 to mature SREBP-1
(55). We have confirmed this finding in chick embryo hepatocytes (data not shown).
Because SREBP-1 enhances LXR activation of ACCα transcription in chick embryo
hepatocytes, we postulate that alterations in mature SREBP-1 abundance mediate the
stimulatory effects of insulin on ACCα transcription. In support of this hypothesis,
insulin does not increase the expression of ABCA1 in the presence of T0-901317 (Fig. 1).
Previous work has shown that the ABCA1 gene is not a target of SREBP-1 (56).
Previous studies performed in rat hepatocytes indicate that insulin induces ACCα
expression by increasing the activity of LXR. For example, Tobin et al. (57) have shown
that insulin stimulates a 10-fold increase in the expression of LXRα mRNA and that
ablation of the LXRα gene abolishes the stimulatory effect of insulin on ACCα
expression. Other laboratories have shown that insulin increases the transcription of
SREBP-1c and that this effect is mediated by two LXR•RXR binding sites in the
SREBP-1c promoter (51, 52). SREBP-1c is a key factor mediating the effects of insulin
on ACCα transcription in rat hepatocytes (25, 58). These findings contrast with our data
indicating that LXR plays a permissive role in mediating the effects of insulin on ACCα
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transcription in chick embryo hepatocytes. The reason for the differences between avians
and rodents in the mechanism by which insulin regulates ACCα transcription is not clear.
They may reflect subtle class-dependent differences in the role of insulin in the control of
lipogenesis and/or other metabolic processes in liver.
Results from DNA binding studies suggest that T0-901317 treatment causes a
transient reduction in the binding of a complex containing LXR•RXR (complex 2)
(Fig. 6). This change in the ACCα LXRE/T3RE protein binding profile would limit the
activation of ACCα transcription by T0-901317. T0-901317 treatment also causes an
increase in the binding of a complex containing TR•RXR (complex 4). The latter
phenomenon would also suppress the stimulatory effects of T0-901317 on ACCα
transcription because unliganded TR•RXR functions as a repressor of gene transcription
(59). Evidence that unliganded TR•RXR is associated with a subset of ACCα promoters
during LXR activation is provided by the observation that T3 causes an increase in
ACCα mRNA abundance in the presence of T0-901317 (Fig. 1). We postulate that T0901317-induced changes in the binding of nuclear receptor complexes to the ACCα
LXRE/T3RE constitutes a mechanism to prevent the over stimulation of
ACCα transcription by the LXR signaling pathway. The mechanism by which T0901317 alters the binding of nuclear receptor complexes to the ACCα LXRE/T3RE is
presently unclear but does not involve changes in the expression of LXRα mRNA
(Fig. 1), TRα mRNA, and TRβ mRNA (data not shown).
The ACCα LXRE/T3RE enhances ACCα transcription both in the absence and
presence T0-901317 and T3 with a greater activation observed in the presence of T0901317 and T3 (Figs. 3 and 4) (7). We previously hypothesized that the enhancer
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activity of the ACCα LXRE/T3RE in the absence of T0-901317 and T3 was mediated by
LXR•RXR heterodimers, as the primary protein complexes that bind the ACCα
LXRE/T3RE in the absence of T0-901317 and T3 contain LXR•RXR heterodimers (7).
Recent studies have shown that unliganded form of LXR•RXR represses gene
transcription due to its ability to interact with corepressor proteins and that the addition of
LXR ligand increases gene transcription by causing the release of corepressors and the
recruitment of coactivators to LXR•RXR (60). In view of these observations, we further
hypothesize that LXR•RXR complexes associated with the ACCα LXRE/T3RE in the
absence of T0-901317 and T3 are bound by endogenous LXR and/or RXR ligands.
Several lines of evidence support this proposal. First, treatment of chick embryo
hepatocytes with naturally occurring agonists of LXR [22-(R)-hydroxy cholesterol] and
RXR (9-cis retinoic acid) has little or no effect on ACCα mRNA abundance (Fig. 1 and
data not shown). Second, the ACCα LXRE/T3RE is not associated with the corepressor
protein, nuclear receptor corepressor (NCoR), in the absence of T0-901317 and T3 (39).
Last, the ACCα LXRE/T3RE is associated with acetylated histone H3 and acetylated
histone H4 in the absence of T0-901317 and T3 (Fig. 7). The ability of T0-901317 to
increase the transcriptional activity and histone acetylation of the ACCα LXRE/T3RE is
likely due to the fact that this synthetic agonist is more effective than endogenous LXR
agonists in stimulating the recruitment of HAT-containing coactivators to LXR•RXR
(40).
In summary, we show that T0-901317 activates of ACCα transcription by
increasing the activity of LXR•RXR and SREBP-1 and the acetylation of histone H3 and
histone H4 on ACCα promoter 2. The identification of small molecules that selectively
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inhibit of one or more of these processes will enhance the utility of T0-901317 in the
treatment of atherosclerosis.
Acknowledgments– This work was supported by a National Research Initiative
Competitive Grant from the USDA Cooperative State Research, Education, and
Extension Service (2001-35206-11133) and by a Grant-in-Aid Award from the American
Heart Association (0355193B).

REFERENCES
1.

Barber, M. C., N. T. Price, and M. T. Travers. 2005. Structure and regulation of
acetyl-CoA carboxylase genes of metazoa. Biochim. Biophys. Acta 1733: 1-28.

2.

Brownsey, R. W., A. N. Boone, J. E. Elliott, J. E. Kulpa, and W. M. Lee. 2006.
Regulation of acetyl-CoA carboxylase. Biochem. Soc. Trans. 34: 223-227.

3.

Leonard, A. E., S. L. Pereira, H. Sprecher, and Y. S. Huang. 2004. Elongation of
long-chain fatty acids. Prog. Lipid Res. 43: 36-54.

4.

Abu-Elheiga, L., M. M. Matzuk, P. Kordari, W. Oh, T. Shaikenov, Z. Gu, and S.
J. Wakil. 2005. Mutant mice lacking acetyl-CoA carboxylase 1 are embryonically
lethal. Proc. Natl. Acad. Sci. U S A 102: 12011-12016.

5.

Hillgartner, F. B., T. Charron, and K. A. Chesnut. 1996. Alterations in nutritional
status regulate acetyl-CoA carboxylase expression in avian liver by a
transcriptional mechanism. Biochem. J. 319 ( Pt 1): 263-268.

6.

Hillgartner, F. B., T. Charron, and K. A. Chesnut. 1997. Triiodothyronine
stimulates and glucagon inhibits transcription of the acetyl-CoA carboxylase gene

74

in chick embryo hepatocytes: Glucose and insulin amplify the effect of
triiodothyronine. Arch. Biochem. Biophys. 337: 159-168.
7.

Zhang, Y., L. Yin, and F. B. Hillgartner. 2001. Thyroid hormone stimulates
acetyl-CoA carboxylase-α transcription in hepatocytes by modulating the
composition of nuclear receptor complexes bound to a thyroid hormone response
element. J. Biol. Chem. 276: 974-983.

8.

Zhang, Y., L. Yin, and F. B. Hillgartner. 2003. SREBP-1 integrates the actions of
thyroid hormone, insulin, cAMP, and medium-chain fatty acids on ACCα
transcription in hepatocytes. J. Lipid Res. 44: 356-368.

9.

Yin, L., Y. Zhang, and F. B. Hillgartner. 2002. Sterol regulatory element-binding
protein-1 interacts with the nuclear thyroid hormone receptor to enhance acetylCoA carboxylase-α transcription in hepatocytes. J. Biol. Chem. 277: 1955419565.

10.

Lehmann, J.. M., S. A. Kliewer, L. B. Moore, T. A. Smith-Oliver, B. B. Oliver, J.
L. Su, S. S. Sundseth, D. A. Winegar, D. E. Blanchard, T. A. Spencer, and T. M.
Willson. 1997. Activation of the nuclear receptor LXR by oxysterols defines a
new hormone response pathway. J. Biol. Chem. 272: 3137-3140.

11.

Janowski, B. A., P. J. Willy, T. R. Devi, J. R. Falck, and D. J. Mangelsdorf. 1996.
An oxysterol signalling pathway mediated by the nuclear receptor LXRα. Nature
383: 728-731.

12.

Teboul, M., E. Enmark, Q. Li, A. C. Wikstrom, M. Pelto-Huikko, and J. A.
Gustafsson. 1995. Or-1, a member of the nuclear receptor superfamily that

75

interacts with the 9-cis-retinoic acid receptor. Proc. Natl. Acad. Sci. U S A 92:
2096-2100.
13.

Willy, P. J., K. Umesono, E. S. Ong, R. M. Evans, R. A. Heyman, and D. J.
Mangelsdorf. 1995. LXR, a nuclear receptor that defines a distinct retinoid
response pathway. Genes Dev. 9: 1033-1045.

14.

Repa, J. J., and D. J. Mangelsdorf. 2002. The liver X receptor gene team:
Potential new players in atherosclerosis. Nat. Med. 8: 1243-1248.

15.

Edwards, P. A., H. R. Kast, and A. M. Anisfeld. 2002. BAREing it all: The
adoption of LXR and FXR and their roles in lipid homeostasis. J. Lipid Res. 43:
2-12.

16.

Zelcer, N., and P. Tontonoz. 2006. Liver X receptors as integrators of metabolic
and inflammatory signaling. J. Clin. Invest 116: 607-614.

17.

Peet, D. J., S. D. Turley, W. Ma, B. A. Janowski, J. M. Lobaccaro, R. E. Hammer,
and D. J. Mangelsdorf. 1998. Cholesterol and bile acid metabolism are impaired
in mice lacking the nuclear oxysterol receptor LXRα. Cell 93: 693-704.

18.

Alberti, S., G. Schuster, P. Parini, D. Feltkamp, U. Diczfalusy, M. Rudling, B.
Angelin, I. Bjorkhem, S. Pettersson, and J. A. Gustafsson. 2001. Hepatic
cholesterol metabolism and resistance to dietary cholesterol in LXRβ-deficient
mice. J. Clin. Invest 107: 565-573.

19.

Joseph, S. B., E. McKilligin, L. Pei, M. A. Watson, A. R. Collins, B. A. Laffitte,
M. Chen, G. Noh, J. Goodman, G. N. Hagger, J. Tran, T. K. Tippin, X. Wang, A.
J. Lusis, W. A. Hsueh, R. E. Law, J. L. Collins, T. M. Willson, and P. Tontonoz.

76

2002. Synthetic LXR ligand inhibits the development of atherosclerosis in mice.
Proc. Natl. Acad. Sci. U S A 99: 7604-7609.
20.

Terasaka, N., A. Hiroshima, T. Koieyama, N. Ubukata, Y. Morikawa, D. Nakai,
and T. Inaba. 2003. T-0901317, a synthetic liver X receptor ligand, inhibits
development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett. 536:
6-11.

21.

Grefhorst, A., B. M. Elzinga, P. J. Voshol, T. Plosch, T. Kok, V. W. Bloks, F. H.
van der Sluijs, L. M. Havekes, J. A. Romijn, H. J. Verkade, and F. Kuipers. 2002.
Stimulation of lipogenesis by pharmacological activation of the liver X receptor
leads to production of large, triglyceride-rich very low density lipoprotein
particles. J. Biol. Chem. 277: 34182-34190.

22.

Chisholm, J. W., J. Hong, S. A. Mills, and R. M. Lawn. 2003. The LXR ligand
T0901317 induces severe lipogenesis in the db/db diabetic mouse. J. Lipid Res.
44: 2039-2048.

23.

Mulligan, J. D., M. T. Flowers, A. Tebon, J. J. Bitgood, C. Wellington, M. R.
Hayden, and A. D. Attie. 2003. ABCA1 is essential for efficient basolateral
cholesterol efflux during the absorption of dietary cholesterol in chickens. J. Biol.
Chem. 278: 13356-13366.

24.

Schultz, J. R., H. Tu, A. Luk, J. J. Repa, J. C. Medina, L. Li, S. Schwendner, S.
Wang, M. Thoolen, D. J. Mangelsdorf, K. D. Lustig, and B. Shan. 2000. Role of
LXRs in control of lipogenesis. Genes Dev. 14: 2831-2838.

25.

Liang, G., J. Yang, J. D. Horton, R. E. Hammer, J. L. Goldstein, and M. S.
Brown. 2002. Diminished hepatic response to fasting/refeeding and liver X

77

receptor agonists in mice with selective deficiency of sterol regulatory elementbinding protein-1c. J. Biol. Chem. 277: 9520-9528.
26.

Goodridge, A. G. 1973. Regulation of fatty acid synthesis in isolated hepatocytes
prepared from the livers of neonatal chicks. J Biol. Chem. 248: 1924-1931.

27.

Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by
acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162:
156-159.

28.

Feinberg, A. P., and B. Vogelstein. 1983. A technique for radiolabeling DNA
restriction endonuclease fragments to high specific activity. Anal. Biochem. 132:
6-13.

29.

Amasino, R. M. 1986. Acceleration of nucleic acid hybridization rate by
polyethylene glycol. Anal. Biochem. 152: 304-307.

30.

Yuan, Z. Y., W. Liu, and G. G. Hammes. 1988. Molecular cloning and
sequencing of DNA complementary to chicken liver fatty acid synthase mRNA.
Proc. Natl. Acad. Sci. U S A 85: 6328-6331.

31.

Lefevre, P., C. Diot, P. Legrand, and M. Douaire. 1999. Hormonal regulation of
stearoyl coenzyme-A desaturase 1 activity and gene expression in primary
cultures of chicken hepatocytes. Arch. Biochem. Biophys. 368: 329-337.

32.

Zhang, Y., and F. B. Hillgartner. 2004. Starvation and feeding a highcarbohydrate, low-fat diet regulate the expression sterol regulatory elementbinding protein-1 in chickens. J. Nutr. 134: 2205-2210.

78

33.

Daval, S., F. Pitel, C. Le Nigen, M. Douaire, A. Vignal, and S. Lagarrigue. 2000.
Cloning and mapping of the ACLY gene to a chicken microchromosome. Anim.
Genet. 31: 412-413.

34.

Handschin, C., M. Podvinec, R. Amherd, R. Looser, J. C. Ourlin, and U. A.
Meyer. 2002. Cholesterol and bile acids regulate xenosensor signaling in drugmediated induction of cytochromes p450. J. Biol. Chem. 277: 29561-29567.

35.

Winberry, L. K., S. M. Morris, Jr., J. E. Fisch, M. J. Glynias, R. A. Jenik, and A.
G. Goodridge. 1983. Molecular cloning of cDNA sequences for avian malic
enzyme. Nutritional and hormonal regulation of malic enzyme mRNA levels in
avian liver cells in vivo and in culture. J. Biol. Chem. 258: 1337-1342.

36.

Baillie, R. A., S. A. Klautky, and A. G. Goodridge. 1993. Transient transfection
of chick-embryo hepatocytes. J. Nutr. Biochem. 4: 431-439.

37.

Gorman, C. M., L. F. Moffat, and B. H. Howard. 1982. Recombinant genomes
which express chloramphenicol acetyltransferase in mammalian cells. Mol. Cell.
Biol. 2: 1044-1051.

38.

Sedmak, J. J., and S. E. Grossberg. 1977. A rapid, sensitive, and versatile assay
for protein using coomassie brilliant blue G250. Anal Biochem. 79: 544-552.

39.

Yin, L., Y. Wang, S. Dridi, C. Vinson, and F. B. Hillgartner. 2005. Role of
CCAAT/enhancer-binding protein, histone acetylation, and coactivator
recruitment in the regulation of malic enzyme transcription by thyroid hormone.
Mol. Cell. Endocrinol. 245: 43-52.

40.

Albers, M., B. Blume, T. Schlueter, M. B. Wright, I. Kober, C. Kremoser, U.
Deuschle, and M. Koegl. 2006. A novel principle for partial agonism of liver X

79

receptor ligands. Competitive recruitment of activators and repressors. J. Biol.
Chem. 281: 4920-4930.
41.

Wiebel, F. F., K. R. Steffensen, E. Treuter, D. Feltkamp, and J. A. Gustafsson.
1999. Ligand-independent coregulator recruitment by the triply activatable
or1/retinoid X receptor-α nuclear receptor heterodimer. Mol. Endocrinol. 13:
1105-1118.

42.

Huuskonen, J., P. E. Fielding, and C. J. Fielding. 2004. Role of p160 coactivator
complex in the activation of liver X receptor. Arterioscler. Thromb Vasc Biol. 24:
703-708.

43.

Lee, S. K., S. Y. Jung, Y. S. Kim, S. Y. Na, Y. C. Lee, and J. W. Lee. 2001. Two
distinct nuclear receptor-interaction domains and CREB-binding proteindependent transactivation function of activating signal cointegrator-2. Mol.
Endocrinol. 15: 241-254.

44.

Naar, A. M., P. A. Beaurang, S. Zhou, S. Abraham, W. Solomon, and R. Tjian.
1999. Composite co-activator ARC mediates chromatin-directed transcriptional
activation. Nature 398: 828-832.

45.

Oliner, J. D., J. M. Andresen, S. K. Hansen, S. Zhou, and R. Tjian. 1996. SREBP
transcriptional activity is mediated through an interaction with the CREB-binding
protein. Genes Dev. 10: 2903-2911.

46.

Belakavadi, M., and J. D. Fondell. 2006. Role of the mediator complex in nuclear
hormone receptor signaling. Rev. Physiol. Biochem. Pharmacol. 156: 23-43.

80

47.

Chakravarti, D., V. J. LaMorte, M. C. Nelson, T. Nakajima, I. G. Schulman, H.
Juguilon, M. Montminy, and R. M. Evans. 1996. Role of CBP/p300 in nuclear
receptor signalling. Nature 383: 99-103.

48.

Ericsson, J., and P. A. Edwards. 1998. CBP is required for sterol-regulated and
sterol regulatory element-binding protein-regulated transcription. J. Biol. Chem.
273: 17865-17870.

49.

Toth, J. I., S. Datta, J. N. Athanikar, L. P. Freedman, and T. F. Osborne. 2004.
Selective coactivator interactions in gene activation by SREBP-1a and -1c. Mol.
Cell. Biol. 24: 8288-8300.

50.

Joseph, S. B., B. A. Laffitte, P. H. Patel, M. A. Watson, K. E. Matsukuma, R.
Walczak, J. L. Collins, T. F. Osborne, and P. Tontonoz. 2002. Direct and indirect
mechanisms for regulation of fatty acid synthase gene expression by liver X
receptors. J. Biol. Chem. 277: 11019-11025.

51.

Cagen, L. M., X. Deng, H. G. Wilcox, E. A. Park, R. Raghow, and M. B. Elam.
2005. Insulin activates the rat sterol-regulatory-element-binding protein 1c
(SREBP-1c) promoter through the combinatorial actions of SREBP, LXR, SP-1
and NF-Y cis-acting elements. Biochem. J. 385: 207-216.

52.

Chen, G., G. Liang, J. Ou, J. L. Goldstein, and M. S. Brown. 2004. Central role
for liver X receptor in insulin-mediated activation of SREBP-1c transcription and
stimulation of fatty acid synthesis in liver. Proc. Natl. Acad. Sci U S A 101:
11245-11250.

53.

Magana, M. M., S. H. Koo, H. C. Towle, and T. F. Osborne. 2000. Different
sterol regulatory element-binding protein-1 isoforms utilize distinct co-regulatory

81

factors to activate the promoter for fatty acid synthase. J. Biol. Chem. 275: 47264733.
54.

Xiong, S., S. S. Chirala, and S. J. Wakil. 2000. Sterol regulation of human fatty
acid synthase promoter requires nuclear factor-Y and SP-1-binding sites. Proc.
Natl. Acad. Sci. U S A 97: 3948-3953.

55.

Hegarty, B. D., A. Bobard, I. Hainault, P. Ferre, P. Bossard, and F. Foufelle.
2005. Distinct roles of insulin and liver X receptor in the induction and cleavage
of sterol regulatory element-binding protein-1c. Proc. Natl. Acad. Sci U S A 102:
791-796.

56.

Schmitz, G., and T. Langmann. 2005. Transcriptional regulatory networks in lipid
metabolism control ABCA1 expression. Biochim. Biophys. Acta 1735: 1-19.

57.

Tobin, K. A., S. M. Ulven, G. U. Schuster, H. H. Steineger, S. M. Andresen, J. A.
Gustafsson, and H. I. Nebb. 2002. Liver X receptors as insulin-mediating factors
in fatty acid and cholesterol biosynthesis. J. Biol. Chem. 277: 10691-10697.

58.

Stoeckman, A. K., and H. C. Towle. 2002. The role of SREBP-1c in nutritional
regulation of lipogenic enzyme gene expression. J. Biol. Chem. 277: 2702927035.

59.

Privalsky, M. L. 2004. The role of corepressors in transcriptional regulation by
nuclear hormone receptors. Annu. Rev. Physiol. 66: 315-360.

60.

Wagner, B. L., A. F. Valledor, G. Shao, C. L. Daige, E. D. Bischoff, M.
Petrowski, K. Jepsen, S. H. Baek, R. A. Heyman, M. G. Rosenfeld, I. G.
Schulman, and C. K. Glass. 2003. Promoter-specific roles for liver X

82

receptor/corepressor complexes in the regulation of ABCA1 and SREBP1 gene
expression. Mol. Cell. Biol. 23: 5780-5789.

FIGURE LEGENDS
Figure 1. The LXR agonist, T0-901317, increases the expression of ACCα and other
lipogenic enzymes in primary cultures of chick embryo hepatocytes. Hepatocytes were
isolated as described under Material and Methods and incubated in serum-free
Waymouth’s medium. At 18 h of incubation, the medium was changed to one of the
same composition supplemented with or without T0-901317 (10 μM) in the absence or
presence of insulin (50 nM), insulin and 9-cis retinoic acid (9-cis RA) (100 nM), insulin
and T3 (1.5 μM), or insulin, T3 and 9-cis-RA. After 28 h of treatment, total RNA was
isolated and the abundance of mRNA encoding acetyl-CoA carboxylase α (ACCα), fatty
acid synthase (FAS), stearoyl-CoA desaturase-1 (SCD1), ATP-citrate lyase (ATP-CL),
malic enzyme (ME), ATP-binding cassette transporter A1 (ABCA1), and liver X receptor
α (LXRα) was measured by Northern analysis. Levels of mRNA in cells treated without
T0-901317, 9-cis-RA, insulin, and T3 were set at 1, and the other values were adjusted
proportionately. Values are the means ± SEM of four experiments. Hybridization
signals from a representative experiment are shown for each mRNA. Ribosomal subunits
(27S and 18S) stained with ethidium bromide are shown as controls for RNA loading.
a

Mean is significantly (P < 0.05) different from that of cells treated without T0-901317,
b

9-cis-RA, insulin, and T3. Mean is significantly (P < 0.05) different from that of cells
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c

treated with insulin. Mean is significantly (P < 0.05) different from that of cells treated
with insulin and T3.

Figure 2. Effect of T0-901317 on the accumulation of triacylglycerols in the culture
medium of chick embryo hepatocytes. Hepatocytes were plated on 90 mm petri dishes (1
x 107 cells/dish) in Waymouth’s medium containing insulin. At 18 h of incubation, the
medium was changed to one of the same composition supplemented with or without T0901317. After 0, 24, 36, and 48 h of incubation with T0-901317, the concentration of
triacylglycerol in the culture medium was measured using a spectrophotometric assay.
Data are the means ± SEM of three experiments. *Mean is significantly (P < 0.05)
different from that of cells incubated with insulin for the same time period.

Figure 3. Effect of mutations of the 5’-flanking region of ACCα promoter 2 on
transcriptional activity in the absence and presence of T0-901317. Chick embryo
hepatocytes were transiently transfected with p[ACC-2054/+274]CAT or equimolar
amounts of other plasmids as described under Materials and Methods. After transfection,
cells were treated with or without T0-901317 for 48 h. Cells were then harvested,
extracts prepared, and CAT assays performed. Left: The constructs used in these
experiments. The number at the left of each construct is the 5' end of ACCα DNA in
nucleotides relative to the transcription initiation site of promoter 2. The 3' end of each
construct was +274 bp. The location of the LXR response element (LXRE) (-101 to -86
bp) and the sterol regulatory element (SRE) (-80 to -71 bp) is indicated by vertical lines.
A block mutation of the SRE is indicated by a X through the vertical line. Right: CAT
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activity of cells transfected with p[ACC-108/+274] CAT and treated with T0-901317 was
set at 1, and the other activities were adjusted proportionately. The fold stimulation by
T0-901317 was calculated by dividing the CAT activity for hepatocytes treated with T0901317 (+T0-901317) by that for hepatocytes not treated with T0-901317 (-T0-901317).
The fold responses were calculated for individual experiments and then averaged. The
results are the means ± SEM of six experiments. aThe fold stimulation by T0-901317 is
significantly (P < 0.05) lower than that of p[ACC-108/+274]CAT. bThe fold stimulation
by T0-901317 is significantly (P < 0.05) lower than that of p[ACC-108/+274]CAT
containing a block mutation of the SRE.

Figure 4. The ACCα SRE alone enhances the transcriptional activity of the ACCα
LXRE in the presence of T0-901317. Fragments of the ACCα gene containing the
LXRE and/or SRE were linked to the minimal TK promoter in TKCAT. Chick embryo
hepatocytes were transiently transfected with these constructs and treated with or without
T0-901317 as described in the legend of Fig. 3 and under Materials and Methods. Left:
The constructs used in these experiments. Numbers indicate the 5’ and 3’ boundaries of
ACCα DNA relative to the transcription initiation site of promoter 2. A block mutation
of the SRE is indicated by a X across the box representing the SRE. Right: CAT activity
in hepatocytes transfected with TKCAT and treated without T0-901317 was set at 1, and
the other activities were adjusted proportionately. The fold stimulation by T0-901317
was calculated as described in the legend to Fig. 3. The results are the means ± SEM of
five experiments. aThe fold stimulation by T0-901317 for p[ACC-108/-66]TKCAT is
significantly (p < 0.05) higher than any other construct.
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Figure 5. T0-901317 increases the concentration of mature SREBP-1 in chick embryo
hepatocyte cultures. Chick embryo hepatocytes were isolated and incubated in serumfree Waymouth’s medium containing insulin. At 18 h of incubation, the medium was
changed to one of the same composition. T0-901317 was added at this time. After 2, 6,
12, 24, and 48 h of T0-901317 treatment, cellular extracts or total RNA were prepared as
described under Materials and Methods. A: The abundance of mature SREBP-1 in
nuclear extracts was measured by Western analyses. The abundance of SREBP-1 mRNA
and ACCα mRNA was measured Northern analysis.. These data are from a
representative experiment. B: Signals for mature SREBP-1 protein from Western
analyses and SREBP-1 mRNA and ACCα mRNA from Northern analyses were
quantitated. Levels of mature SREBP-1 protein, SREBP-1 mRNA, and ACCα mRNA in
hepatocytes treated with T0-901317 for 0 h were set at 1. Values are the means ± SEM
of four experiments. Asterisks indicate that the mean is significantly (P < 0.05) different
from that of cells incubated with T0-901317 for 0 h or without T0-901317 for 24 or 48 h.

Figure 6. Effect of T0-901317 treatment on the binding of nuclear receptor complexes to
the ACCα LXRE/T3RE in chick embryo hepatocytes. Eighteen hours after being placed
in culture, chick embryo hepatocytes were incubated in Waymouth’s medium containing
insulin with or without T0-901317 for the indicated time periods. Cells were harvested
and nuclear extracts were prepared as described in Methods and Materials Nuclear
extracts were subjected to gel mobility shift analyses using an oligonucleotide probe
containing the ACCα LXRE/T3RE (-108 to -82 bp). Specific protein-DNA complexes
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are indicated by arrows. Previous studies have shown that complexes 1 and 2 contain
LXR·RXR heterodimers, whereas complex 4 contains TR·RXR heterodimers (5). A:
Data from a representative experiment. B: Signals for complex 1, complex 2, and
complex 4 were quantitated. The binding activities of complex 1, complex 2, and
complex 4 in hepatocytes treated with T0-901317 for 0 h were set at 1, and the other
activities were adjusted proportionately. Values are the means ± SEM of four
experiments. Asterisks indicate that the mean is significantly (P < 0.05) different from
that of cells incubated with T0-901317 for 0 h or without T0-901317 for 24 or 48 h.

Figure 7. Treatment of chick embryo hepatocyte cultures with T0-901317 causes a
transient increase in histone acetylation at the ACCα liver X receptor response unit.
Chick embryo hepatocytes were isolated and incubated in serum-free Waymouth’s
medium containing insulin. At 18 h of incubation, the medium was changed to one of the
same composition. T0-901317 was added at this time. After 2, 6, 24, and 48 h of T0901317 treatment, the association of acetylated histone H3 and acetylated histone H4
with ACCα and SCD1 genomic sequences was measured. ChIP assays were performed
as described in Materials and Methods. Immunoprecipitates were analyzed by PCR using
primers that flanked the liver X receptor response unit (LXRU) of ACCα promoter 2 and
an uncharacterized region of the SCD1 promoter. The region of the ACCα gene and
SCD1 gene that was amplified by PCR is indicated at the top of the figure. Chromatin
samples that were processed in parallel without the application of primary antibody
served as controls. The input lanes show the results of PCR reactions using chromatin
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samples taken before the immunoprecipitation step. Results are representative of three
independent experiments

TABLE 1.
Effect of T0-901317 treatment on the acetylation of histones at the acetyl-CoA
carboxylase-α LXR response unit
T0-901317 Treatment (h)
0

2

6

24

48

Ac-H3

1.0

1.4 ± 0.1*

1.8 ± 0.1*

1.1 ± 0.2

1.1 ± 0.1

Ac-H4

1.0

1.7 ± 0.1*

2.2 ± 0.2*

1.0 ± 0.1

1.1 ± 0.1

Signals from ChIP assays using the indicated antibodies were quantitated. The data are
expressed as the fold difference relative to samples from hepatocytes treated with T0901317 for 0 h. Values are the means ± SEM of three experiments. Results from a
representative experiment are shown in Fig. 7. *Significantly different (P < 0.05) from
cells treated with T0-901317 for 0 h.
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INTRODUCTION
The liver X receptors (LXRs) have emerged as important regulators of genes
involved in lipid and lipoprotein metabolism in higher vertebrates. LXRs were initially
identified in 1995 as orphan members of the nuclear receptor superfamily (61, 70). Two
isoforms exist with different expression patterns. LXRα is expressed at high levels in
liver, adipose tissue and macrophages, whereas LXRβ is expressed ubiquitously (64, 70).
The majority of the LXR proteins are localized in the nucleus and require
heterodimerization with the retinoid X receptor (RXR) in order to bind DNA and regulate
transcription (70).
The screening of organic tissue extracts using a cell-based reporter assay led to
the breakthrough discovery that oxysterols were the endogenous ligands that bound and
activated LXRα and LXRβ (35, 40). The most potent endogenous LXR ligands are
24(S)-hydroxycholesterol, 22(R)-hydroxycholesterol, and 24(S) epoxycholesterol. LXR
agonists activate a battery of genes involved in cholesterol efflux (ABCA1, ABCG1,
ABCG5, and ABCG8), cholesterol clearance (cholesterol ester transfer protein and
apolipoprotein E), and cholesterol catabolism (cholesterol 7α-hydroxylase) (reviewed in
(18, 57). Because oxysterols are produced in proportion to cellular cholesterol content,
LXRs have been proposed to function as sensors in a feed-forward pathway that
stimulates reverse cholesterol transport and cholesterol excretion in response to high
cholesterol levels in the diet. Consistent with this proposal, mice lacking the LXRα
and/or LXRβ gene exhibit diminished cholesterol excretion and elevated cholesterol
levels in the blood and liver when fed a high-cholesterol diet (2, 50).
The effects of LXR agonists on gene transcription are mediated by cis-acting
sequences that are comprised of hexameric half-sites arranged as direct repeats with a 4
bp spacer separating the half-sites (70). These sequences, termed LXR response elements
(LXREs), bind heterodimers comprised of LXR and RXR. Ligand-bound nuclear
receptors activate transcription by recruiting auxiliary transcriptional regulatory proteins
referred to as coactivators (71). Examples of coactivators of LXR include steroid
receptor coactivator-1 (69) and PGC-1α (48). Coactivators facilitate the ability of LXR
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to activate transcription by directly interacting with the basal transcriptional machinery,
by modulating interactions between LXR and the basal transcriptional machinery, and by
modifying chromatin structure.
We and other investigators have shown that LXR agonists also activate the
transcription of genes involved in triglyceride synthesis including ATP-citrate lyase, fatty
acid synthase, stearoyl-CoA desaturase, and ACCα (36, 60). In the case of ACCα, we
have shown that this effect is mediated by both a direct mechanism involving the
activation of LXR/RXR heterodimers on the ACCα gene and by an indirect mechanism
involving the increased expression of SREBP-1. SREBP-1 binds a site adjacent to the
ACCα LXRE and enhances the ability of LXR/RXR to activate ACCα transcription.
LXR agonists increase the expression of SREBP-1 by activating a LXRE on the SREBP1 gene (56).
HMG-CoA reductase inhibitors (statins) are currently the first-line agents to treat
and prevent atherosclerosis in humans. Unfortunately, statins are not effective in
reducing circulating cholesterol and LDL levels in a significant fraction of patients with
dyslipidemia (11). This has triggered a strong interest in the development of new
pharmacological approaches to achieve atheroprotection. LXR agonists represent one
such approach because these compounds stimulate reverse cholesterol transport and
cholesterol excretion. Accordingly, several laboratories have identified non-steroidal,
synthetic compounds that are more effective than endogenous oxysterols in stimulating
LXR activity (15, 60). The atheroprotective properties of two of these synthetic LXR
agonists, designated T0901317 (N-(2,2,2-trifluoro-ethyl)-N-[4-(2,2,2-trifluoro-1-hydroxy1-trifluoromethyl-ethyl)-phenyl]-benzenesulfonamide) and GW3965 (2-(3-{3-[[2-chloro3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]propoxy}-phenyl)acetic acid), have
been evaluated in murine models of atherosclerosis. Oral administration of T0901317 or
GW3965 to mice lacking the LDL receptor or apolipoprotein E stimulates an increase in
blood HDL levels and reverses the formation of atherosclerotic lesions in the aorta (36,
46, 65). These exciting findings are tempered by the observation that treatment with
T0901317 or GW3965 also causes hypertriglyceridemia and the development of a fatty
liver (14, 26, 60). These undesired effects of T0901317 and GW3965 are due to an
increase in hepatic fatty acid synthesis. One approach to overcome this problem is to
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activate another signaling pathway that selectively inhibits the effects of LXR agonists on
lipogenic gene transcription without altering their ability to stimulate genes involved in
reverse cholesterol transport.
In the present study, we show that, in primary hepatocyte cultures,
chenodeoxycholic acid (CDCA) inhibits the stimulatory effects of T0-901317 on the
expression of ACCα and other lipogenic enzymes and enhances the stimulatory effects of
T0-901317 on expression of ABCA1, a key gene controlling reverse cholesterol
transport. We also demonstrate that CDCA decreases ACCα transcription by inhibiting
the activity of LXR and SREBP-1 and that extracellular signal-regulated kinase (ERK)
and p38 mitogen-activated protein kinase (p38 MAPK) are components of the signaling
pathway(s) mediating this response.

EXPERIMENTAL PROCEDURES
Preparation of isolated hepatocytes
Hepatocytes were isolated from livers of 19-day-old chick embryos as previously
described (Chapter 2). Cells were incubated in serum-free Waymouth's medium
MD752/1 containing penicillin (60 µg/ml) and streptomycin (100 µg/ml) on untreated
petri dishes at 40°C in a humidified atmosphere of 5% CO2 and 95% air. Hormone and
other additions were as described in the figure legends. The triacylglycerol concentration
of the culture medium was measured using an enzymatic kit (Sigma).

Isolation of RNA and quantitation of mRNA levels
Medium was removed and RNA was extracted from hepatocytes by the
guanidinium thiocyanate/phenol/chloroform method as described (Chapter 2). Total
RNA (20 µg) was separated by size in 1% agarose, 0.7 M formaldehyde gels, and then
transferred to a Nytran membrane (Schleicher & Schuell) using a Vacuum blotting
apparatus (Pharmacia Biotechnology). The RNA was crosslinked to the membrane by
UV and baked at 80°C for 15 min. RNA blots were hybridized with 32P-labeled DNA
probes labeled by random priming. Hybridization and washes were as described.
Membranes were subjected to storage phosphor autoradiography. Hybridization signals

99

were quantified using ImageQuaNT software (Molecular Dynamics). cDNAs for chicken
ACCα, FAS, SCD, SREBP-1, ABCA1 have been described (Chapter 2).

Plasmids
Reporter plasmids are named by designating the 5' and 3' ends of the ACCα DNA
fragment relative to the transcription start site of promoter 2. A series of 5' deletions and
3' deletions of ACCα promoter 2 in the context of p[ACC-2054/+274]CAT have been
previously described (Chapter 2). An ACCα promoter construct containing a mutation of
the SRE-1 between -79 and -72 bp in the context of p[ACC-108/+274]CAT has been
previously described. p[ACC-108/-66]TKCAT, p[ACC-84/-66]TKCAT and pTKCAT
constructs containing mutations in the -108 to -66 bp ACCα fragment are described
(Chapter 2).

Transient transfection
Chick embryo hepatocytes were transfected as described (Chapter 2). Briefly,
cells were isolated and incubated on 60 mm petri dishes. At 6 h of incubation, the
medium was replaced with one containing 10 μg of lipofectin (Invitrogen), 1.5 μg of
p[ACC-2054/+274]CAT or an equimolar amount of another reporter plasmid and
pBluescript KS(+) to bring the total amount of transfected DNA to 1.5 μg per plate. At
18 h of incubation, the transfection medium was replaced with fresh medium with or
without T0-901317 (6 µM). At 66 h of incubation, chick embryo hepatocytes were
harvested, and cell extracts were prepared as described in (4). CAT activity (20) and
protein (53) were assayed by the indicated methods.

Western blot analysis
For detection of mature and precursor SREBP-1, nuclear extracts were prepared
from chick embryo hepatocytes as described (69). The proteins of the nuclear extract
were subjected to electrophoresis in 10% SDS-polyacrylamide gels and then transferred
to polyvinylidene difluoride membranes (Millipore) using an electroblotting apparatus
(BIORAD). Immunoblot analysis was carried using a mouse monoclonal antibody
against SREBP-1 (IgG-2A4) (American Type Culture Collection, Manassas, VA).
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Antibody/protein complexes on blots were detected using enhanced chemiluminescence
and or fluorescence, ECL-Plus (Amersham Biosciences). Chemiluminescence on the
blots was visualized using a FluorChem 8000 imager (Alpha Innotech Corporation) and
signals for mature form of SREBP-1 were quantified using FluorChem V200 software.
Fluorescence was detected by scanning the membrane on Typhoon 9400 scanner
(Amersham Biosciences) and the signals quantified using ImageQuaNT software.
For detection of phospho- and total MAP kinase, western analysis was performed
as described (56). Briefly, total cell lysates were prepared in a buffer containing 10 mM
Tris, pH 7.4, 1% SDS. Protein concentration was determined using Bradford assay
(BIORAD). Proteins were run on 10% polyacrylamide gels and transferred to
polyvinylidene difluoride membrane (Millipore). Membranes were blocked in 5% nonfat
dry milk for 1 h and incubated with primary antibody diluted in 5% bovine serum
albumin overnight at 4°C. The primary antibodies against phospho-Akt (Ser473),
phospho-p38 MAPK (Thr180/Tyr182), phospho-AMPK (Thr172), phospho-LKB1
(Ser428), phospho-ACC (Ser 79), phospho-PKC (pan, βII Ser660), phospho-S6 kinase
(Thr389), phospho-MKK 3/6 (Ser189/207), phospho-MEK 1/2 (Ser 221), phospho-JNK
(Thr183/Tyr185), phospho-Raf and total Akt, total p38 MAPK, total AMPK, total ACC,
total p38 MAPK, total JNK, total ERK were obtained from Cell Signaling Technology.
Anti-rabbit IgG conjugated with horseradish peroxidase (Cell Signaling Technology) was
used as the secondary antibody, and the signals were detected by enhanced
chemiluminescence, ECL-Plus (Amersham Biosciences). Images were visualized on
Typhoon 9400 to detect fluorescence and/or Alpha Innotech to detect chemiluminescence
and quantified by densitometry using ImageQuaNT software (Amersham Biosciences).
MEK1/2 inhibitor, U0126 was purchased from Cell Signaling Technology. p38 MAPK
inhibitors, SB203580 and SB202190 were purchased from Calbiochem.

Real-time RT-PCR
Total RNA from cells were isolated as described. Real-time RT-PCR assays
using SYBR-green (BIORAD) were carried out in ninety-six well plates. 100 ng of total
RNA was added per well to a total volume of 20 µl. Thermo-cycling conditions were as
follows: 15 min at 50°C for reverse transcription; 10 min at 95°C to activate DNA
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polymerase and to deactivate reverse transcriptase; 35 cycles of 15 s at 94°C to denature
and 1 min at 59°C to anneal and extend DNA template. Reverse transcription and PCR
amplification were performed by using iCycler thermal cycler from Bio-Rad. The
primers used for genes have been described. Primers of chicken ACCα, SREBP-1 and
SCD were used as described (51). Primers for the following genes were designed using
PrimerQuest from IDT. The name of the genes and the corresponding Pubmed accession
numbers are indicated in parentheses. SHP (AY700583), PGC-1α (AB170013), INSIG-1
(XM_418547), INSIG-2 (XM_422123), HMG-CoA reductase (AB109635), ABCA1
(NM_204145), LXRα (AF492498).

Gel mobility shift analysis
Nuclear extracts were prepared from hepatocytes incubated with or without
CDCA in the presence of T0-901317. A double-stranded oligonucleotide containing the
ACCα LXRE/T3RE (-108 to -82 bp relative to the transcription initiation site of ACCα
promoter 2) was labeled by filling in overhanging 5’-ends using Klenow fragment of E.
coli DNA polymerase in the presence of [α-32P] dCTP. Binding reactions were carried
out as previously described (Chapter 2). DNA and DNA-protein complexes were
resolved on 6% nondenaturing polyacrylamide gels at 4 ºC in 0.5 X TBE (45 mM Tris,
pH 8.3, 45 mM boric acid, 1 mM EDTA). Following electrophoresis, the gels were dried
and subjected to storage phosphor autoradiography.

Histone acetylation
The extent of histone acetylation on ACCα promoter 2 was measured using a
chromatin immunoprecipitation (ChIP) assay. The procedure for this assay was the same
as that described (68). Chromatin immunoprecipitations were carried out with antibodies
against acetyl-histone H3 (06-599) and acetyl-histone H4 (06-866) (Upstate
Biotechnology). Precipitated DNA was analyzed in PCR reactions using Taq DNA
polymerase (New England Biolabs) and primers specific for the ACCα and malic enzyme
promoters. The cycling parameters were: 1 cycle of 95°C for 4 min, 30 cycles of 95°C
for 1 min, 61°C for 1 min, 72°C for 1 min, and 1 cycle of 72°C for 10 min. The forward
primer of the ACCα gene was 5’-TCCCCTCCGTCAGCAGCCAATGGG-3’; the reverse
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primer was 5’-ATCCCCGGTCCCGCCCTCGGCTCC-3’. The forward primer of the
SCD1 gene was 5’-AGCGAACAGCAGATTGCGGCAG-3’; the reverse primer was
5’-AGGAAGGATGCTGAGGAAGAGGA-3’. Amplified products were subjected to
electrophoresis in 2% agarose gels and visualized by ethidium bromide staining.

RESULTS
Regulation of LXR signaling by Hexanoate and cAMP
Previous work from our laboratory has shown that cAMP and hexanoate inhibit
the activation of ACCα expression caused by insulin and T3. cAMP and hexanoate
inhibit ACCα transcription at least in part by repressing the ability of T3 and insulin to
increase the levels of mature SREBP-1 resulting in a disruption of the positive interaction
between SREBP-1 and nuclear T3 receptor on the ACCα gene (72). We have also shown
in Chapter 2 Figure 1, that T0-901317 increases the mRNA abundance of lipogenic genes
such as ACCα, FAS and SCD. We wanted to determine whether cAMP and hexanoate
inhibited the stimulation of ACCα, FAS, SCD, SREBP-1, LXR and ABCA1 caused by
T0-901317. Our experiments showed that cAMP had no effect on T0-901317 induced
expression of ACCα and other lipogenic genes (data not shown). In contrast, hexanoate
inhibited T0-901317-induced mRNA abundance of lipogenic genes such as ACCα, FAS
and SCD in a dose-dependent manner Figure 3.1. Hexanoate had no effect on the
abundance of these genes in the absence of T0-901317. Hexanoate also inhibited T0901317-induced ABCA1 mRNA expression in hepatocytes in a dose dependent manner.
Thus, hexanoate does not qualify as an agent to selectively inhibit the actions of LXR
agonist on lipogenic gene expression. As shown previously in Chapter 2, T0-901317
increases SREBP-1 and LXRα mRNA. Hexanoate had little or no effect on SREBP-1
and LXRα mRNA expression both in the absence and presence of T0-901317.
Chenodeoxycholic acid inhibits T0-901317-induced expression of lipogenic genes in
primary cultures of chick embryo hepatocytes
As discussed previously, an increase in bile acids has been shown to be inversely
correlated with a decrease in triglycerides, and vice versa (5, 10, 28, 158, 207, 185, 168).
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The above observations prompted us to determine whether bile acids could inhibit the
stimulation of ACCα and other lipogenic genes caused by T0-901317. Chick hepatocytes
were incubated in the presence of insulin and insulin and T0-901317. Chenodeoxycholic
acid (CDCA) was added in the absence and presence of T0-901317 in increasing
concentrations. Incubation of chicken embryo hepatocytes with CDCA in the absence of
T0-901317 had no effect on expression of ACCα, FAS and SCD mRNA abundance
Figure 3.2. In contrast, CDCA inhibited T0-901317-induced mRNA abundance of
lipogenic genes such as ACCα, fatty acid synthase (FAS), stearoyl CoA desaturase
(SCD) in a dose dependent manner. Interestingly, CDCA further potentiated T0-901317induced expression of ABCA1 mRNA, indicating that the effects of bile acids on LXR
signaling are gene specific. CDCA has no effect on the mRNA abundance of ABCA1 in
the absence of T0-901317.
3-hydroxy-3-methyglutaryl-CoA (HMG-CoA) reductase serves as the ratelimiting enzyme in cholesterol biosynthesis (45). Inhibitors of HMG-CoA reductase,
collectively referred to as statins, are extensively used to lower plasma cholesterol both as
a preventive measure, and cure for heart disease resulting from increased LDL (21). One
of the rare, but major side effects of statins is the occurrence of rhabdomyolysis, that
limits the use of these drugs in some patients (58). Therefore, it is important to
investigate other agents that inhibit HMG-CoA reductase, or agents that inhibit other
genes of the cholesterol synthesis pathway. CDCA has no effect on HMG-CoA reductase
mRNA abundance in presence of insulin and causes a slight reduction at 75 µM. T0901317 increases HMG-CoA reductase mRNA by 3-fold in presence of insulin. CDCA
inhibits T0-901317-induced expression of HMG-CoA reductase in a dose dependent
manner.

The decrease in ACCα mRNA by CDCA was correlated with a decrease of the
ACCα protein by CDCA. Primary chick hepatocytes were incubated in the presence of
T0-901317 in the absence and presence of CDCA. Total protein was harvested at the
indicated time points and western blot analysis was performed to detect the amount of
total ACC. CDCA inhibited total ACC protein as early as 2 h and further inhibited at 6 h,
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12 h and 24 h, with maximal inhibition obtained at 24 h Figure 3.3A. To determine
whether CDCA mediated decrease in ACCα expression was associated with a decrease in
triacylglycerol production, the triacylglycerol concentration in the culture medium was
measured in hepatocytes treated with T0-901317 in the absence and presence of CDCA.
Medium was collected and total triglyceride in the medium was determined as outlined in
Materials and methods. CDCA inhibited triacylglycerol accumulation in the medium at
24 hours Figure 3.3B. These results support that T0-901317-induced
hypertriglyceridemia can be inhibited upon administration of CDCA.

CDCA inhibits T3-induced expression of lipogenic genes
Previous work in our laboratory showed that thyroid hormone stimulates ACCα
expression, and that this effect is mediated at least in part, by the binding of the nuclear
T3 receptor (TR) to a composite T3RE/LXRE (73). We next asked if bile acids also
modulated the activity of the nuclear T3 receptor signaling pathways. Our results showed
that bile acids inhibit T3-induced expression of ACCα, FAS, SCD and malic enzyme
(ME) in a dose dependent manner Figure 3.4. CDCA had no effect on the mRNA
abundance of these genes in the absence of T3. T3 causes a small decrease in ABCA1
mRNA. However, as shown in the previous figure, CDCA also increases expression of
ABCA1 in a dose dependent manner with a two-fold induction at 75 µM, in the presence
of T3. We propose that a common mechanism may be involved in mediating the effects
of bile acids on T0-901317 and T3 signaling.
Identification of a bile acid response unit on the ACCα promoter that mediates the
effect of CDCA on ACCα transcription
We have previously shown that T0-901317 regulation of ACCα is mediated by a
23 bp region in promoter 2 of the ACCα gene. This region consists of a DR-4 element (101 to -86 bp) that binds heterodimers comprised of TR•RXR and LXR•RXR and a SRE
(-82 to -71 bp) that binds SREBP-1 (Chapter 2). To determine if these cis-acting
elements or other sequences in the ACCα gene mediate the effects of CDCA on ACCα
transcription, transient transfection experiments were performed using reporter constructs
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containing portions of ACCα promoter 2 linked to chloramphenicol acetyl transferase
(CAT) gene. In chick embryo hepatocytes transfected with a reporter construct
containing -2054 bp of 5’-flanking DNA, CDCA caused a 58% decrease in promoter
activity Figure 3.5A. 5’-deletion of ACCα sequences to -391, -136, and -108 bp had no
effect on CDCA responsiveness. Deletion of ACCα sequences containing the DR-4
element (-108 to -84 bp) abolished the inhibitory effect of CDCA on ACCα transcription.
Further deletion to -41 bp had no effect on CDCA responsiveness. Mutation of the SRE
(-80 to -71 bp) in the context of 108 bp of 5’-flanking DNA caused a 35% attenuation of
CDCA responsiveness on the ACCα promoter. These results indicate that the DR-4
element (LXRE) is required for CDCA regulation of ACCα transcription and that the
SRE enhances the ability of the LXRE to inhibit ACCα transcription in the presence of
CDCA.
To determine whether the functional interaction between the ACCα LXRE and
SRE required the presence of additional cis-acting sequences, hepatocytes were
transfected with constructs containing fragments of the ACCα gene linked to the minimal
promoter of the herpes simplex virus thymidine kinase (TK) gene Figure 3.5B. The TK
promoter alone was unresponsive to CDCA. When a DNA fragment containing both the
ACCα LXRE and ACCα SRE (-108 to -66 bp) was linked to the TK promoter, treatment
with CDCA caused a 60% decrease in promoter activity. Mutation of the ACCα SRE in
the context of the ACCα -108 to -66 bp fragment caused a 23% decrease in CDCA
responsiveness. When a DNA fragment containing the ACCα SRE alone (-84 to -66 bp)
was appended to the TK promoter, CDCA treatment almost completely abolished ACCα
promoter activity. These data demonstrate that the ACCα SRE can function alone to
enhance CDCA regulation conferred by the ACCα LXRE.
CDCA inhibits ACCα gene transcription by inhibiting the abundance of mature
SREBP-1 via a post-translational mechanism in chick embryo hepatocytes
In our previous studies analyzing the regulation of the ACCα gene by T0-901317,
we showed that T0-901317 treatment increased the abundance of mature, active form of
SREBP-1 in chick embryo hepatocytes and this effect contributed to the activation of
ACCα transcription by T0-901317 Chapter 2, Figure 5. Further, our studies in Figure
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3.5 suggest the involvement of the ACCα-SRE in CDCA regulation of the ACCα gene.
We wanted to determine the mechanism by which CDCA inhibits ACCα gene
transcription, and whether SREBP-1, at least in part, mediates the inhibition. We
performed time course experiments to determine the effects of CDCA on the abundance
of mature SREBP-1 protein, ACCα mRNA, SREBP-1 precursor and SREBP-1 mRNA in
hepatocytes cultured in the presence of T0-901317. Nuclear and membrane extracts and
total RNA was isolated at the indicated time points and Northern and Western blot
analysis was performed to detect levels of RNA and protein respectively. CDCA
inhibited the abundance of the mature, active form of SREBP-1 as early as 2 h with
maximal inhibition of about 40% at 12 h Figure 3.6A. The decrease in mature SREBP-1
by CDCA is correlated with the fact that treatment with CDCA caused a 20% decrease in
the abundance of ACCα mRNA as early as 2 h, with maximal inhibition of about 50%
obtained at 6 h Figure 3.6B. This observation is consistent with the proposal that
alterations in SREBP-1 levels play a role in mediating the regulation of ACCα
transcription by CDCA. Interestingly, CDCA increased the abundance of the inactive
precursor form of SREBP-1 in the membrane, significantly at 12 h and 24 h by 3- and 5fold respectively Figure 3.6C. CDCA had no effect on SREBP-1 mRNA abundance
Figure 3.6D. An increase in precursor SREBP-1 suggests a mechanism by which CDCA
increases retention of SREBP-1 in the membrane and implicates a posttranslational
mechanism that is involved in regulation of ACCα.
Several factors are associated with retention of inactive precursor SREBP-1 in the
membrane. For example, Insig-1 and Insig-2 are two proteins that have been shown to
play a role in transporting SREBP-1 from the ER to the Golgi (16, 24, 65-67). We
measured the mRNA abundance of these two genes upon addition of CDCA in presence
of T0-901317. CDCA caused a transient increase in mRNA abundance of Insig-1 about
200% at 2 h, but inhibited the abundance of the mRNA at 12 h and 24 h Figure 3.6E.
CDCA inhibited mRNA abundance of INSIG-2 mRNA transiently at 2 h Figure 3.6F.
CDCA had no effect on INSIG-2 mRNA at later time points. It is unclear whether the
transient increase of INSIG-1 mRNA at 2 h by CDCA, is sufficient to cause retention of
the precursor (inactive) form of SREBP-1 in the membrane. At the same time, CDCA
significantly inhibits INSIG-2 mRNA which would cause a decrease of the precursor
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accumulation in the membrane. Thus, the opposing effects of CDCA on INSIG-1 and -2
mRNA at 2 hours should have no effect on SREBP-1 processing. Therefore, our data
would suggest that other factors independent of the INSIG proteins may be mediating the
post-translational modification of SREBP-1 by CDCA.
CDCA modulates the binding of nuclear receptor complexes to the ACCα LXRE/T3RE
In previous work, we showed that the ACCα LXRE/T3RE (-101 to -86 bp) bound
four protein complexes in nuclear extracts prepared from chick embryo hepatocytes.
Three of these complexes (designated complexes 1, 2 and 3) contained LXR•RXR
heterodimers, whereas the fourth complex (designated complex 4) contained TR•RXR
heterodimers (73). In the absence of nuclear receptor agonists, complexes 1 and 2 were
the predominant complexes that bound to the ACCα LXRE/T3RE. Further, we have
shown that T0-901317 has opposing effects on the binding of LXR•RXR and TR•RXR
complexes to the ACCα-LXRE/T3RE Chapter 2, Figure 6. These findings have led us
to hypothesize that changes in the binding of nuclear receptor complexes to the ACCαT3RE/LXRE may play a role in mediating the inhibition of ACCα transcription by
CDCA. Gel mobility shift assays were performed using nuclear extracts from chick
embryo hepatocytes treated with or without CDCA in the presence of T0-901317. As
reported previously, a DNA probe containing the ACCα-LXRE/T3RE bound to complex
1, complex 2, and complex 4 in nuclear extracts from hepatocytes incubated in the
presence of nuclear receptor agonists.
CDCA had no effect on the binding of Complex 1 to the ACCα-LXRE upto 12 h,
but caused a slight decrease in Complex 1 binding at 24 h Figure 3.7. CDCA inhibited
the binding of Complex 2 to ACCα-LXRE at 6 h and further inhibited the binding at 12
and 24 h. As discussed previously, Complex 4 is composed of TR•RXR heterodimers,
that bind to ACCα-LXRE in the presence of thyroid hormone. We have previously
shown that T0-901317 increased the binding of Complex 4 to the promoter, in the
absence of T3 and presence of T0-901317 Chapter 2, Figure 6. CDCA inhibits the
binding of Complex 4 to the ACCα-LXRE significantly at 2 hours, and further inhibits
the binding over time. The inhibition of Complex 4 by CDCA is more dramatic than
CDCA inhibition of Complex 2. The inhibition of TR•RXR heterodimer binding to the
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ACCα-LXRE could be due to the fact that CDCA inhibits TRα mRNA abundance over
time Figure 3.8D.
The latter phenomenon would suppress the inhibitory effects of T0-901317 on
ACCα transcription because unliganded TR•RXR functions as a repressor of gene
transcription (73). It is possible that CDCA-mediated changes in the binding of nuclear
receptor complexes to the ACCα LXRE/T3RE constitutes a mechanism to prevent further
inhibition of ACCα transcription by the LXR signaling pathway. The mechanism by
which CDCA alters the binding of nuclear receptor complexes to the ACCα LXRE/T3RE
is presently unclear but does not involve changes in the expression of LXRα mRNA
Figure 3.8E.
CDCA modulates expression of several genes that may mediate inhibition of CDCA on
ACCα mRNA expression
Short heterodimeric partner (SHP) is an unusual nuclear hormone receptor that
lacks a DNA binding domain. SHP functions by dimerizing with other nuclear hormone
receptors, such as TR and LXR, and represses their ability to activate transcription. In
rodents, bile acids stimulate SHP expression via activation of the LXR signaling
pathway. Bile acid induction of SHP expression has been shown to play a role in
mediating the inhibitory effects of bile acids on cholesterol 7α hydroxylase transcription,
the rate limiting gene for synthesis of bile from cholesterol (19, 40). Human SHP
promoter has been shown to be activated by SREBP-1. Overexpression of SREBP-1
activated the human but not mouse SHP promoter (31). Thus SREBP-1 may mediate the
species-specific regulation of cholesterol and bile acid homeostasis via modulating SHP
gene expression.
To assess the role of SHP in mediating the inhibitory effects of bile acids on T0901317 induced lipogenic gene expression, we performed time course experiments with
CDCA treatment to determine whether CDCA stimulated SHP expression in chick
hepatocytes in presence of T0-901317. Surprisingly, CDCA inhibits the SHP mRNA
abundance in the presence of T0-901317 as early as 2 h and further inhibited over time
Figure 3.8A. This result suggests that SHP does not play a role in mediating the
inhibitory effects of bile acids on lipogenic gene expression in chick hepatocytes.
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PGC-1α has been shown to be a coactivator for LXRα. In transient transfection
studies, PGC-1α potentiates the LXR-mediated autoregulation and transactivation of the
LXRα promoter via the LXRE on the cholesteryl ester transfer-protein (CETP) gene
promoter in a ligand-dependent manner. Further, mutational analyses showed that the
LXXLL motif of PGC-1α is essential for coactivation of LXR-mediated transcription
(46). We wanted to determine if CDCA inhibits LXR activity by inhibiting PGC-1α
mRNA. CDCA inhibits PGC-1α mRNA abundance maximally at 2 h by 50% Figure
3.8B.
Recently, PGC-1β has been shown to be a coactivator of SREBP-1 and LXR.
This increase in SREBP-1 and LXR activity increases de novo lipogenesis and
lipoprotein secretion. PGC-1β coactivation of SREBP and LXR by high fat leads to
hypertriglyceridemia and hypercholesterolemia (39). We wanted to determine if CDCA
inhibition of ACCα mRNA is mediated by a decrease in PGC-1β levels. Our data shows
that there is a transient decrease in PGC-1β mRNA at 2 h by 25% Figure 3.8C.
However, CDCA has no effect on PGC-1β mRNA at later time points. It is unclear
whether this decrease of PGC-1β at 2 hours results in ACCα inhibition.
We have shown that CDCA inhibits the binding of unliganded TR•RXR on the
ACCα-LXRE. We wanted to determine whether this decrease in the binding of the
complex is due to changes in TR mRNA levels. Our results showed that CDCA inhibits
TR mRNA maximally at 2 h Figure 3.8D. This may explain the decreased binding of the
TR•RXR on the ACCα-LXRE. We have also shown that CDCA inhibits the binding of
LXR•RXR heterodimers on the ACCα-LXRE. This decrease in binding could be either
due to the inhibition of LXR mRNA abundance or the inhibition of LXR•RXR binding to
the ACCα-LXRE. Our results showed that CDCA had little or no effect on the
abundance of LXRα RNA in presence of T0-901317 Figure 3.8E.
Recent work has shown that bile acids stimulate fibroblast growth factor-19
(FGF-19) expression in human hepatocytes via a FXR-mediated mechanism. FGF-19 is
a member of the fibroblast growth factor (FGF) family of secreted signaling molecules.
FGF-19’s action is initiated by binding to the membrane-bound, tyrosine kinase receptor,
FGFR4. Studies with transgenic mice have shown that overexpression of FGF-19
enhances basal energy metabolism and reduces adipose stores. Expression of malic
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enzyme (ME) and stearoyl CoA desaturase (SCD) are reduced in FGF-19 transgenic
mice. (22, 23, 59, 64, 71).
Based on this information, we hypothesized that bile acids stimulate FGF-19
expression and that increased FGF-19 levels inhibit lipogenic gene expression.
Consistent with results reported for human hepatocytes, CDCA caused a transient
increase of FGF-19 mRNA abundance in chick hepatocytes in presence of T0-901317 by
750% at 2 h Figure 3.8F. CDCA increased expression of FGF-19 mRNA by 450% at 6h
and 12 h. FGF-19 mRNA levels were further increased to 600% by CDCA at 24 h.
CDCA increases the phosphorylation and activation of the mitogen activated protein
kinase (MAP Kinase) pathways
Bile acids have been shown to increase phosphorylation and activation of MAP
kinase pathways in several cell types (44). Recently, two reports showed an involvement
of ERK and p38 MAP kinase pathways as inhibitors of lipogenic gene expression (7, 56).
We hypothesized that CDCA inhibits ACCα mRNA by activating MAP kinase pathways.
Primary chick hepatocytes were treated with T0-901317 in the absence and presence of
CDCA, for the time points indicated in the figure. Total protein was isolated and western
blot analysis was performed to determine the levels of phosphorylated, active ERK, JNK
and p38 MAPK Figure 3.9. CDCA increased the phosphorylation of ERK, JNK and p38
MAP kinases at 5 min and this increase in phosphorylation was sustained upto 24 h.
CDCA also increased the phosphorylation and activation of MEK1/2, a MAPK kinase
(MAPKK), responsible for phosphorylation and activation of ERK. This increase in
phosphorylation and activation of MEK1/2 is correlated with the activity of ERK. CDCA
also increases phosphorylation and activation of MKK3/6, another MAPKK, that is
responsible for phosphorylation and activation of p38 MAPK. Again, this activation of
MKK3/6 is correlated with the activity of p38 MAPK. We also measured the
phosphorylation of Raf and found that CDCA has no effect on phosphorylation of the
protein. This shows that the effects of CDCA on phosphorylation of MAP kinases are
selective.
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ERK and p38 MAPK mediate the inhibitory effects of CDCA on ACCα mRNA
abundance
In Figure 3.9 we have shown that CDCA increases the phosphorylation and
activation of ERK, JNK and p38 MAPK. To determine whether one or all of these
MAPKs mediate CDCA inhibition of ACCα mRNA, we used inhibitors of MAPK
activity, such as U0126 for ERK, SP600125 for JNK and SB203580 for p38 MAPK.
Primary chick hepatocytes were treated with T0-901317 in the absence and presence of
CDCA. Medium was changed after 12 hours with the addition of insulin and T0-901317
in all plates and CDCA in the indicated plates. 12 hours later, cells were treated with
either the inhibitors or DMSO as control. 6 hours after addition of inhibitors and DMSO,
total RNA was isolated and ACCα mRNA was measured using real time RT-PCR. In
vehicle treated cells, CDCA inhibited the ACCα mRNA expression by about 60% Figure
3.10. However, in presence of the ERK inhibitor, U0126, the inhibition of ACCα mRNA
by CDCA was significantly decreased to about 27% Figure 3.10A. As U0126 inhibits
MEK1/2 activity, it inhibits phosphorylation and activation of ERK. Western blot
analyses with proteins isolated from identically treated plates showed that U0126
completely inhibits the phosphorylation and activation of ERK Figure 3.10C.
In presence of the p38 MAPK inhibitor SB203580, CDCA inhibition of ACCα
mRNA was almost completely abolished Figure 3.10B. We also observed similar effects
with another p38 MAPK inhibitor, SB202190 (data not shown). Our studies with the
JNK inhibitor SP600125 remain inconclusive. At the least, our data would suggest that
JNK mediates the activation of ACCα mRNA abundance by T0-901317. In presence of
T0-901317, SP600125 completely abolishes the increase in ACCα mRNA abundance by
T0-901317. More about the role of JNK in ACCα expression will be discussed in
Chapter 4, Figure 4.10.
CDCA increases FGF-19 mRNA abundance via both ERK and p38 MAPK and inhibits
PGC-1α mRNA via p38 MAPK, but not ERK
Our data upto this point shows that CDCA increases FGF-19 mRNA abundance
and increases the phosphorylation and activation of ERK and p38 MAPK. To determine
whether the increase in FGF-19 is mediated by the MAP kinases, we measured mRNA
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abundance of FGF-19 in the absence and presence of CDCA in presence of vehicle,
U0126 and SB203580. In vehicle treated cells, CDCA increases FGF-19 by about 640%
Figure 3.11. This data is consistent with our previous results showing that CDCA
increases FGF-19 over time. In presence of the ERK inhibitor U0126, the increase of
FGF-19 mRNA by CDCA was completely abolished Figure 3.11A. Similarly, in
presence of p38 MAPK inhibitor SB203580, the increase in FGF-19 mRNA by CDCA
was completely abolished Figure 3.12B. These results show that CDCA increases FGF19 mRNA via ERK and p38 MAPK.
Next, we wanted to determine whether the inhibition of PGC-1α mRNA by
CDCA is mediated by ERK and/or p38 MAPK. Chick hepatocytes were plated in the
absence and presence of CDCA in the presence of vehicle, U0126 and SB203580. Total
RNA was isolated and real time RT-PCR was performed to measure relative mRNA
abundance. In vehicle treated cells, CDCA inhibited PGC-1α mRNA by 60%, in
agreement with our previous data Figure 3.12. U0126 had no effect on CDCA inhibition
of PGC-1α mRNA Figure 3.12A. However, SB203580 completely abolished CDCA
inhibition of PGC-1α expression Figure 3.12B. These results show that CDCA
inhibition of PGC-1α is mediated by p38 MAPK, but not ERK.
Hepatocytes infected with adenovirus vectors expressing PGC-1α does not reverse
CDCA inhibition of ACCα mRNA
As discussed previously, PGC-1α is a coactivator of LXR. Our data show that
CDCA inhibits PGC-1α mRNA in chick hepatocytes, and that p38 MAPK but not ERK
mediates this effect. To establish a role of PGC-1α in mediating inhibition of ACCα
mRNA by CDCA we infected hepatocytes with adenovirus containing PGC-1α in frame
with GFP. Cells were also infected with adenovirus containing GFP and no DNA (null),
and no virus as controls. Hepatocytes were treated with equal amounts (2.2 x 1012) of
null, GFP and PGC-1α virus particles. The fluorescence of cells treated with GFP and
PGC-1α was determined to ensure infectivity. After 24 hours, 90-100% of cells treated
with both GFP and PGC-1α expressed green fluorescence (data not shown). CDCA
inhibits ACCα mRNA in uninfected cells and cells infected with adenovirus containing
null, GFP and PGC-1α Figure 3.13. Cells treated with adenovirus containing PGC-1α
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had a 10-fold increase in PGC-1α protein levels over control cells (data not shown). One
interpretation of these findings maybe that PGC-1α does not mediate CDCA inhibition of
ACCα mRNA in chick hepatocytes. However, as we cannot measure endogenous PGC1α protein for lack of a suitable antibody, our results are inconclusive. Adenovirus was
prepared by Callee M. Walsh in Dr. Salati’s lab.
Inhibition of p38 MAPK activity, but not ERK activity attenuates the effects of CDCA
on mature SREBP-1
Previous reports have shown that phosphorylation of Thr426 and Ser430 of
SREBP-1a by Gsk3β facilitates binding of the ubiquitin ligase, SCFFbw7, which targets
SREBP for 26S proteasomal degradation. Inhibition of Gsk3β activity by LiCl or insulin
increases the accumulation of SREBP (55), (32). Another report showed that n-3
polyunsaturated fatty acids (PUFAs) decrease the mature, active form of SREBP-1 in
primary rat hepatocytes through 26S proteasome and Erk-dependent pathways. Specific
inhibitors of these pathways attenuate the inhibitory effect of PUFA on mature SREBP-1
levels (7). The mechanisms by which Erk phosphorylation, and 26S proteasomal mediate
degradation of mature SREBP-1 are yet to be identified.
Based on these reports, we wanted to determine whether CDCA inhibition of
mature SREBP is mediated by ERK and/or p38 MAPK. We plated hepatocytes in the
absence and presence of CDCA in presence of either vehicle, U0126 or SB203580. As
shown previously, CDCA inhibits mature SREBP by 60% in vehicle treated cells Figure
3.14. In presence of U0126, CDCA inhibition of mature SREBP was not affected as
compared to vehicle treated controls. However, inhibition of p38 MAPK activity by
SB203580 significantly attenuated CDCA inhibition of mature SREBP-1 by about 35%.
We propose that CDCA mediates inhibition of ACCα mRNA by increasing p38 MAPK
pathway, which in turn, phosphorylates SREBP-1 and targets it for degradation.
Effects of CDCA on ACCα mRNA abundance, ERK and p38 MAPK activity are
selective
CDCA increases low density lipoprotein receptor (LDLr) gene expression via
ERK activation-mediated stabilization of LDLr mRNA via activating SHP (44). These
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authors reported that ursodeoxycholic acid (UDCA) had no effect on LDLr and SHP
mRNA. These results suggested that the structural difference between CDCA and
UDCA, specifically the 7β-hydroxy epimer of CDCA, is critical for the activation of
ERK and binding to FXR (41, 48). The lack of inhibitory effect of UDCA on LDLr can
be accounted for the fact that UDCA does not activate ERK (8). Octyl β-Dglucopyranoside, a detergent also had no effect on ERK activity (43). These results
suggest that bile acids activate MAP kinases in a specific manner, not by their detergent
effects, but by specific side chain residues and three-dimensional structure.
We wanted to determine whether other bile acids besides CDCA, demonstrated
similar effects on ACCα mRNA, ERK and p38 MAPK. We tested cholic acid (CA),
deoxycholic acid (DCA), ursodeoxycholic acid (UDCA), taurocholic acid (TCA),
hyodeoxycholic acid (HDCA), and taurodeoxycholic acid (TDCA) for their ability to
modulate ACCα mRNA abundance, ERK and p38 MAPK activity. Chick hepatocytes
were plated in presence of T0-901317 in absence and presence of the indicated bile acids.
6 hours after incubation with bile acids, total RNA and protein was isolated. Real time
RT-PCR analysis showed that CDCA inhibits ACCα mRNA about 50%, and all other
bile acids tested had no effect Figure 15. Western blot analysis showed that only CDCA
robustly activates ERK and p38 MAPK. There may be a slight effect of CA and DCA on
p38 MAPK activity. These results showed that the effects of CDCA are highly selective.
CDCA is the most potent modulator of gene expression
As discussed in Chapter 1, relative hydrophobicity is a major determinant of bile
acid action. CDCA is one of the most hydrophobic bile acids. We wanted to determine
whether effects of CDCA on gene expression are specific and also wanted to determine
the effects of other bile acids on gene expression. We performed Northern blot and real
time RT-PCR analysis to determine mRNA abundance of FAS, SCD, FGF-19, ABCA1,
PGC-1α and PGC-1β Figure 3.16. We have shown that CDCA inhibits FAS, SCD and
PGC-1α, increases FGF-19 and ABCA1, and has no effect on PGC-1β mRNA. Both CA
and DCA inhibit FAS and SCD mRNA abundance by about 50%. CDCA inhibits both
these genes by about 80%. Other bile acids had no effect on FAS and SCD mRNA
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abundance. CDCA causes an 8-fold increase in FGF-19 mRNA. CA and DCA cause a
two-fold increase in FGF-19 mRNA. Other bile acids had no effect on FGF-19 mRNA.
CDCA causes a two-fold increase in ABCA1 mRNA. TDCA causes a significant
(1.5-fold) increase in ABCA1 mRNA, although the extent of increase is not as great as by
CDCA. All other bile acids had no effect on ABCA1 mRNA. CDCA causes a 60%
decrease in PGC-1α mRNA, but other bile acids had no effect on PGC-1α mRNA.
CDCA had no effect on PGC-1β mRNA. Both DCA and UDCA significantly inhibited
PGC-1β by 30% and 25% respectively. Other bile acids have no effect on PGC-1β
mRNA. The effect of CDCA on all these genes is consistent with results shown in this
Chapter.
CDCA inhibits the recruitment of acetylated histones H3 and H4 on the ACCα
promoter
The decrease in ACCα transcription by CDCA may be mediated in whole or in
part by alterations in histone acetylation on the ACCα promoter. Previous studies have
shown that the activation of LXR•RXR heterodimers by LXR ligands/agonists recruits
coactivator complexes containing histone acetyltransferase (HAT) activity (1, 61). We
have shown that T0-901317 causes a transient increase in histone acetylation on the
ACCα promoter Chapter2, Figure 7. Increased histone acetylation causes a chromatin
decondensation that enhances the accessibility of the basal transcriptional machinery and
other transcription factors to the target promoter. On the other hand, decreased histone
acetylation causes chromatin condensation that inhibits the recruitment of basal
transcription machinery and cofactors on the promoter.
To investigate the role of histone acetylation in mediating the inhibition of ACCα
transcription by CDCA, chromatin immunoprecipitation (ChIP) were performed in chick
embryo hepatocytes incubated in the absence or presence of CDCA. Hepatocytes were
treated with 1% formaldehyde to cross-link DNA to associated proteins. Protein-DNA
complexes were immunoprecipitated with an antibody against acetylated histone H3 or
acetylated histone H4. Immunoprecipitated DNA was analyzed by PCR using primers
that flanked the ACCα LXRE/T3RE. In hepatocytes incubated in the absence of CDCA,
acetylation of histone H3 and histone H4 was detected at the ACCα LXRE Figure 3.17.
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Addition of CDCA to the culture medium caused a significant decrease in the acetylation
of histone H3 and H4. We also performed ChIP analysis in an uncharacterized region of
the SCD1 promoter using a primer set that amplified SCD sequences between -369 and 193 bp. In contrast to the data for ACCα, CDCA had no effect on histone acetylation on
SCD.

DISCUSSION
Data so far demonstrated that the previously identified ACCα-LXRE confers
CDCA regulation on ACCα promoter 2. We also demonstrated that SREBP-1 is an
accessory factor that enhances the ability of LXRE to inhibit ACCα transcription by
CDCA Figure 3.5. Our results showed that CDCA decreases the concentration of
mature, active form of SREBP-1 in chick embryo hepatocytes. As shown previously,
CDCA inhibits mature SREBP-1 by inhibiting post-translational modification of SREBP1 Figure 3.6.
We have shown that p38 MAPK but not ERK mediates inhibitory effects of
CDCA on ACCα expression by modulating mature SREBP-1 levels. It is possible that
activation of p38 MAPK by CDCA results in phosphorylation of SREBP-1 at Thr426
and/or Ser430 as these residues are conserved in chicken. Dr. Johan Ericsson has kindly
provided us with a phospho-Thr426 antibody. Data from western blot experiments
performed with this antibody are inconclusive. We speculate that p38 MAPK
phosphorylates SREBP-1 at Thr426 and/or Ser430 and targets the protein for
degradation.
Although we have provided evidence that shows LXRE mediates ACCα
inhibition by CDCA, data from in vitro binding assay showed that CDCA does not
directly modulate binding activity of LXR•RXR heterodimers on the ACCα-LXRE
Figure 3.7. We have shown that CDCA enhances the recruitment of unliganded
TR•RXR on the LXRE. This would result in an increase in ACCα expression as previous
reports have shown that unliganded TR•RXR is an inhibitor of ACCα expression.
Therefore it is possible that the increase in binding activity of TR•RXR acts to prevent
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inhibition of ACCα mRNA below basal levels to allow the cells to have a steady supply
of fatty acids that are an integral part of membranes.
Our data shows that CDCA mediates its inhibitory effects on ACCα mRNA
expression by activation of p38 MAPK. Using SB203580, a p38 MAPK inhibitor, the
inhibition of ACCα mRNA by CDCA was completely abolished. It is interesting to note
that SB203580 alone causes a 60% increase in ACCα mRNA in the absence of CDCA
Figure 3.10. In the absence of CDCA, P-p38 MAPK levels are readily detected, as
shown in Figure 3.9. Taken together, these results would suggest that basal levels of Pp38 MAPK have an inhibitory effect on ACCα mRNA expression. Upon CDCA
addition, p38 MAPK is further activated, and this results in ACCα mRNA inhibition as
shown in Figure 3.10B. The role of basal P-p38 MAPK as an inhibitor of ACCα mRNA
is also consistent with the fact that SB203580 alone increases mature SREBP-1 levels
Figure 3.14, Lane 5. We have previously shown that an increase in mature SREBP-1 is
correlated with an activation of ACCα mRNA expression Chapter 2, Figure 5. As
discussed in Chapter 1, oxysterols (oxidized derivatives of cholesterol) are endogenous
ligands/agonists of LXR. An increase in oxysterols would lead to an increase in
lipogenic enzyme expression that would lead to the formation of triglycerides. Thus, p38
MAPK prevents the over-activation of the lipogenic pathway, thereby preventing the
accumulation of plasma triglycerides.
One interesting finding in our work is the sustained activity of the MAPKs Figure
3.9. The sustained activation of ERK and p38 MAPK may be required for the sustained
inhibition of ACCα mRNA. Early activation of ERK and p38 MAPK trigger cellular
processes that inhibit ACCα initially. Once ACCα mRNA levels are inhibited, other
processes may be involved to ensure that ACCα mRNA levels are still reduced. Our
studies on CDCA inhibition show the involvement of multiple pathways that mediate
CDCA inhibition of ACCα such as SREBP-1, histone acetylation and possibly FGF-19.
Activated MAPKs at later time points act to ensure low abundance of ACCα mRNA in
presence of T0-901317.
The mechanisms responsible for the sustained activity of MAPKs are unclear.
One possibility is that CDCA inhibits the activity of the specific phosphatases that
inactivate MAPKs. For example, it has been reported that MAPK phosphatase-3 (MKP-
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3), which is a highly selective phosphatase that inactivates ERK, inhibits insulinmediated repression of the PEPCK promoter (11). However, this study also showed that
the effect of MKP-3 is not due to dephosphorylation and inactivation of ERK. It is
possible that in hepatocytes the activity of other MKPs is inhibited by CDCA.
We have also determined that CDCA increases the phosphorylation and activation
of JNK. Our data with ERK and p38 MAPK inhibitors showed that both these MAPKs
mediate inhibitory effects of CDCA on ACCα mRNA. In contrast, studies with the JNK
inhibitor SP600125 showed that JNK mediates activation of ACCα mRNA by T0-901317
(Chapter 4). The mechanism for such selective activity by the MAPKs is unclear.
The role of bile acids in recent times have emerged from that of lipid solubilizers
to signaling molecules that modulate several important cellular processes. Recently the
identification of a cell surface receptor TGR5, a member of the G-protein coupled
receptor (GPCR) family has further established an endocrine role for bile acids. In fact
reports have shown that bile acid treatment increases cAMP levels, that is a classic
measure of GPCR activity (30). Another report has shown that bile acids promote energy
expenditure by increasing cAMP. GPCRs have been shown to activate MAPKs (42). It
is therefore tempting to speculate that bile acids bind to a cell surface receptor on
hepatocytes that belong to the GPCR family. The activated GPCR increases cAMP
levels that would in turn activate MAPKs, which in turn would lead to an inhibition of
lipogenic genes. This theory although attractive, is probably not the mechanism for
ACCα inhibition by CDCA in chick hepatocytes. First, cAMP does not inhibit T0901317-induced ACCα mRNA expression in chick hepatocytes (Data not shown).
Second, cAMP does not activate any MAPK pathways in chick hepatocytes (Data not
shown). Taken together, these reports suggest that in hepatocytes, bile acids inhibit
lipogenic enzyme expression by a mechanism not involving cAMP.
Finally, this report shows that CDCA inhibits T0-901317-induced expression of
lipogenic genes by increasing MAPKs such as p38 MAPK. CDCA mediates inhibition of
ACCα by modulating mature SREBP-1. Identification of the signaling pathways
mediating CDCA inhibition of lipogenic genes may lead to identification of compounds
that would combat atherosclerosis.
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FIGURE LEGENDS
Figure 3.1: Hexanoate inhibits the stimulatory effect of T0-901317 on acetyl CoA
carboxylase α (ACCα), fatty acid synthase (FAS), stearoyl CoA desaturase (SCD) and
ATP-binding cassette protein A1 (ABCA1) mRNA, but not sterol regulatory element
binding protein-1 (SREBP-1) and liver X receptor α (LXRα) mRNA expression, in a dose
dependent manner. Chicken embryo hepatocytes were plated in the absence of hormones
overnight. Medium was changed and the cells were treated with indicated amounts of
hexanoate, T0-901317 (6 µM), and insulin (50 nM) for 24 hours. Total RNA was
isolated and Northern blot analysis was performed to determine the mRNA levels of the
genes. Data shown are representative of two experiments for SREBP-1 and LXRα, and
three experiments for ACCα and ABCA1.

Figure 3.2: Chenodeoxycholic acid (CDCA) inhibits the T0-901317 induced expression
of ACCα, FAS, SCD and HMG-CoA reductase mRNA, but increases the T0-901317
induced expression of ABCA1 mRNA in a dose dependent manner. Chicken embryo
hepatocytes were plated in the absence of hormones overnight. Medium was changed
and the cells were treated with the indicated amounts of CDCA, insulin (50 nM) and T0901317 (6 µM) for 24 hours. Total RNA was isolated and Northern blot analysis was
performed to determine mRNA levels. HMG-CoA reductase mRNA was detected using
real time RT-PCR as described in Methods. Data represents mean ± SE of at least four
experiments. The values for mRNA abundance for the treatments have been calculated
with respect to the insulin treatment (Lane 1), the value of which was set to 1.

Figure 3.3: CDCA inhibits total ACC protein and triglyceride secretion in medium. A)
Chick hepatocytes were plated in the absence of hormones overnight. Medium was
changed and insulin and T0-901317 were added to all plates. 24 hours later, medium was
changed again with the addition of insulin and T0-901317 to all plates and CDCA (75
µM) was added in the indicated plates. Total protein was isolated from plates at the
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indicated time points and western blot analysis was performed to determine total ACC.
B) For triglyceride measurements, cells were plated in the absence of hormones
overnight. Medium was changed with the addition of insulin (50 nM) and T0-901317 (6
µM) to all plates in the absence and presence of CDCA (75 µM). Medium from the
plates were collected 24 hours later, and triglyceride assay was performed according to
manufacturer’s protocol (Sigma). Data shown are mean ± SE of three experiments.

Figure 3.4: Chenodeoxycholic acid (CDCA) inhibits the T3-induced expression of
ACCα, FAS, SCD and ME mRNA, but increases the expression of ABCA1 mRNA in a
dose dependent manner. Chicken embryo hepatocytes were plated in the absence of
hormones overnight. Medium was changed and the cells were treated with the indicated
amounts of CDCA, insulin (50 nM) and T3 (1.5 µM) for 24 hours. Total RNA was
isolated and Northern blot analysis was performed to determine mRNA levels. Data
represents mean ± standard deviation of two experiments. The values for mRNA
abundance for the treatments have been calculated with respect to the insulin treatment
(Lane 1), the value of which was set to 1.

Figure 3.5: A) Effects of deletions of the 5'-flanking region of ACCα promoter 2 on
transcriptional activity in the absence and presence of CDCA. CEHs were transiently
transfected with p[ACC-2054/+274] chloramphenicol acetyltransferase (CAT) or
equimolar amounts of other plasmids as described under Experimental Procedures. After
transfection, cells were treated with T0-901317 and insulin in the absence or presence of
CDCA for 48 h. Protein extracts prepared as described in Materials and methods, and
CAT assays performed. Left: The constructs used in these experiments. The number at
the left of each construct is the 5'-end of ACCα DNA in nucleotides relative to the
transcription initiation site of promoter 2. The 3'-end of each construct was +274 bp.
The location of the LXR response element (LXRE) is between -101 to -86 bp and SRE-1
is between -80 to -71 bp is indicated by the vertical lines. Right: CAT activity of cells
transfected with p[ACC-108/+274]SRE(mut2)CAT and treated with T0-901317 and
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insulin was set at 1, and the other activities were adjusted proportionately. The percent
inhibition by CDCA is the CAT activity of cells treated with T0-901317, insulin, and
CDCA expressed as a percentage of that in cells treated with T0-901317 and insulin and
subtracted from 100. The results are the means ± SEM of at least four experiments.
Significant differences between means within the column (P < 0.05) are as follows: a
indicates that p[ACC-108/+274]SRE(mut 2)CAT is different from all other constructs. b
indicates that p[ACC-82/+274]CAT is significantly different from all other constructs.
B) Fragments of the ACCα gene containing the LXRE and/or SRE-1 were linked to the
minimal thymidine kinase (TK) promoter in TKCAT. CEHs were transiently transfected
with these constructs and treated with T0-901317 and insulin in the absence or presence
of CDCA as described in Part A (above) and under Experimental Procedures. Left:
Constructs used in these experiments. Numbers indicate the 5' and 3' boundaries of
ACCα DNA relative to the transcription initiation site of promoter 2. Right: CAT
activity in CEH transfected with p[ACC-TKCAT and treated with T0-901317 and insulin
was set at 1, and the other activities were adjusted proportionately. The percent
inhibition by CDCA on ACCα promoter activity was calculated as described in the
legend to Part A. The results are the means ± SEM of at least five experiments.
Significant differences between means within the column (p < 0.05) are as follows: a,
versus any other construct.

Figure 3.6: CDCA inhibits ACCα mRNA by inhibiting mature SREBP-1 via a posttranslational mechanism. CEHs were plated in the absence of hormones overnight.
Medium was changed with the addition of insulin (50 nM) and T0-901317 (6µM) in all
plates. 24 hours later, medium was changed again, with the addition of CDCA (75 uM)
in the indicated plates. Total RNA, nuclear and membrane protein extracts were prepared
at the indicated time points. ACCα, SREBP-1, INSIG-1 and INSIG-2 mRNA abundance
was measured using Northern blot analysis. Mature and precursor SREBP-1 was
determined using Western blot analysis. The signals from blots were quantified using
ImageQuaNT software. The value of insulin and T0-901317 treated sample at time 0,
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was set at 1. Data represents mean ± SE for at least three experiments. * indicates
significant values at p<0.05.

Figure 3.7: Effect of CDCA on the binding of hepatic nuclear proteins to the ACCα
LXRE. A) Eighteen hours after being placed in culture, CEHs were incubated in
Waymouth's medium containing insulin (50 nM), and T0-901317 (6 µM), with or without
CDCA 75 µM for the indicated times. Cells were harvested and nuclear extracts were
prepared as described in Experimental Procedures. Nuclear extracts were subjected to
gel mobility shift analyses using an oligonucleotide probe containing the ACCα LXRE (108 to -82 bp). Specific protein-DNA complexes are indicated by arrows. Previous
studies have shown that complexes 1 and 2 contain liver X receptor (LXR)•retinoid X
receptor (RXR) heterodimers, whereas complex 4 contains nuclear T3 receptor
(TR)•RXR heterodimers. These data are representative of five experiments employing
independent preparations of nuclear extract. B) Signal from the complexes was
quantified using ImageQuaNT software. The value for the samples treated with insulin
and T0-901317 at 0 h was set to 1. Data represents mean ± SE of four experiments.

Figure 3.8: CDCA modulates the mRNA abundance of short heterodimeric partner
(SHP), PPAR-gamma coactivator -1α (PGC-1α), PPAR-gamma coactivator -1β (PGC1β), thyroid receptor (TR), liver X receptor (LXR) and fibroblast growth factor-19 (FGF19). CEHs were plated in the absence of hormones overnight. Medium was changed
with the addition of insulin and T0-901317 in all plates. 24 hours later, medium was
changed again, with the addition of insulin (50 nM), T0-901317 (6 µM) and CDCA (75
µM) as indicated. Total RNA was harvested from the plates at the indicated time points
and relative mRNA abundance was measured using realtime RT-PCR. The value for
insulin and T0-901317 treated sample at time 0 was set at 1. Data represents mean ± SE
of at least three experiments.
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Figure 3.9: CDCA phosphorylates and activates mitogen-activated protein kinase
(MAPK) pathways. CEHs were plated in the absence of hormones overnight. Medium
was changed with the addition of insulin (50 nM) and T0-901317 (6 µM) in all plates. 24
hours later, medium as changed again, with the addition of insulin and T0-901317 in all
plates and CDCA (75 µM) in the indicated plates. Total protein was harvested from the
plates at the indicated time points. Western blot analysis was performed to determine
MAPK levels using antibodies as described in Methods. Phosphorylation of Raf at all the
corresponding time points serves as a negative control. Data are representative of at least
three experiments.

Figure 3.10: CDCA mediates inhibitory effects on ACCα mRNA abundance via ERK
and p38 MAPK pathways. CEHs were plated in the absence of hormones overnight.
Medium was changed with the addition of insulin and T0-901317 in all plates. 12 hours
later, medium was changed again with the addition of insulin and T0-901317. 12 hours
later, ERK inhibitor U0126 (20 µM) A), and p38 MAPK inhibitor SB203580 (20 µM)
B), was added to the indicated plates. Control cells were treated with equal volume of
DMSO. DMSO by itself has no effect on ACCα mRNA levels (data not shown). 1 hour
after the addition of inhibitors, CDCA was added to the indicated plates. Total RNA was
isolated 6 hours after the addition of CDCA and relative mRNA was determined using
real time RT-PCR. The column indicates percent inhibition by CDCA for vehicle
treated, U0126 treated A), and SB203580 treated B), plates. The percent inhibition by
CDCA relative mRNA abundance of cells treated with T0-901317, insulin, and CDCA
expressed as a percentage of that in cells treated with T0-901317 and insulin and
subtracted from 100. * represents that the data is significant at p<0.05. Data represents
mean ± SE of five experiments.

Figure 3.11: CDCA mediates stimulatory effects on ACCα mRNA abundance via ERK
and p38 MAPK pathways. CEHs were plated in the absence of hormones overnight.
Medium was changed with the addition of insulin (50 nM) and T0-901317 (6 µM) in all
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plates. 12 hours later, medium was changed again with the addition of insulin and T0901317. 12 hours later, ERK inhibitor U0126 (20 µM) A), and p38 MAPK inhibitor
SB203580 (20 µM) B), was added to the indicated plates. Control cells were treated with
equal volume of DMSO. DMSO by itself has no effect on FGF-19 mRNA levels (data
not shown). 1 hour after the addition of inhibitors, CDCA was added to the indicated
plates. Total RNA was isolated 6 hours after the addition of CDCA and relative mRNA
was determined using real time RT-PCR. The column indicates percent activation by
CDCA for vehicle treated, U0126 treated A), and SB203580 treated B), plates. The
percent activation by CDCA relative mRNA abundance of cells treated with T0-901317,
insulin, and CDCA expressed as a percentage of that in cells treated with T0-901317 and
insulin. * represents that the data is significant at p<0.05. Data represents mean ± SE of
four experiments.

Figure 3.12: CDCA mediates inhibitory effects on PGC-1α mRNA abundance via p38
MAPK, but not ERK pathway. CEHs were plated in the absence of hormones overnight.
Medium was changed with the addition of insulin and T0-901317 in all plates. 12 hours
later, medium was changed again with the addition of insulin and T0-901317. 12 hours
later, ERK inhibitor U0126 (20 µM) A), and p38 MAPK inhibitor SB203580 (20 µM)
B), was added to the indicated plates. Control cells were treated with equal volume of
DMSO. DMSO by itself has no effect on PGC-1α mRNA levels (data not shown). 1
hour after the addition of inhibitors, CDCA was added to the indicated plates. Total
RNA was isolated 6 hours after the addition of CDCA and relative mRNA was
determined using real time RT-PCR. The column indicates percent inhibition by CDCA
for vehicle treated, U0126 treated A), and SB203580 treated B), plates. The percent
inhibition by CDCA relative mRNA abundance of cells treated with T0-901317, insulin,
and CDCA expressed as a percentage of that in cells treated with T0-901317 and insulin
and subtracted from 100. * represents data is significant at p<0.05. Data represents mean
± SE of five experiments.
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Figure 3.13: Chick hepatocytes infected with adenovirus overexpressing PGC-1α does
not reverse the inhibitory effects of CDCA on ACCα mRNA expression. CEH were
plated in the absence of hormones. Four hours later, medium was changed with the
addition of insulin (50 nM) and T0-901317 (6 µM) and infected with adenovirus
containing the indicated proteins. Cells were treated with approximately 2.2 x 1012 virus
particles of null, GFP and PGC-1α per plate. Hepatocytes that were uninfected by virus
and treated in parallel served as controls. 24 hours after addition of the adenovirus,
medium was changed again with addition of insulin and T0-901317 in all plates and
CDCA in the indicated plates. 24 hours later, total RNA was harvested from the cells and
real time RT-PCR was performed to determine relative ACCα mRNA levels. Data is
representative of three experiments.

Figure 3.14: CDCA inhibits mature SREBP-1 via p38 MAPK, but not ERK. CEHs
were plated in the absence of hormones overnight. Medium was changed with the
addition of insulin and T0-901317 in all plates. 12 hours later, medium was changed
again with the addition of insulin and T0-901317 in all plates. 12 hours later, DMSO
(vehicle), U0126 and SB203580 were added in the indicated plates. One hour after the
addition of inhibitors, CDCA was added to the indicated plates. 6 hours later, nuclear
extracts were prepared and western blot analysis was performed to determine mature
SREBP-1 levels. The signals for SREBP-1 were quantified by ImageQuaNT. The values
for CDCA, insulin and T0-901317 treated cells were expressed as a percent of cells
treated with T0-901317 and insulin. * represents significance at p<0.05. Data represents
mean ± SE of five experiments.

Figure 3.15: CEHs were plated in the absence of hormones. Eighteen hours later,
medium was changed with the addition of insulin and T0-901317 to all plates. 12 hours
later, medium was changed again, with the addition of insulin and T0-901317 in all
plates. 12 hours later, cells were treated with CDCA, cholic acid (CA), deoxycholic acid
(DCA), ursodeoxycholic acid (UDCA), taurocholic acid (TCA), hyodeoxycholic acid
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(HDCA) and taurodeoxycholic acid (TDCA). The concentration of all bile acids in the
medium was 75 µM. 6 hours after addition of bile acids, total RNA and total protein was
harvested from cells. ACCα mRNA abundance was determined using real time RT-PCR
analysis. ERK and p38 MAPK were determined by western blot analysis using
antibodies as described. Data are representative of three experiments.

Figure 3.16: CEHs were plated in the absence of hormones. Eighteen hours later,
medium was changed with the addition of insulin and T0-901317 to all plates. 12 hours
later, medium was changed again, with the addition of insulin and T0-901317 in all
plates. 12 hours later, cells were treated with CDCA, cholic acid (CA), deoxycholic acid
(DCA), ursodeoxycholic acid (UDCA), taurocholic acid (TCA), hyodeoxycholic acid
(HDCA) and taurodeoxycholic acid (TDCA). The concentration of all bile acids in the
medium was 75 µM. 6 hours after addition of bile acids, total RNA and total protein was
harvested from cells. FAS, SCD, FGF-19 and ABCA1 mRNA was determined by
Northern blot analysis, and PGC-1α and -1β mRNA was determined by real time RTPCR analysis. The value of the sample treated with insulin and T0-901317 was set to 1.
Data represents mean ± STDEV for FAS, SCD, FGF-19 and ABCA1 mRNA and mean ±
SE of three experiments for PGC-1α and -1β.

Figure 3.17: CDCA inhibits recruitment of acetylated histones on the ACCα promoter.
Chick hepatocytes were plated in presence of insulin (50 nM) and T0-901317 (6 µM) n
the absence and presence of CDCA (75 µM). The association of acetylated histones H3
and H4 with ACCα and SCD gene was measured by chromatin immunoprecipitation
assay as described in Methods. Immunoprecipitates were analyzed by PCR using primers
described in Methods and indicated in the figure. Chromatin samples that were processed
identically in the absence of primary antibody served as controls. Data are representative
of three independent experiments.
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Chapter 4
Appendix
RESULTS
CDCA activates PKC, but synthetic activators of PKC do not mimic the effects of
CDCA in chick embryo hepatocytes
Previous reports have shown that bile acids induce the expression of
inflammatory cytokines such as tumor necrosis factor-α (TNFα) and interleukin (IL-1β).
These cytokines are recognized by high affinity receptors on hepatic parenchymal cells,
that activate protein kinase-C (PKC) (13). Activation of PKC has been shown to increase
Mg2+ accumulation in hepatocytes via ERK and p38 MAPK (18). We wanted to
determine whether bile acids activate PKC in chick hepatocytes, and whether activation
of PKC results in ACCα mRNA inhibition via ERK and/or p38 MAPK. Chick
hepatocytes were plated and treated with CDCA and inhibitors as described in Chapter 3.
6 hours after addition of CDCA, total protein was harvested from cells. Western blot
analysis showed that CDCA increases phoshorylation and activation of phospho-PKC at
6 h Figure 4.1. ERK inhibitor U0126, and p38 MAPK inhibitor SB203580 did not
reverse the effects of CDCA on PKC activation. These results suggest that PKC
activation by CDCA is not mediated by ERK and p38 MAPK and that both these MAPKs
are probably downstream of PKC.
Next, we wanted to determine whether phorbol esters that are very well
documented activators of PKC (11, 12, 20) were able to mimic the inhibitory effects of
CDCA on ACCα mRNA expression and activation of ERK and/or p38 MAPK. Chick
hepatocytes were treated as described above. 12-O-tetradecanoyl-phorbol-13-acetate
(TPA) was added to plates as indicated and total RNA and protein was isolated at the
indicated time points. ACCα mRNA was detected using real time RT-PCR. TPA had no
effect on ACCα mRNA both at 6 h and 12 h. Moreover, addition of the p38 MAPK
inhibitor SB203580, also had no effect on ACCα mRNA in the presence of TPA. To
determine whether TPA activated PKC and ERK and/or p38 MAPK, we performed
western blot analysis to determine the levels of phospho-PKC, phospho-ERK and
phospho-p38 MAPK. Our results showed that TPA had no effect on the phosphorylation
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of PKC, ERK and p38 MAPK (Data not shown). One explanation for this observation is
that TPA is not active in chick hepatocytes.
To further determine the role of PKC in mediating CDCA inhibition of ACCα, we
incubated chick hepatocytes in presence of insulin and T0-901317, insulin and T0901317 and CDCA, and insulin and T0-901317 and CDCA plus the PKC inhibitor GF109203X. The PKC inhibitor did not attenuate or abolish the effects of CDCA on ACCα
mRNA (Data not shown). It is possible that GF-109203X is not active in chick
hepatocytes or that PKC does not mediate CDCA inhibition of ACCα. At present our
results are inconclusive.
CDCA increases phosphorylation of AMP-activated protein kinase in presence of
insulin and T0-901317
We have shown in Chapter 3 that CDCA inhibits ACCα mRNA levels by
inhibiting mature SREBP-1. We wanted to determine whether CDCA activates other
agents that inhibit SREBP-1 expression. Reports in the literature has shown that
phosphorylated active AMP-activated protein kinase (P-AMPK) inhibits SREBP-1 (22).
Further, studies have also shown that activators of AMPK such as 5-aminoimidazole-4carboxamide 1-beta-ribofuranoside (AICAR), and the alkaloid drug berberine, inhibits
triglyceride and cholesterol synthesis (1, 6, 16). LKB1 is upstream kinase of AMPK (8,
15, 19). CDCA increased phosphorylation of AMPK at Thr172 at 6 h, 12 h and 24 h
Figure 4.2. The activation of AMPK at 6 h was preceded by an increase in
phosphorylation and activation of the AMPK upstream kinase, LKB1. CDCA activates
LKB1 at 2 h and the activation is sustained through 24 h. CDCA also activated
phosphorylation of ACC at Ser79. Phosphorylation of ACC at Ser 79 is a direct measure
of AMPK activity (1, 3, 6). As we showed previously in Chapter 3, CDCA inhibited total
ACC levels. Phospho ACC/total ACC ratio was greater than 1.5 from 6 h. CDCA had
no effect on total AMPK levels.
AICAR has no effect on ACCα mRNA abundance in presence of insulin and T0901317
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Since CDCA increases AMPK activity, we wanted to determine whether known
activators of AMPK such as AICAR, can mimic inhibitory effects of CDCA on ACCα
mRNA. We incubated chick hepatocytes in the presence of insulin, insulin and T0901317 for 40 hours. AICAR was added to the plates after 40 hours. 6 hours after
addition of AICAR, total RNA was isolated and real time RT-PCR was performed to
determine ACCα mRNA. Surprisingly, AICAR had no effect on ACCα mRNA
abundance in presence of insulin and T0-901317 and insulin Figure 4.3.
Next, we wanted to determine whether AICAR phosphorylated AMPK, ACC
protein and p38 MAPK. Cells were plated and treated with AICAR as described above.
Total protein was harvested from the cells 6 hours after addition of AICAR. Western blot
analysis showed that AICAR had no effect on phosphorylation of AMPK, ACC and p38
MAPK. The lack of effect of AICAR on AMPK is surprising as AICAR is a very well
documented activator of AMPK. These results suggest that increase in AMPK activity
by CDCA does not mediate inhibition of ACCα mRNA.
AICAR inhibits T3-induced ACCα mRNA expression by activating AMPK, p38 MAPK
and inhibiting mature SREBP-1
Our results showed that CDCA inhibits both T0-901317 and T3 induced
expression of lipogenic genes in chick hepatocytes. We also showed that CDCA
activated P-AMPK in presence of T0-901317. However, AICAR that is an activator of
AMPK, had no effect on ACCα expression or AMPK activation in presence of insulin
and insulin and T0-901317. We therefore wanted to determine whether AICAR inhibits
ACCα mRNA in presence of T3 by activating AMPK. Chick hepatocytes were plated
and treated as described. 40 hours after stimulation with T3, AICAR was added in the
indicated concentrations. 6 hours after AICAR addition, total protein and RNA was
isolated. Western blot analysis was performed to determine P-AMPK, P-ACC and P-p38
MAPK, and real time RT-PCR was performed to analyze ACCα mRNA levels.
Consistent with our earlier findings, AICAR had no effect on P-AMPK, P-ACC,
P-p38 MAPK and ACCα mRNA in presence of insulin Figure 4.4. Surprisingly, AICAR
phosphorylated and activated AMPK and p38 MAPK, and phosphorylated ACC. AICAR
also inhibited mature, active SREBP-1 protein. The increase in p38 MAPK activity and
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decrease of mature SREBP-1 by AICAR is correlated with an inhibition of ACCα mRNA
inhibition by AICAR in presence of T3 in a dose dependent manner. These data provide
evidence that AMPK mediates the inhibitory effect of CDCA on T3-induced ACCα
mRNA expression, but not T0-901317-induced ACCα mRNA expression. The
implications of AMPK activation and specificity of effects are unclear.
It has already been established that feeding a high carbohydrate diet causes an
increase in insulin and T3 that mediate an increase in lipogenic gene transcription in liver
(4, 5, 10). Increase in T3 concentration in liver activates the transcription of the genes for
ACCα (9), fatty acid synthase (17) and malic enzyme (14). Feeding carbohydrate also
increases the levels of nuclear T3 receptors (TRs) in liver that may result in the
stimulation of lipogenic gene transcription by dietary carbohydrate (2). Thus inhibition
of lipogenic gene expression in presence of insulin and T3 by bile acids may act to inhibit
lipogenic gene transcription in a feedback mechanism.
CDCA inhibits T3-induced ACCα mRNA via a cis acting element on the promoter
We have previously shown that T0-901317 and CDCA regulation on ACCα is
mediated by a 23 bp region (-101 to -71 bp) in promoter 2 of the ACCα gene. This
region consists of a DR-4 element (-101 to -86 bp) that binds heterodimers comprised of
TR•RXR and LXR•RXR and a SRE (-82 to -71 bp) that binds SREBP-1. To determine
whether the functional interaction between the ACCα T3RE and SRE required the
presence of additional cis-acting sequences, hepatocytes were transfected with constructs
containing fragments of the ACCα gene linked to the minimal promoter of the herpes
simplex virus thymidine kinase (TK) gene. The TK promoter alone was unresponsive to
CDCA Figure 4.5. When a DNA fragment containing both the ACCα T3RE and ACCα
SRE (-108 to -66 bp) was linked to the TK promoter, treatment with CDCA caused a
50% decrease in promoter activity. Mutation of the ACCα SRE in the context of the
ACCα -108 to -66 bp fragment had no change in CDCA responsiveness. Similarly, when
the ACCα T3RE was linked to the TK promoter, there was no change in promoter
activity by CDCA. When a DNA fragment containing the ACCα SRE alone (-84 to -66
bp) was appended to the TK promoter, CDCA treatment almost completely abolished
ACCα promoter activity.
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CDCA modulates the binding of nuclear receptor complexes to the ACCα LXRE/T3RE
in presence of insulin and T3
In previous work, we showed that the ACCα LXRE/T3RE (-101 to -86 bp) bound
four protein complexes in nuclear extracts prepared from chick embryo hepatocytes ().
Three of these complexes (designated complexes 1, 2 and 3) contained LXR•RXR
heterodimers, whereas the fourth complex (designated complex 4) contained TR•RXR
heterodimers. In the absence of nuclear receptor agonists, complexes 1 and 2 were the
predominant complexes that bound to the ACCα LXRE/T3RE. T3 treatment caused an
increase in the binding of complexes 3 and 4. These findings have led us to propose that
changes in the binding of nuclear receptor complexes to the ACCα-LXRE/T3RE play a
role in mediating the activation of ACCα transcription by T3. In this experiment, we
wanted to determine whether treatment with AICAR inhibited the binding of nuclear
receptor heterodimers on the ACCα-LXRE/T3RE. Gel mobility shift assays were
performed using nuclear extracts from chick embryo hepatocytes treated insulin alone,
insulin and T0-901317 and insulin and T3, in the absence and presence of AICAR. As
reported previously, a DNA probe containing the ACCα LXRE/T3RE bound to complex
1, complex 2, and complex 4 in nuclear extracts from hepatocytes incubated in the
absence of nuclear receptor agonists.
There was no change in binding activity of complex 1 in presence of insulin, and
insulin and T0-901317, in the absence and presence of AICAR Figure 4.6. T3 causes a
small increase in complex 1 binding activity in presence of T3 and AICAR caused a
small reduction in binding of complex 1. However, the decrease in complex 1 binding
activity by AICAR in presence of T3 is not significant. There was no change in binding
activity of complex 2 in presence of insulin and insulin and T0-901317 in the absence
and presence of AICAR. Treatment of T3 did not change binding activity of complex 2
in the absence of AICAR. However, AICAR caused a slight reduction in complex 2
binding activity in presence of insulin and T3.
T0-901317 caused an increase in binding activity of complex 4. This result is
consistent with that shown in Chapter 2. AICAR had no effect on complex 4 binding
activity in presence of insulin and insulin and T0-901317. T3 caused a 4-fold increase in
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complex 4 binding activity. This result is consistent previous findings from our lab that
showed complex 4 mediates the increase in enhancer activity of ACCα-LXRE/T3RE in
presence of T3 complex 4 mediate the increase in enhancer activity of ACCαLXRE/T3RE caused by the addition of T3 (21). AICAR caused a 75% inhibition of
complex 4 binding activity. This result shows that AICAR inhibits ACCα mRNA
abundance by inhibiting TR•RXR heterodimers recruitment to the ACCα-LXRE/T3RE in
presence of insulin and T3.
CDCA increases FGF-19 mRNA in presence of insulin and T3
Our data shows that bile acids inhibit T0-901317-induced ACCα mRNA and that
FGF-19 mRNA may mediate this process. We have also shown that bile acids inhibit T3induced ACCα mRNA expression. We therefore wanted to determine whether FGF-19
may mediate this effect in presence of T3. Consistent with results reported for human
hepatocytes, and in chick hepatocytes in presence of insulin and T0-901317, CDCA
increased FGF-19 mRNA abundance in chick hepatocytes in a dose dependent manner in
absence and presence of T3 Figure 4.7. This result would further suggest that CDCA
inhibits T0-901317- and T3-induced ACCα mRNA expression by increasing FGF-19.
Recombinant human FGF-19 has no effect on gene expression in chick hepatocytes
We investigated whether recombinant human FGF-19 modulated lipogenic gene
expression in chick hepatocytes. Addition of FGF-19 at concentrations that were within
or exceeded the physiological range had no effect on mRNA abundance of ACCα, ME,
FAS, SCD, ATP-CL, SREBP-1 and ABCA1 in the absence or presence of T0-901317 or
T3 Figure 4.8. One interpretation of this finding is that FGF-19 is not a mechanism
mediating the effects of bile acids on lipogenic gene expression in chick hepatocytes.
However, it is possible that human recombinant FGF-19 (61% sequence homology with
chicken FGF-19) is not active in the chicken system or that recombinant FGF-19 derived
from bacteria has low biological activity due to improper folding. This experiment was
performed in collaboration with Sushant Bhatnagar in our lab.
It has been reported that FGF-19 has a unique loop that binds heparin. This loop
accounts for the affinity of FGF-19 for the receptor FGFR4. Studies have shown that
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heparin also facilitates functioning of FGF-19 (7). We treated chick hepatocytes with
insulin and T0-901317 and heparin in the absence and presence of recombinant human
FGF-19. FGF-19 had no effect on ACCα mRNA abundance even in the presence of
heparin.

Hepatocytes infected with adenovirus vectors expressing chicken FGF-19 inhibits
ACCα mRNA expression
As discussed previously, recombinant human FGF-19 had no effect on ACCα
mRNA abundance. To establish a role of FGF-19 in mediating inhibition of ACCα
mRNA by CDCA we infected hepatocytes with adenovirus containing chicken FGF-19.
Cells were also infected with adenovirus containing no DNA (null) and no virus as
controls. CDCA inhibits ACCα mRNA in uninfected cells and cells infected with
adenovirus containing null virus Figure 4.9. Cells infected with chicken FGF-19 virus
inhibited ACCα mRNA in a dose dependent manner. Cells treated with adenovirus
containing FGF-19 had a 10-25-fold increase in FGF-19 mRNA levels over control cells.
Western blot analysis using an antibody against chicken FGF-19 (provided by Dr.
Ladher) to detect overexpression of FGF-19 protein was inconclusive. Adenovirus was
prepared by Callee M. Walsh in Dr. Salati’s lab.
Effect of the specific JNK inhibitor SP600125 on CDCA mediated inhibition of
lipogenic genes
Previous work has established that bile acids activate JNK and that this pathway
is involved in the bile acid-mediated inhibition of cholesterol 7α hydroxylase
transcription in human hepatocytes. We have confirmed this finding in chick
hepatocytes. To investigate the role of JNK in mediating the reduction of lipogenic gene
expression caused by bile acids, we used a specific inhibitor of JNK, SP600125 to
measure lipogenic gene expression.
Consistent with our previous experiments, CDCA inhibits both T3 and T0901317-induced ACCα, FAS and SCD expression, and increases FGF-19 expression
(Lanes 3 and 7) Figure 4.10. SP600125 inhibits expression of ACCα and FAS in
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presence of both T3 and T0-901317 compared to T3 and T0-901317 alone (Lanes 2 & 6
vs. Lanes 1 & 5). In presence of T3, SP600125 has no effect on expression of SCD, but
in presence of T0-901317, SP600125 inhibits expression of SCD (Lanes 2 & 6). In
presence T0-901317, SP600125 increases expression of FGF-19 (Lane 6), but SP600125
does not increase expression of FGFG-19 in presence of T3.
In presence of CDCA, SP600125 has an additional inhibitory effect on expression
of ACCα, FAS and SCD than CDCA alone, and an additional inductive effect on
expression of FGF-19 than CDCA alone, both in the presence of T3 or T0-901317 (Lanes
5 & 11). SP600125 decreases expression of lipogenic genes by almost half and increases
FGF-19 expression two fold, with respect to CDCA alone, in presence of T0-901317.
Results from this experiment are inconsistent with bile inhibiting lipogenic gene
expression via activation of JNK. Results from this experiment suggest that JNK
mediates activation of lipogenic genes by T0-901317 and T3. These results would also
suggest that JNK inhibits activation of FGF-19, at least in presence of T0-901317.
However, this experiment provides further data of an inverse correlation between
lipogenic gene expression and FGF-19 expression in chicken embryo hepatocytes.
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FIGURE LEGENDS
Figure 4.1: CDCA activates PKC and phorbol esters have no effect on ACCα mRNA
abundance. Chick hepatocytes were plated in presence of insulin (50 nM) and T0901317 (6 µM). 12 hours later medium was changed with the addition of insulin and T0901317. 24 hours later, medium was changed again, with the indicated treatments. Total
protein and RNA was harvested and western blot and real time RT-PCR was performed.

Figure 4.2: CDCA activates AMPK signaling pathway. CEH were plated in absence of
hormones overnight. Medium was changed with addition of insulin (50 nM) and T0901317 (6 µM) in all plates. 24 hours later medium was changed again with addition of
insulin and T0-901317 in all plates and CDCA in the indicated plates. Total protein was
isolated from cells at the indicated time points and western blot was performed using
antibodies as described in Chapter 3.

Figure 4.3: AICAR has no effect on ACCα mRNA abundance, AMPK and p38 MAPK
in presence of insulin and T0-901317. Cells were plated in absence of hormones. 16
hours later medium was changed with addition of insulin (50 nM) and T0-901317 (6 µM)
in all plates. 24 hours later, medium was changed again with addition of insulin and T0901317. 18 hours later, AICAR was added in the indicated concentration. 6 hours after
AICAR addition, total RNA and protein was harvested and A) real time RT-PCR analysis
was performed to determine ACCα mRNA abundance and B) western blot analysis was
performed to determine P-AMPK, P-ACC and P-p38.

Figure 4.4: AICAR activates AMPK signaling pathway, inhibits mature SREBP-1 and
inhibits ACCα mRNA abundance in presence of insulin and T3. CEH were plated and in
absence of hormones overnight. Medium was changed with addition of insulin (50 nM)
and T3 (1.5 µM) in all plates. 24 hours later, medium was changed again with the same
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treatments. 18 hours later, AICAR was added to the indicated plates and concentration as
indicated. 6 hours later, total RNA, total protein and nuclear protein was harvested. Data
represents mean + SE of three experiments. * represents significance at p<0.05.

Figure 4.5: Fragments of the ACCα gene containing the T3RE and/or SRE-1 were
linked to the minimal thymidine kinase (TK) promoter in TKCAT. CEHs were
transiently transfected with these constructs and treated with T3 (1.5 µM) and insulin (50
nM) in the absence or presence of CDCA as described in Part A (above) and under
Experimental Procedures. Left: Constructs used in these experiments. Numbers indicate
the 5' and 3' boundaries of ACCα DNA relative to the transcription initiation site of
promoter 2. Right: CAT activity in CEH transfected with p[ACC-TKCAT and treated
with T3 and insulin was set at 1, and the other activities were adjusted proportionately.
The results are the means ± SEM of three experiments.

Figure 4.6: Effect of CDCA on the binding of hepatic nuclear proteins to the ACCα
T3RE in presence of insulin and T3. A) Eighteen hours after being placed in culture,
CEHs were incubated in Waymouth's medium containing insulin (50 nM), and T3 ( 1.5
µM), with or without CDCA 75 µM for the indicated times. Cells were harvested and
nuclear extracts were prepared as described in Experimental Procedures. Nuclear
extracts were subjected to gel mobility shift analyses using an oligonucleotide probe
containing the ACCα T3RE (-108 to -82 bp). Specific protein-DNA complexes are
indicated by arrows. Previous studies have shown that complexes 1 and 2 contain liver X
receptor (LXR)•retinoid X receptor (RXR) heterodimers, whereas complex 4 contains
nuclear T3 receptor (TR)•RXR heterodimers. These data are representative of three
experiments employing independent preparations of nuclear extract. B) Signal from the
complexes was quantified using ImageQuaNT software. The value for the samples
treated with insulin and T3 at 0 h was set to 1. Data represents mean ± SE of three
experiments.
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Figure 4.7: CDCA increases expression of fibroblast growth factor 19 (FGF-19) in the
absence and presence of T3 in a dose dependent manner. Northern Blot analysis was
performed to determine mRNA levels. Chicken embryo hepatocytes were treated with the
indicated amounts of CDCA, insulin (50 nM) and T3 (1.5 μM). Data shows mean ±
standard deviation of two experiments. The values for mRNA abundance for the
treatments have been calculated with respect to insulin treatment, the value of which was
set to 1.

Figure 4.8: Recombinant human FGF-19 has no effect on gene expression. CEH were
plated in absence of hormones. 16 hours later, medium was changed with addition of
insulin (50 nM), T0-901317 (6 µM) and T3 (1.5 µM). FGF-19 was added to the
indicated plates at indicated concentrations. 24 hours later total RNA was isolated. A)
Northern blot analysis was performed to measure relative mRNA abundance of the genes.
This part of the experiment was performed in collaboration with Sushant Bhatnagar. B)
Real time RT-PCR was performed to measure relative mRNA levels of ACCα.

Figure 4.9: Hepatocytes infected with adenovirus expressing chicken FGF-19 inhibit
ACCα mRNA expression. CEH were plated in the absence of hormones. Four hours
later, medium was changed with the addition of insulin (50 nM) and T0-901317 (6 µM)
in all plates and infected with adenovirus containing the indicated proteins. The amount
of adenovirus is used in plaque forming units (pfu). Hepatocytes that were uninfected by
virus and treated in parallel served as controls. 24 hours after addition of the adenovirus,
medium was changed again with addition of insulin and T0-901317 in all plates and
CDCA (75 µM) in the indicated plates. 24 hours later, total RNA was harvested from the
cells and real time RT-PCR was performed to determine relative ACCα and FGF-19
mRNA levels. Data is representative of three experiments. * Significant at p < 0.05.
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Figure 4.10: Effects of the JNK inhibitor SP600125 on gene expression. CEH were
plated in the absence of hormones overnight. Medium was changed with addition of
insulin (50 nM) in all plates and T3 (1.5 µM) and T0-901317 (6 µM) in the indicated
plates. SP600125 and CDCA were added to the plates indicated. 24 hours later total
RNA was isolated and Northern Blot analysis was performed to determine relative
mRNA levels.
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